var title_f6_58_7072="Joint space narrowing in RA";
var content_f6_58_7072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP view of the pelvis demonstrates diffuse bilateral symmetrical narrowing of the hip joints without hypertrophic changes consistent with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7072=[""].join("\n");
var outline_f6_58_7072=null;
var title_f6_58_7073="Carpipramine: International drug information";
var content_f6_58_7073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carpipramine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prazinil (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Carpipramine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of anxiety disorders and psychosis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 50 mg 3 times/day; range: 50-400 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10352 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7073=[""].join("\n");
var outline_f6_58_7073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303339\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978183\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978185\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978188\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978184\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821227\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978187\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10352|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7074="Compression bandage placement";
var content_f6_58_7074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Compression bandage placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 677px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKlAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKxPFF81vaLBBOsU8zhS2eUU9T+mPxpSdlcqMXJ2Rt0VzvhuF0nl+csEGGOeGz0NdFSjLmVwnHldgoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqerajDploZ7gnBYKoHdj0Ht9aAF1O7FnZyyL80oRjGn94gVwSyy3S3F1L88E7KsqseQemc/XtU8+qXNzcpcyTK5UnES4IUH0x3qIvK6zrFbkCb729gBn1rmm3NnZTUaa13Oi8IrPHJdQzOHRFQq3cg7sZ/Kukrh/DU8tvrqi6nz56GMKowoI5H9efeu4rWn8Njnqu8rhRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3xAYjTrf083+hrqa5j4gLnSIm/uyj+RqZbFR3OU0tcjNaZJBrK0h/krTY55rBmxW1EPhZYyVdDuUjsRXe6NfrqWnQ3K8Fhhh6MOo/OuIkG9CDVjwfqBsNUaylP7i5OUz/C/wD9fp+AqoOzJmro7yiiitzEKKKKACiuB1nSNN1n4j3ia0nm2tto8EqhpmRUJmn3NwQOijk+leT/AAg1/SvGnje80vV/DlrZ6bdwS3miTRy3CtcQxzNGdxaQhm+XPAX7rcdKAPpaiuT+Fq7PBlvGCxWO6u413MWIVbmUKMnngAD8K6ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsHxum/QJT/ddT+uP61vVl+J4/M0K7A7KG/Ig0nsNbnm2mvtyK2UbctYNsdkhFbFu1YM3Jehqvew5UOhIcHIYdj6irDUoIZSDSA7PQNRXU9Njn4Eg+SRfRh1/x/GtGvPNDvzo+qbpDi0m+WX0X0avQkZXQMjBlYZBByCK2hK6MZRsxaKKKsk8q+JKiTXdesJby80xdV0GKzjvodOmvAh86beMRjrtbuR94GuRsfCvhHSNQ8F32g61r1peeHjtkabTdQuEuoyuJEVH+WHdlj8gx8x4PFfQdFAHK/DAN/whtuzxyx+Zc3cqrLG0bbWuZWUlWAIyCDyO9dVRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUYvPsLmIDJeNlH1IqxRQB4y7bbg/WtS1kGBVrWtIimvrkxxus3mN8ynA6/57VlDTL2M/8fAx/u1m6TNVNGm8yjvVeS9RM0yLS5ZSPNnk/DAq/p+h2jXDmRDIEGPnYkEn/P60vZMPaIyJb9ZTtUFyeyjJq5pDa7asTYu0EJ52Sncp/wCA9vwrqLe1toV/dxoo9hUj/OwijOCepH8Iq1SS3JdRsu6ZrKywIt9tiuBw5UHZn2P+Na6MrqGQhlPQg5rDS2jCBFXgUxbcwtugdo2/2TitOUi50FFYKahewuEO2cnsw2kfiP8ACrC6rIv+ttifdGz+h/xpWA1qKzl1i1P3xLH/ALyZ/lmpRqlkcf6TGCezHB/I0gLlFRR3MEv+qmjf/dYGpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikDAnB4PpQAtFFFAHH3T41G7UnnzG/nVGZxup/iXdZ667YISUBx78c/rVIyBzuzWiEXI3ABJqOyvl8knP3mLfrx+lZ+o34tbfao3Svwo/qaxDcyjCp0AxSA66fUVUE7uBzVmznKruP+sblvb2/CuJjmkMyBzx94/hW3BfqoGTQB1kVxnvU0lyFUYG5jwB6mubi1FMdasWV35rmY9PuoP5mgDfgVUUljuc8s3qf8KkKqaz0n4qUT8UATPCuCSBVS3thIWmI4f7v+7/8AXpZ5/MKwg/f+9jsveriyKAAOBTAqtZoeqiomsgoOwsnupxWkrgnmm3DDyiF+8eB9TSAx7ZLmO3XZczrkdnNSQXeopuUXTMVOPmUHP6VomJVVVXoBgVBFEDNMfcD9P/r0AC6rfxn51hcf7pH9amTXXH+utD9UfP8AOkkiGahkhFFkBfTW7Uj5xLH9Uz/LNWbbULW5fZDMC3oQVJ/OsJ4OKy9UhAjBIyAc0mrK6GtXZneUV55A08Y/cXE0eOyuQKtw6vqtswPnidB1SVR/Mc1z+2XVHR9XfRncUVk6RrcGonyyDDcf882PX6HvWtWqakrowlFxdmFFFFMQUUUUAFFFGaACikLUxpAvXpQBJRSKwYZUgg+lLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHNKEHXmgCQmmNIBVVrgY61BJNweaALjTjNRSSbhwdrDofSqCyFn9qkzQBpWs4nj3DhgcMvoamrFEjW8yzoCQOHUfxL/iK2I3WSNXjYMjDII7igCrqWnW+owiO5TOPusOCv0rj9d0GbTLKS5inWVFIG0rtPJx713lZniRd2jzj3X/0IUNtIFueXvZ3dxN5jFVz6jNNk0u6Ays5z7KP8K6cxgAdKjYYzWDnLubKKOQeG8gcs+JR05GP5U37SvSRWiPvyK6x0VuoFVJ7COT+EU1UaBwTMFJJNwCPuDHAI5rftLgRqq9ABgCl0LRIJNcto51Jjk3Dg4P3Sf6Vt6j4OlXLWE4cdkk4P59K3jO5lJWK0F2Mdak+2gd65+/s77TnC3MLx56E9D9CODVV5pWUIMhnO3NUSdZYzmQGY9X6ey1eE9YNrOAgAOAO1WRPnHNMDZW496RJ/Mn6/LH/P/wDV/OsZ71YkJzkjgD1NWbdvLiVScnqT6mkBredk1HbT7hI3q5/Tj+lUJLgRxs5PCjNJaM5hCKBuUAtk9zzQBrNKKDICKzxJkA00yZuIkJIVs9DjOKYGgz5FZmsEfZnx6Gpt2wuueAeOapXzeaEjHO5gP8aV9ARPYwr8+71qy9suOlLZR7Ww3JIyKtsOK45JM6oto5+7gMbCWIlJEOQw6g11+iX39oadHM2PMHyyAdmH+c/jWBeplTTvB0wj1C7tyeHUOB7jg/zH5VNJ8srdy6q5oX7HW0UUjEKpJ4ArrOMWms2KZJKB3qpLcDPWgC2ZAKga6XdjNZt3d7UODVK3lZ3LE0AdD5mRTHfjmq9q5ZcGpiMjFAFVrh4X3RNg91PQ1o2d2l0px8si/eQ9R/8AWrLuYccikhjYbZEO2RehoA3aKpW9+rMI5x5chOB/db6GrtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANkbajN6DNYF9ffNkGuhrj9ctXs7zrmGXJQ+h7rQA5dRG7BNW451lHBrnnU5zipbeUx96YHSIABxTqp2Vx5gwTVykAU7TZ/s1x9nc/u5Duj9m7j8ev502o54lmTaw+ntQBu1neIP+QVN9V/9CFM069dZBbXbZc/6uQ/x+x9/wCdO8RHbpUn+8v/AKEKT2GtzlpTgVWkcKCTwKLy4SJSWYACsNJLjV7sW9sWWAH95KBworC12bbGlFerKZvJRpFhG6Qr0UVYRg6hl6GpdWktNF0Wa3sY1UOuwerseOap2nyWsYbqAKJKwou5raIf+J3Y/wC+3/otq7evK76ZswNHK8ZRy5KNtONrd/xruPB+oSX+lZnYvLE5QsTnI6g1dN9CZrqbM0Uc0bRzIsiNwVYZBrj9e8JncJ9LHTJMJP8A6CT/ACNdnRWtzM8hZ5beRklRlZeCrDBFI9/tFeoanpNnqSYuYgXxgOvDD8a4PxF4WuLFfMgHnwk43qOU/wB4envVpiMywla4n81vuRnj3b/61a6z+9YIcWyLHHnaOp9T609L33pgbFxN5jRwjoxy30HNWtPuN17cKem1CP1rCt7ku8jIpdzhFCj8z/L8q0NJjmS9kkm2qXjxtBzgA/8A16ANCOcKi7jjAxTPtKy31qsR3bX+YjkAEEVWEduJXLgM24/eOe9WEuI1aMDao3A56CgC1cq5uXHm7FIDcLk+n9Kbb24N0HMjHapxn19f51Bc3IkmLIQRgDIOf89asxNhd397p9Kyqu0TSnG8jQh+/kc7RirAbctUbRsHGeKtEZztOPWua5u1Yr3f3DWFZ3f2HxBaSk4Qvsb6HitdnLb1PIHQ1zetoQcjgis5aO5tTV9Geq0HmqOh3f27SbW4zlnQbvqOD+tXq7U7q5wNWdmY2ph7TDcmBjgH+77Gs57j8a6iRFkRkdQysMEHoRWLc6AuS1pO0f8AsP8AMv59f50xGNMzSNz0qWE7VwKbdW93aEi4hwo/jXlfz7fjUcbseoxQBrW1wEGDV5ZlbvXK3mpJaukYG6VhkLnAA9SauWNxJPGWZdjA9M5BqeZX5epXJLl5uhvOA4oVQo4rLW4ZOM1LaXheUo1USW7iFZUKsM5pttcTWfyybpYe3dl/xFLLMqDk0qMJFzQBpwypNGHiYMp7in1hsssDGS1fax6g8hvqK0bC+S6BUjy5l+8h/mPUUAW6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq9/aR3tq8EvRuhHVT2IqxRQBw/lNDM9vcACWM4Pv6H8aZNGu04roPElgZYxeQLmaEYZR/Gnp9R1H41gbhJGCpyCKYFe1uTbzYJ4roredZUBBrl7hPmzViwuzEwUnigDp6KhglEigg1NSAZLGsiFXGQazfEWpONL+xOSbtmXYcHDDPUnoD/kVo3E0dvA80zBI0UszHoAK5rT7htUu5Z5U2pJGdqMOUA7H8wfxpPsNX3Ks3hyW4SOS5ui4PLInH61u6XbLY6bHbxxhSB83HU+tOsRtaSPJIRio/A1bYDFJK2wNtnnniO4LeJPs8pxHAgYD3POf5VI+oJ5eA1SeKdEuZtbe9hG6OSNQQOoIGP6VjnS7tjtCN6dKzktTWLViSe5MrhYz8xVwPqRivRfh8pWzufcr+fNcdZeCNaS4jmeFQFOdpkXP869L8P6cdNsBE5BkY7mx0z6UQi73FNqxpUUUVsZBRRRQBkap4e0/USWki8uU/xx8H8R0Ncrf+CbqMMbOWKbjgN8p/wr0GincDy+30nU9Pt3hNlOSWyGRd2fyot11KGRj/Z9yzEYGYm4/SvUKKLgeXJZ6pIxIsLnJOcmJhVyHRNZl5+ybAf7zqP616LRRzAeVa08+iX0NvdxqzOokyrZGMkY/StdbpLi3WRD1FYPxQuDJ4qjiX/llAg/Ekn+tXdFybTB/Kuao77nZTikkzbs3zV98lfl61mWfDVqIeKhDnuZcgkRizDP0rL1RTJDnGCRmujuFBQg1h3aMVcP07VM9R09GbPw7ud+mT2xPzQyZA9m/wDrg11led+B5/s/iF4CeJ4yMe45H6A16JXRRd4GGIjab8wooorUwCsLxDDZ2sH2hiIZWO1QMAO3XB/LrWvd3MVpbvPO22NBkmuK1S7TXnlVnkgELBoVPB6dSM4IPNZznyrzNaVPnd3sZsd48a/bVBZsbbiEryoGcY9RyfzrU0uaJrKMxPvHTd61RlligFnPLtjYIUlXPX0+vf8AOn6RG8ulNNHD5cUcjLgDG0E5BI/Gs6V+a7Nq9uWyNSSQbTUMDeVl2PJqkZypw1MmnJGM10HIacTtdSgZ+WtyFAiACuZ067RCFDDdV/UtajsLLzT80jfLGufvGgCxqupraMIIV8y6YZCj+EeprMnfUEQXO8rIhDAbRik0KF5biW4nO+Z2ySa6K/gBtSv95SKm4Gpbu0lvE7rtZlBK+hx0qSobObz7WKXu6gkeh71NVAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXKavp/2C4DxD/RZTwP7jen0PaurqK6gS6t5IZRlHGDQBxE8WRkVQeMq2RWw0MlrcPbXH315Vuzr2NRTwgDNMBmn3TIQrVuxSB1yKwrWznuiPs0LuP72ML+Z4ro7LR8Qlb1t4YYKISB+J70Aec+LteF9qg0+NitjCQZDjAmcdge6j9TWzohI8xnBQlTkMMY3Yx+i5rpW8N7XJt72RF/utGrY/HiobnwqLmIxyX8oUnJ2IBmo5dblud48pSsJCxklJxvYt+Zq2ZQR1FOi8JRooX7dcEfQVPH4Yt1+9c3Tf8CA/pTsQQSpA0K4+eRiAFHUn0rTsdIihdJZgrzLyoH3VPt6n3P6Uum6Naae++ESM4GAZG3bfpWlTAKKKKACiiigAooooAKKKKACiiigAoopGIVST0AzQB4x4xb7X4xvn6hHEY/AAVu6Iu2DBrnwftWpXE/UySs/5nNdJYHb8o61x3u7npNcsUi9D+7DsegrTh5UH1rNUEkZ6VoQfKPY0zFhNycYzWPO33kbluSa2ZtzkKMgY5NZlxEsZZV/XvRIIbnP28/2LXbO4zgJKu4+xOD+hNetV49rKc5r1jTLgXenW04/5aRq35iqw73QYpaRkWaKKK6TjOM8ZTt/aMcYY7VQHHbOT/wDWqjDD56hpckjjripvGny60nvGp/U0lq4EIrCW5tHYabSFclY1DeuOan8M3RtNWa2k5huRtwem4dP6j8qZvBNVb5PlDoSrKchh1B9aSdncbV1Y3df0ICNp7BDxy0Q/mv8Ah+Vc1YxLLP8AvjmJeo9T6f59q7fS9Zt7nSEvLiWOLb8ku5sBXHUf1H1rza+1RZ9QupIHBBlc4Axxk44+laylpoZxjqdZPbQ3MQAABHTHGK5jXrW5NxatKd0MG7oOTnjn8KmstWxgMcVoz3iS2+SRjIyfQZrNOxbRp+Go5Sg84YY8kela95dQtN5IkTeOq55rnr3VQmmNBoz+ZdyDG9eiDuc+tcpo8F7Y6hH9ody+VyGOQ5J5xWl1sZ8r3PUtDbEEsBPMTnH0PI/Un8q0qydPY/a4to+/Gd/0BGD+v61rVSJCiiimAUVmz69pEEzxT6rYRSodrI9wgKn0IJ4po8RaISANY00k8AC6T/GgDUooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCpqFhDfBPNLKyHKuhwR602DS7WLBMfmuP4pPm/ToPwq7RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVm+JLn7HoV7NnBERA+p4H860q5L4k3GzRYrdTgzygH6Dn+eKmbtFs0pR5ppHFaUg2g962bU7SeayrEYUYGMcVoqT5fA471xI9CRdecBsLknH8PNalkzOilgRx371lafGvzOCWJOOR0ratxxWiMJErZxjFZ12hJYn6CtMZwc1UuhxTZETjtXRtxGOMV3ngSfz/DduD1iLRn8D/gRXIapHkGtr4aT/ALi+tifuuHA+owf5VNJ2ma1lekdrRRRXYcBw3j9dmoW8nrHj8if8azLW4BjAzW58QY8raN7OP5VydirMQqgk1jLc2jsaxk4yKcYZrmPC/Ih/iYf071NaW6KAZMO/6D/Gr45FTYdzJGlxQRHGWc9WY/5xXPatpXzmSPKsOjDrXZSDPXpVOeIN1FAjhkmeJ9lwNp/vjp+PpWlBcvF3yKv6hpqSgkDmsGWKaxbABePup7fSgo6iw1CPpgCr800EqDeRn19K4tJg6b4SeOo7ilhuZriXy8nb3x39qLhY77QdbEV+IG/fiZlj83OCvYD35Pt+NdpXnXg60+16pAQuI7cea/PfkL9P/rV6LWsL21MZWuFFFFWSfN/xQ1GXw94Riv8ATEt4Lu88ZXNncXH2CG5laFpZyQA6Pk/KMYBPGPajSr1NT0H4o6dqEdtcDSkB06S802Kzv/LZCS0kSxoVGduDsUnP0rpfEvhg67ps2ka1oXikLaa/catbXWlfZcMTJIYz+9Y5GHzgr1qO80CVLHxVcWvh/wAX6h4i162FtLfal9jHCrtVcROqqowOi54oA9vooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8/+JE3m6lYW4P8Aq42kP/Ajj/2WvQK8w8TSfa/FN0c/LGVjH4Dn9c1jXfu2OjDL379iG1jyigD8allfLKkY3AdfSp4UATaPSmCIKcSP8voOM1hFHTJmlp2xohsAA9B61qW4OfasSzkWKZFi+bccYroIxxVpGMncfVa5GRVqoJxxQxI5/UI854pfAj+Tr8sZ4EsRH4gg/wCNWrxc5qhoP7nxLZkd2Kn8QRULSSZs9YNHpFFFFdp55zXjtM6dA4GWEu38wf8ACuPsZBGCi9e59a73xZAJtFlb+KIhx/I/oTXmsLFZjWU9zSOx0UMnFWUmAPWseOfaKcLjmoLsbZYMKhbBqjFOfWrKSZoAGSqN3aCUHIzWmBms7UtRhtGWPIaVuiigRzGo6c8EhliOxh37fjWjpGhardPuTTpYmkI+eUbUAx1yf/110fh65sA4n1KKQzg5TK7kT3A659z+GK7OG/tJlBjuImB/2hmtFT7kufYr6FpUWkWQhjO+RjukkI5dv8PQVo0A55HSitNjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK838ZvYL4r1e61/UNWt9J0vQ4rxkstTubUA+bNuOIZE3MQqgZz0ArH8E6bceJbTTdTl0TxBZaLqCebDKfGmoPcJGRlHkiLqoDDH3XYjI464APYKK5b4ZPK/g63E89xcNHc3cQkuJmmkKpcyqoLsSzYUAZJJ4rqaACiimyAFSD0oAdRWdNfNaH9788frnB/+vUkWp28igneg/21xigC7RRRQAUUUUAFFFFABRRRQAUUUUABIAyegryaFjc3087dZJGf8zmvTtWkMOl3cg6rExH1xXm9hFtA4rCtukdeG0TZejUZBpskQL5ctjOQKnRadCu9mDDIrJGkmWrARsSyKoI4yK1I+lULaEoMKcCrqxkMrDoBzVIyZNUUw4qYUyRcimJGVdLWVCPK1a0k/uzIf1FbtwmRWPdptcMOoOahrU2i+h6HRQORmiuw4Cpq6htKvAf+eL/+gmvJ5fluSPevXbyMzWk8Y6ujKPxFeR36Fbndjg81nM0gT5yKjLlTTUcmiQcVky0TxTkdTV+GfC7mICjqTWBNOluMyHk/dUdTVRnmvWBnO2IdEB4/H1oQzbvNaluMw6cCF6GYj+Q/rVKDT280SyEsxOSx5Jq1ZCKNQBir0kiBByMZqo7kvY1rO1UW6jbuduFHrWnDpcSJyAznq3rVXS2HliRuGYcD0Faizc11GBALTy/9U7p/usRQ815AhYXTgKMknDfzq0JQetQyETzrGPuJ8z/0H+fSgBkV5qQQM8yljyVKDA/Kpl1S8X78UL/TK/41LtWjygaLAQya88ZTfZn5jjiTOP0qT/hILZdu+C4XPGdoIH61BcQgyxLjuWP0A/xIqC5twYnyOMGlYDWj1qxf/lqyn/aRh/SrMV7azcRXELH0DjNYEVvujUkclRTGtFPUCjlC51VFccLbY37ssh9VOKlFxeRfcuZfxO7+dHKFzrKK5SHX7yNmSSOKXb3+6cVcTxIg/wBdayL7owP+FZOcU7M1VKTV0b9FZlnrdjdSCNZTHIeiyDbn6dq06pNPYhxcdwooopiCiiigAooooAKKKKACiiigAooooA8r+IX9hXPifXtJ8TajFp9nqvh+K2WWRtvPnT8r6lcqcVnfD/xg2g6Vo+h6r4i8Hy6fp0ItjewXkhmnjRdsY8koFRsAZO9unTnI9looA5L4VyJN4Kt5omDRS3V5IjDoym6lII9iCDXW0UUAFMY8U89Kic0AU79xHCzcVzouDI+ex4rS1ifcPLU9eKzZIvK2KBQBs2MxitI3WTYNoyDyv5f4VNHrlmxKu5DD+6C4/MVmW1sZkxNkRJwB6+/8qsg28AwFUYoA2Le6guBmGRW9u4/CpqwCIJsHGCOhHBFPEl3DjyLjeP7sg3D8+v60AblFZkWpuB/pNsy/7UZ3D8v/ANdWor61l4WZAf7rfKfyPNAFmigEEZBBHtRQAUUUUAZ/iDnRroDuuP1FcZbwFQK7XWhnTpF9SB+tc+lvgdKxqK7Oii7RKapyBVmKPnpU4gGelTRxVFi3IIU4q0q8UkaVOq00iGyPb0wcUjLU4WkZKdibmfMnFZt3DkGtySOqssOe1JxLjI37c7oIj6qD+lSVFaf8ekP+4v8AKpa3RzsK4/xJoDM7T2yF0YliqjJU/wCFdhRQ1cE7HkwtPLJBI/OiW1u5MR2FrJcSn+6pKr7k16wUUnJUE/SlAA6DFRyFc55Ing/WTmWW1Z5D1y65/nUFxpV7Z/8AHzazRD1K8fn0r2KgjIwelPkQc7PGRHIOg4o8xmuooj937zfSvVLvQ9PuclrdUc/xR/Kfy6fnXL6n4Nlima4sJTPkco+Awx6HoaIxs9Qcrojtrjgc1fScY5NcrK1xaSmOZHjcdVYYIp66kehPNbGZ1D3axoWJ4AzUtpIVjy332O41y0V2Zp0TOVHzt+HT9a2o5/egDYWb3qRZ8DrWMs5z1pZrkhVRT87naPb3oA1oZQ7PLnr8o+g/+vTLuQfZpcdSpA/GqiSBUCrwoGBUc82fLX+84/Tn+lAGsGHamkjNUxPg4zzR5x9aALRUZqGRBg1F9oLZIUlQdpPvnFK0vFMDKnAS8YDuufyI/wAauJBvQGqcnz3kh9Ex+ZH+FbFqCYxxxXNVWtzenJpWM24slZTkCrmiatLazpZ3jF4WO1JGPKHsD7fyqxImRWVqMIKHisLuLujfSatI7iiqWi3RvdNgmY5cjDf7w4NXa607q5xtWdmFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFACMQoJYgAckmuKv7x9Q1K5k+0KbS3O1IgeowMv/P8AAVN4y1NmdLCFiIZVZXkXgbsjAz+fHf8ASsto5zMdwX7XAgyRwsqY6H9a56k76I6qNOy5mdzpyPHYRLISTyfm64zx+lJdSbIyadYs7afbGU7pDGpY+pwM1Dd4I+at1scz3McKWkMsnAHSopJEklAyM0zUbrqq9KyIpT9pHNMR0c0vlw4z2rHMjzy8Hipb6YlFUd6WxQbhQBbgjcL3qwpZaezqiAd6OqZoAdFcfNtap52iSFpJdoUDJJ7VmRgtMKyvGF63nWemRHBm/eS+yA8D8Tn8qANK0lvLmYXVm3lQg/KmP9YP9quqhmSZd0bZ7Edx9a53RpAqrGOwrSljaNxNBxIOo7MPQ1KY7GnRUVtOtxEHTjsQeoPoalqhFbUV3wBfVhWf5HtWtKu5QPeofLqWrlxlZGeIeelPWKrnl0ojqeUfMV1jxUgWpglKFp2Fci20bKmC0u2iwXKrR0xos9qubaNlOwcwtuMQRj0UCpKRBhAKWqICiiigAooooAKKKKACiiigCG7tYLuMx3MSSp6MM4rkdY8H4Jl01tw/55OefwP+NdpRRcDx+MNa3EokBVw20g9Rjt+eavxXYx1rutZ0Cz1MFmXyp/8Anqg6/Ud64XWdBvNMYllLw9pV6fj6VaYhzXwVevNOsLgyu0zfd+6n9TXOssskyx5ILHr6D1rXinRFCJwqjAFMDcWf3qB5vMuW5+WJD+Z/+tVAXIx1pscoitWeQ4MmXb+g/KgDdSUG3tnUABgOnuM1IJPesq1lY6NbMq7mAUYzj2qVPtDjlo4/zb/CkgLls+6G8UdVc4/IGm/aRIAYgzA9wMA/iaXTYlg84Fy5JBZj3NRwzEogJ4CigB1ggfMjg5diMH24/wAa17Q/u8ds4FUUcRwqCOQKtQfdBHJHNckpXZ0qNkWHrOv/ALhq7JKoAycZqlecqahmkdyz4Kucrd2pPKMJAPY8H+VdPXnvh6c2viSEfwzZjP49P1Ar0KtqLvExrxtK/cKKKK1MQooooAKKKKACiiigAooooAK5vxDrckM7WVk4jlXHmSHGVyM4AP1HNdJXneuyf8Te5z/z0IqJuyLhvcjadvs0tvMrzK5J3gcn3z6+9Q3V1dTPuiQRNs8suTuOPp0q3BygpWTisLI3c2zpPCc/m6DDGzs8kBMbFjk8cj9CKXU5SoIFYXhy7FlqZikOIrkBcns38P8AMj8a3NVibklTXRB3RzyVmc1dMSxzVROJgauXCHNQrGc5xVEj55MsM1Zs5tvNUpUJpFyq8UAbUU3myDmtCQgRAVgWTlTk1oG4yAM0AXbNMvmuIvpjP4unuXOYs+WnsF4/nk12Etx9n0+eZfvKh2/Xt+tY2naTFc2RjlO3jO/up9aARY0+48u7ViflNdU7Ex7l5rzSS4m06Ro5mSaHPEsTBh9eK7Pw7qP2mNYnPOOPeoKNBTIj+bb4D/xKejVpWtwlwhK5Vh95D1FZGq3semLHJJ1kfYo6fjVsyJJbi4jIEkfOR3HcU0xGlSYpaKoQm2jbS0UAJijFLRQAmKMUtFACYpcUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBAIIIBB7GiigDmdW8J29wZJbAi3mbqp+4f8AD8PyridT0XUNPYmeF1X++OVP4165RTTA8RlaRFCkn5uPwrZeO3iYNN+9f1bp+Ar0W+0XT74H7Raxknjco2k/iKzZPCGnP/HcD/gQ/wAKdxHMG4RNPRdyhmwQO/XNQi7OOXrqV8GacP8Alpc/99D/AAqeLwlpSEbo5ZP96Q/0ouByCXbAMqvw3XjmrNg8ck5RpFDAA7c8mu2t9H063wYrOEEdyuT+ZryG/nWLxXqDW+FVbl+B0+8azqS0sjalDmd2ds7YbBq7bH5ax1cyxo49K07JsqK5VudUloT3JURnoD61TBDQ4HO3irk8QkXmqE0JjZfmIUc1T2MluYuoloLhJo+HRgyn3HNemWsy3NtFOn3ZEDj6EZrznU1DJkc11ngq58/Q0QnLQu0Z+nUfof0p0XaTRVdXimb9FFFdJxhRRRQAUUUUAFFFFABRRRQAV5p4pPla7cj/AG8/mAf616XXm3jtfL1uQ/3grf8AjoH9KiexcNx9k+5BVsrWTpsuUFaRlMgxCM+rHoP8axNSrfKApZm29812HhjWE1WywxP2mEBZARjPo344rkp4MrlyWb1P9Kh0u+OlatFc8iE/JKPVT1/Lr+FVB2ZMldHosllayNue2hZvUoDTG06zZcG1hA9kAP5irQORkdDRW5iY0/h+2ckxvJH7ZyP15/Ws+48OToCYZEl9iNp/rXU0UAcE8ElvIUlRkb0IpoY7gK7ueCK4TZPGrr6Gsa70BS++1cAf3H/oaAMa8JeyWIf8tHA/r/SppItkMMA6OCzfQY/x/SrLWE4uIVeB+M9BkZ47jgfjUXibdpq2UpG7cXR2HTJwQP0NTLYcdzF1HTkkz8oqLRJvsmYQSCjDBz0U9aJtZQjBxmsma7VrlHBwCcGsk9TVq6Os8cQNPaWEkbYMUuCeoBI7/lVSx1S9tbMwPAko9QdmPw5qXV7vzPB9xIxO6FUkJPUnd/8AWxWA2rjyQVIyRTk2noKKTWp1cHjMG6WK4sfKTI3OJd20euNorr68YjMk8RPV52Cgkd2IAH6ivZ6uDb3JmktgoooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbK4iieRvuqCx+grwO1Y3GoSStyzsWJ9yc17X4nlMPh/UHHXyWUfiMf1ryTTbYBgdtYVXrY68NHRs6u0AFonHatGzPAqjaqDAF6VbjO112/dA5x3rJFyNIciql4AyMGyF9atJyvFVL3CxkNliTwBVGZl3yARkAVf8Ah/Ni4voCeoVwPpkH+YqlMGMOXPNQ+F5vs3iWEZwsoaM/iMj9QKiLtNG0lzU2j0eiiiu088KKKKACiiigAooooAKKKKACvPfiNHjUY5P4TCPzDN/9avQq4r4iplrJsdA/48r/ACqZ7FQ3OZ0uMsgMhwv931+v+Fb0LfKB+Vc9YSHFacM+CBWBsaLjctZd9FgZxnPAA71oRSBhTfLEsjPxhflX69z/AE/OmI1vB+s74l0+9dRMgCxN03j0+orqq8yu7PIyKu6b4ovNOAhulN5Gfulmw6/j3H1/OtIz7kSh1R6BRWRpniHT9QwqS+VMf+Wcvyn8Ox/CtetL3M7WCiiigArF8WlW0loHAbznC4PoOT/Ktquc8QSia88sdIF5/wB5sHH5AfnUydkVFanB33h+GQ5iyh9jisS50S8hbEMzn2JzXcycEmoIY98hY1hc2OM1W712TR00x1Uw7gWI4LAdAapwtOFCywSDHHHNd3NGHnHAwKQW8YZiUHNO4LQzPB++81/TYRGQiP5jE/7Iz/QV7BXI+DrNBeyzhQNkeB9WP/1v1rrq1gtDKb1CiiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/H1wIfD7x55mdUH55/pXD2EWEBxXQ/Ei43XNjag9A0jD68D+RrItgBGtclR3md9FWprzNC0/1YDdatwsokxnk9KoiQRKCevvU1pHJKVcuFXOQMZP50kEjai6YXtTWQKrZPJ5zToF2pinOmVPNUZMxrg/J047YrDaX7PqEE68eXIrfka6K8QbCPSubvotoP1rORvTPWgQQCOh5oqjoc/2nR7OXu0S5+oGDV6u1O6uee1Z2CiiimIKKKKACiiigAooooAK5f4gw7tJhmxzHLg/Qgj+eK6isTxmofw9cA+qH/x4UpbDjueY2UmHIq8HwayojtmI96u81gbl/wC1GNMr948Ae9aVu4WNVB6D8zXNCTNyoPRBu/E9P61qW84x1oA1WO4VTjtxNukI4bhfoP8AE/0pJZx5YQNhnO0H+ZqwkiqAF4UDAFAinNpwOcCpre+1SxULBdyhB/C2HH65/Sriyg9ahusPGUU4L/ID6Zouw3LNn4u1AKGuLWCVT025Qkdjnn+VakPi63YfvrS4Q/7G1h/MVk+Um3AAAHQVE8KY6VXOxcqOjXxZo+cSXLRt6PE39BismWRpFeWQEPKxcg9Rnt+AwPwrl3tRc63bRgZVW3t9B/kV0V2/QCk5XQKNirO3GKkhG2HNV3+ZhVljhMVJRXQfMSaH54HU8Clpjkj7v3ug+v8Ann8KFqB2vhy38jTUYjDSnf8Ah0H6YrUrlrfX7xVUPbQsoGPlJX/Gr8Wvof8AW20qf7pDD+ldKjZHO3c2qKzRrVl/FI6n0MbH+Qq/FLHKoaJ1dfVTmgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFHSgDyzxbObrxXOA2Vi2xj8Bz+pNSQDgVjxym61Ge4PJkkZ/wAzmtgHyUBxyeBXDe7bPUa5YpE53GQrGNx7jtWtbrgCsCDcr+YCWYtnjoK6G1IlTK1djBsuxjK08jikiXaop5HFMzM27Xg1gagmQa6O6Gc1jXqcGs5I2ps6bwPJv0FFzny5GX9c/wBa365PwBJ+5vYf7rq/5jH9K6yuuk7xRyVlabCiiirMwooooAKKKKACiiigAqlrNqb3S7mBfvuny/Ucj9RV2igDxC5iaG5YEEEHoR0qQXGBgivTdd8M2uqOZVPk3B6sBkN9RXPN4EuCeLqED1waxcGbKaOIFwd8j+rYH0H+TTkvGBNdpZfD58/6beqqg9IVyT75PT8jWlJ4B0poSiS3asR9/eCf5UcjDnR5/Dfl5dx6KMD+pq/He571sXfw/uohmyu4pQOiupQ/1H8qw73RNR04E3VrKiD+MDcv5jIFJxaGmmXY7sHvUkdyJLgHPEYz/wACP/1v51z5mKDI+YnoB3qWCUxrgnLHkn1NIZ0wuM96V5hsJzWDHdH1pLu/KxELyx4A96QG3oagvcXTdXOxfoOv6/yqzO25zVO0mWG2jiHRRiniQN3oAeBzmnFs00MKKAFNLZR+fcY7L/P/AD/Oop3CRkk4q/oC/uTIw5Y5rSkru5E3ZGnFajbzS/ZxzU4kAo8yukxKMsHymsmGNQ7AcMGIBHFb8rAqaxbZQ16/purOrHmiaUpOLJ1mvIv9TeTr7Fiw/I1btPEF3akLfILhP76gKw/Dof0qXyVI4xVee3BHTiuO8o7M6vdlujqrW5iu4Fmt3Dxt0IqauI0e5fTdURd2LeZgjg9Mnoa7eumnPnRzVIcjCiiirMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqjrlx9l0a9mHVImI+uOP1q9WD43k2aBIn/PV1T9c/0qZOybLgrySPPdJix1ArWwCpLjgVXsUCrjFX1UEHNcaR6EnchgkZnKRKCMZFammQyI7PLgZ4AFUQGQgxjIrYtzhV7n2rQwZcWnHpTI2DA+1SHpTIKVyOKyLwZBrauBxWTdLxUSRpAk8DPs1e6j7NFu/Ij/Gu4rgfCp8vxHGP76Mv6Z/pXfVvR+ExxHx3CiiitTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMvU9B07UmL3NuPNxjzEO1v06/jXJ6p4HnjBfT5hOP+eb4Vvz6H9K9AopOKY1Jo8TvLS4s5miuYnikXqrDH/6x71QizJchzyiH8zXtusaVa6taGC8TI6qw4ZT7GuD1fwlcWCFoB59uO6Lgr9V/wAKzcbGqmmc8bkjoasQXZ71Tmt2X3qIArUFG7Hcg96nWYHvWCkpFTifC5zSsBbvJ/MljiXncwB/OumtAYYxG2MgA8fj/hXF2jl5HmPRSMfga7GeTa6H1X+X/wCuummrIxm7st7+KjicNb28uSS4G4k56iqb3sSKcsCfQcmn2wkOjp/A6njIzjDelWQWpZQAcmq2nxkhpW6MxP4f5FMmh3RP++dm2nHYZ/Cr6RrHGEU8YAA9qzqysrGlON9TQAG0YHFRSLkU9H7HA9KGxz61zM2Rh6rGDGwrr9Guftel20xOWZAGP+0OD+oNctqQyjVf8C3O+1urZusL7h9G/wDrg/nTpO0rFVVeF+x09FFFdJyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXM+OTutLWP1kLfkP/r101c74sTzZLRfQMf5VFT4TSl8aOat48CrGwlcAVOkGKliiOSDXOkdTkNtoyFANaEKAHIFMijq3GlUkZtgqY5HfrTvbvUgXil207EXKc68Gsy4TNbUqZBqhNFmpaLizN0VfL8Q2jf7RH5qa7yuNtItmqWrekg/nXZVrS0TIru7QUUUVqYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGDrXhy2vQ0luqw3B5/2W+o7fUfrXD6hpMtrKY54mR/Q9x6j1r1aorm3huYjHPGsiHswqHG5Sk0eNyWpXtWfeSeUuM4J4H1r1HUPCaTZNpcGIH+F13D8+tcvqXgPUY72Ke3kjukQggD5COfQn+tSoO+pbmrGRY2k72bfKIoyOr/AHiPpXSXixskBm+YAEdfaqlzpmrIf+PKcjphVJ/lTpbfVpyu7TrhQvQCJq6DEsxywxD5FUD2FSfa0+xlAwLsx4B6fNVaLRtYk+7ZMB/tMq/zNXY/DmpmJnkEKlQSFL8n24FF0Ay1YyMR+J+lW9x3g5rn/D2tC4kaCWMIck5zmtrf89clSXMzspw5VZmnGdyj1pkzNHIvOcnmnW5ylQ3KSFgR0pLUl6MjvVyhqn4WnNp4gEZOEnUofr1H+feruS4KlcYFY90GgvIpk+8jBh+BqNnc1j70XE9IopsTiWJJF5VgGH0NOrsOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyNZj8y4T2T+ta9VLqPdNn/AGQP50pK6Ki7MxhB7U9YfatDyvagRVnymnMVUi9qsJHUqx1IEosJyIQnFO21MFpdtOwrlR0yKqyRe1abJUTRZ7Uco1IykhxcwtjpIv8AMV0dZphwynHRgf1rSpxViZu4UUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVV1Sb7Ppt1N/ciZvyFWqxfGcpi8NX2z7zpsH4kCk3ZXHFXaR5HoLkzI2DkNXcqM7a5LRrRkYHBz1rtI4SVTiuV6s73oXbX7oq3tyKrWy8kenFXdvy1SRhJlGWNg4Cfd71nX0Ga2ZF2sCR8uOlQ3EO4HihxHGVjV8PyF9Kgz1QFPyrRrJ8PHbDLF6NuH4//AKq1q3jsc8/iYUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMuTmlooAjKCk2VLRilYdyMJS7afijFFguM20uKdijFMQzbSbakxRQBGUqSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwPGIMmnRwjkvID+QrfrK1mPzpoV7KCfz/AP1VMti4aSuctY2JTBIrZWEgDFWktgB0qcRgCs+U1c7laGLGPWrYXC8cmljQ5PHFWFTAqkiHIqtCM7j1/lTZIs1dKZprJTsK5V05fLuSP7wxWpVNE2yKferlOJMndhRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVSVN8xb8Kt1GBSY0RCOl8sZqbFGKLBcYFpwFOxRRYBuKQin4ooERFamFNIpw6UwCoL65Szsp7mUHZChcgdSAM4FTkgDJOAK4PWNZfUL5lRDLp8O9JI174ON3Xnp0/nUTkoo0pwc2ammajqc91H9pIjLsD5IC42k9iMn9a6iuK8Pyyw6pawyKZVO4RS9flxk59xgV2tKk21qVWSUrIKKKK0MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADSUpooAMUYoozQAUU1mAFRW0oLNETll5Ge4oAnooooAMUmcDJOAKWqOtn/iU3I7Muw/QnB/nQw3Of13W5LgNBYx7oFYF5CcF/ZR6fzrKjuLaC/+0REKsikSJgksfX61UCqr7EACjgD0q7FDkDAxXNLV3Z1RlyqyQ3Sb6WG8sERSsMcgDPJxlT8vT6GvQ64Ke0BiPHaup8P6gL6yCu4NzCAso7+zfjj+daU3bQyq66mpRRRWpkFFFckvjQzXF2lh4d169jtriS2aeCOHYzxsVbG6UHGQe1AHW0Vxep+O20vTbvUL/wAK+I4bO0heeaQx25CIoLM2BNngAmu0oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopDUE0wUdaAJmfFRNJVKS6BNIkm6gC0z5FULgvG6yRnDqcirWaa67hQBdtp0uIRJGeOhHcH0qWueEx0+5EgJ8tiA6jv2/OtS51S0t4BLLMAGHyqPvH8KALtcF4v8XwCaPTbBhJvlVZZR0A3Dgev1o8QeIbm8jaC1BggIwcH5m+p7D2Fec6lG0V1FIP4WBrKU76I0jHqzslf9+frWpbsCtYrHExNaNq/FZmhrAho6z7K9/svXFmY4hdQkv8Au5PP4HmkW6LErCN3qx+6P8arm2ad5S7FiQBnHA69B+NNPqJ9j0kEMAQcg8g0VheE7syWRtJTma34Ge6dj/T8K3a3TuYNWCvmz4yRRzfD/TopkWSJ/HsiujjIYGa4BBB6ivpOvPL7wJqdzDe2cl54XvtKmv5r+O21Xw+12Y3kdm6/aVUkb2AO0cGmB5f4sgh0Txn8RtF8IJFD4d/4Q26n1Gztzi3trrbIF2qPlRyuPlAHBJ7cfSdea3HgLXD4W1Tw/Yal4S0vTtRt5beZNP8ADckGBIhRmAF3jdg9SDXpVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARXMgjTPrxWLeTE9K176IzW7BfvjlfrXPh/MXnrQBAZju71ct5unNUZUw2aFkCDJOBQBuRuGFLLMsaFmYAAZJNY89zNb2T3IglaJcZIGBz357e9crqmo3V4cXEbrCOQsb8fj60AdC90L+8Tnbbod/PcDuap39pIshugpw5LMvoKb4ekDLjYETOcZySfeukJUr82MGpeo07HLvbrImVGa5rX7baucV30ulsSXtGUDujdPw9K5vxBCfs7pIpVwM4NZOLRqpJlMSB4IJf76KeO+RV6CJmUedkKf4Af51naWGSwtmkxkLtX2Gf61rI/ygmpKLHQADgelXLBQUf3c/wAhWcHHrWlppHkA/wC0386EIjd5bG8W7tvvpwVPRl7g12Vjdw3tsk9u25G/MH0PvXMTKGyD0qnA9xp1z59o2M/eQ/dce/8AjWkZWJlG53dFYdl4lspQFuibWX0flf8Avr/HFbaOrorowZSMgg5BrRO5k1YWiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVb2/trLZ9olCs/wB1cZJ/AVJeXMNnbST3LiOJBlmJrirq4ivdXa4lR0adB9mdn4AA6ccZzk496ic+VGlOnzvXY7e3njuIhJC25D3qSqmlRhLGMjGXG849TVuqWxD0YUUUUxBRRRQAUUUUAFFFFABRRRQAVzetwNaXBnXmGU56fdNdJSMoYEMAQexoA5a0srm+wyjZEf426fgO9bdlpVva4Yr5so/jft9B2q+KKAIb2AXNpNA3SRCv5ivP/sm6DDjnoR6EV6NXKaxGLW8lDAhJDvQ9jnqPzpMDnbFzbT7DwO1dDIxktdynFYlwiSMGX1zW7p8fn2EqhsZXAPpQByw8UTJeSwWsBmVDtL78c9xiqOveISNPmju7WTcw+VsDCn1zWDZmXTNSmtLn/WRuQSe/PX8a6aaa0urRkuVUkjAHrWTkzVRRieHdQW500LnJjcr+B5/qa6GJ8xjFYj6EdGETBDH9oXzduegyQP0GfxrRtXzGBUllvdWlpsv7ph6Of5A1kFuM0ukXDGWbcflblB9ODSA6LzhmmM4NZzz4PWljuM9adxElzCr9qppf6jpEitZXDCFjgxP8yA/Q9M+2KuCTdUcsaTI0b/dYYovYLGnbeM5wyx3Nghc/xJIQCfoQf51pxeKbc/662uE9wAw/nXFY89olPyyRZLezDgf1Nb1mI5olbAGR09PUVSmyeRHQx+ItMfrcFD/tow/pVuPVLCT7l5bn/toK5lrOJv4RUL6dC3YVXOxch2qTRSfckRvowNPrzyXS4xkqoqrNNf6fE7WFzLGwH3Qcg+2DxR7QXIem0V5vBr+rumRfMQVBB8tP/iaks9Y1ryQ5vGY5IIZFOcH6U/aIORnolFcVF4o1KL/X20Eo9RlD/X+VXofF0JH7+znQ/wCwQ388U+dC5WdPRWHF4o05/vtNH/vRk/yzWpZXtvexl7WVZFBwcdR9RTTTFZosUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMwVSzEBQMkntS1xni7VJGu2sQR9nXG8BuXPXB9ulKTsioq7sR+KLuTUTHLZMGtrZnVyrffHAJGOvQ1SjtYVK25ObWWMSJg/dI649OxqKHeu42+EV+SvUUyWMyBUlnYgDAjj+Xj8Oa5mnJ3Z1qairI7rw5JHJotoYZPMATDN/td/1zWlXJeDLxoZn0+RFjjOXhGMEY6j+tdbXRF3RyS3CiiiqJCiszXNe0rQIYpta1C2sY5X8uNp3ChmwTgepwCfwrI/4WJ4Q/6GPTf+/woA6qisvQvEGk6+kz6LqNtfLCwWQwOG2EjIB9OK1KACiiigAooooAKKKKACiiigApksUc0ZSVFdD1VhkGn0UAZF14fsJo9sUfkN1DR8fpVX+zrrT3j+zs1zB/EAACD/UV0NFAHDa54Uk1i4a4SJYJcZDMfvH04qTwv4PNs8dzqoVpVOViByB6Z7V2tFTyrcd3scT8RLclraZR1UofwOf6n8q4u3l2nmvYNSsYdQtGt7gfKeQR1U+orgdR8IX0Ex+zr58Z6FCB+hNRKLvcuElazMSe4xbuV644HvTDL9m8or0j4/Doa0H8OaqFH+hSkBh6ev1rStPB+oTjM/lQL6O2T+Qz/Op5WW2jINyCc5600TgHg1r3nhG+tEAhC3CDuhwR7YNYlzY3Fs2JopI/99SP50ONgTuW4rjHU1YEwPesX51NPSVh1qRmi8ix3e8YxMuD/vD/AOtV3S7jbLLHnjIYf1/pWDdSkW5buhDj+v6VJb3QW7hcHhgVP+fwoA7FZwe9KZhnrWOlxkA5qQT07isaDyDHWqUwDAiozNmm78mkBk2IMNxPA38LfL/u9R/M1u6aoNqp9WY/+PGsLVG+z3SXA+6VKt+HI/rW3YHy7WJCeVQA/WkhstlB6VE0SkdBT/MFBaqEVZIF7Cs2Xzba8Se3ZkkQZBU4NbWARVK4QeZ/wE/zFVBe8KT0NSLVdRQDbcbx/tqDVlPEV5GR51tFIvfaSp/rWfpiebCmf7o/lVxrYYrNuUXuarkktUb2m6ta6h8sTFJgMmN+G/8Ar/hWhXB3VsVYPGSrqchlOCDXUeH9SOoWpEuBcRHa49fQ/jWlOpzOzMqlLlXNHY1KKKK2MQooooAKKKKACiiigAooooAKKKKACiiigAooooAK8v8AEkSf23dbgcmUk4Yj+XtXqFebeLk2a/ce7A/+OionsXDcdZW0OwZVj9XYj+daUCxxqRGiqPYYqhZH92KsmVYyNzYzwPesTUgupJLO5iu4QC8TbgD39R+IyK720uI7u2iuITujkUMp9jXE3EUs8ZCx4B7ucfpU/gy/e0vJNMuSNkhLwkHgHuv9fzrSDs7ETV1c7SiiitTI5XxV/wAjf4K/6/bj/wBJJq808EeL9Y13xx4vsdW8SeI4YtO12Sys4NN0ZJoBEJCAssotX29AMs6nHOe9emeM7TU31Pw9qGkWK3zafdSSSwmdYiVaCSPIJ46sK4LRfCfiLQtb1jUdFtddsjq182oXdumo2DxvIzEkDfbswXnHDZx3zzQB3nh3/ke/F3/bn/6KNdVXK+ELXVf7c1/U9XsFsPtrQCKITrKcIhUkkcdTXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIyhlIYAg9QaWigDKu/D+mXWS9qqMf4ozt/QcVzmpeDpo8vYSiZf7j4Vvz6H9K7iipcUxqTR47e20kJeG4jeN8YZWGDisFZ3jtwWPzRNz+B5r3i+sre+gMV1EsiH16j6HtXnXiHwBc+ZNJpsgnt258hiFYHvz0I6en41m4WNFNPcy4rvKDmphce9YcUc9uhhuI3jljO1ldSCMexpwnK8VJZurPUqTZPWsJLrnrVmK4B70WEXtSUTWcmf4cN+A5P6Zq9HJhRg9azo5h36d6LOXZGYSeYzt/Dt+mKVhmushp4l96oCUcU4SCgDQEvHWqtxJhpD6KP601WDEYNJbxtPejBBj3/MO/A/xFXT0dyZaqxt6YhUBV7DH5VosvFVICBJHjj1q9kMMioepSVilcR8GquizG112JR9yYGNh+o/Wr833ea57UZWtp450+9Gwcfgc1F7NM2iuZNHo1FMhkWaFJIzlHUMD6g0+uw4QooooAKKKKACiiigAooooAKKKKACiiigAooooAK848eFk1w7UJyinOR9P6V6PXBfEWPbfW0o/jjx+R/+vUT2KhuZtkZJIhucIPReT+Z/wrTtvLhGUXDd2PJP41i6dIdgrUjORWJsaIlDLWLqkbrIk0LFZI23Kw7Ec1cV8UroZ/kXr1Lf3R60xHXaFqSarp6TrgSD5ZEB+63etCvNYTcaLei5sTweJEJ4kHof8a7vSdVttUh3274cffjbhl+o/rW0ZXMpRsX6KKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjXNAs9XUtMpjuAMCVOv4+orzLX9ButKnKzrmMn5JF+63/ANf2r2SormCK5haK4jWSNuCrDINS4plKVjwN1ZDTo52U16XrXgiKUmTTXEZ/55SHI/A9fzzXF6joV1YuRdW7xD+8R8p+h6Vm00aJplOK5NTG4xIrj+MbT9R0/TP5VB9lZe1HkkoyHgHofQ9jUjLgufepBcE96y41dh0wwOCPQ1NHG5I60Aa0d0EUsx4AzWp4bYvCZj7j8Tyf8+9ctfMYoApOC5C/T3rs9Na2/s+MWmfKA79fqaHKyKjFt3NCCTdISwq4G2DB5Has62bL1oBgq5NStSpKwxpA+ccEdqwdYTMbGtQSr9obHOeD7VT1FQ0bdxipki6b1Og8F3f2rQolY5eAmI/h0/Qit2uG8AT+Xf3lqx4kUOB7g4P8/wBK7muilK8Uc1aPLNhRRRWhkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcd8SIibSzl7K7IfxGf/Za7Guc8fReZ4edv+ecit/T+tTLYcdzg9Pf5a1on461zllNtataOfgVgbmgW9OSeAB3NX4VEMW3ILHlj6mse3lDTF8/LHwPdj/gKvLIWoAnkAk4NVlsTLMHiLIEP31ODn0BqXeRtCY3sdqg+v+ea0YdiIqL0UY+vvTEOstVvbLCT/wClRf7Rw4/Hv+P51sQa5Yy4DS+Sx7SjaB+PT9ax2CtUUkCbSWxgck1Sm0S4pnVpcQOQEmjYnoAwOalrhV0xGQs6/O/zHjp7VJFBcW/FvczIPRWIH5Diq5yeQ7aiuQW91WP/AJey49GRf8KVdc1YpuCWpXsTG3Pv96nzoXIzrqK5IeJL+P8A1tpA/wDukr/jTh4tkB/eaawH+zLn+lPnQcrOrormk8YWWCZoLmPHU7QR/OrMHirSZetw0ef+ekbL/SnzIXKzcoqpb6lZXGPIu4Hz2WQZq2DkcUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQeetFFAFC40fTrgkzWcJY9SFwfzFUn8LaSx/492X6SN/jW5RSsh3ZgxeE9Hjl8z7MXbGPmdiP51fi0bTYjlLG2B9TGDV+iiyC7OC+K7x22j2UMaKu+fICjHRT/jWD4VlJgaPPuKvfF+Xfd6XbjkqrufxIA/9BNZ3hgFQOKwqNXsdlKL5EzpLfKyVqJhl5rMiOXPoK0oDxULQJakU1uDkgc+lUJduwxjOQO9a8hxjFZzhSrlR3oZMdDG0mb7F4itJTwpfYfoeP616dXk2r5Rw68EHIr1KwnF1Y2846SRq35iroPdBiVtInoooroOQKKKKACiiigAooooAKKKKACiiigAooooAKx/F67/Dt4PZf/QhWxVfULcXdjcW5482Nkz6EjrSew1ueJRkq5q55/lxFj1HT3pl3bSQXDpIpV1JDKex7ioAd7g/wr09zWBuadtIY4lUn3J9TV2G6HrWGGY9KkLOiMxB4FIDbt7vdcu+eEG1fqep/l+tX47sHvXJxCSGMA/e6n6mpo7pwec0AdhHcA96eZllkWHsfmb/AHR/icD865eO/wBikscAcmp9PviUaVuGkOf+A9h/X8aLhY60SA0FgfSsKO9B71Ol170XFY0pTlQi8M52g+nqfyyak2pgAAADgCsu3ug8jyZ4X5F+vf8ApVgXHvTAttEp7CoWt0PYVGLj3oNyACSeKAIJbOOSZUKjavzt/Qf59Khm0+NjnbVqKbCbm+853H29B+VK0oNAGRJpkZ/hFNjtpoD+4mmj/wBxytarODUZIoAiTU9Wtx8l7IwH98Bv5itvR/FkNxui1BDBMn8Sgsr+p4HFYsmMVnRJi73dvMI/T/69VFvUTS0uejRapYy42XcOfQuAfyNW1YMuVIIPcVwptQw+7TIluLCTzLKRo27js31FSqzW6LdBPZnfUVkaHrKaipikAjukGWTsR6itet1JSV0c8ouLswooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8n+IMn2nxW6dRDGifpu/8AZqg0KfGpXFqQNsUUcgI6/MXGD/3z+tY3i2ZNQvr6eS1uruKW4IAtywYAZwfl56AdKt+CEEVrOscEsCJLgJMoEn3VPzep56nnGK427ts9K3KlE7FWUKQD8zcA1o2pwApGMDjmssMAoJrQtHDBSvemmZNFqXGAST7AVmlHMpLDaMHArUKDIJOSOlVLgnzDj05pshHN6ynyGuz8Dzmfw5bhjkxlo/yPH6YrkdWIZSO9bXw1nzbX1uT9yQSAfUY/9lqaTtUNKq5qXodnRRRXYcIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYev+HLbV2Em8wT9C6jO4e44rEHgTHAv1A/64f/ZV29FS4pjUmjkrfwTbof313I/+4gX+eauSeEdMZFAE6sDncJOfyPH6V0NFHKg5mcrP4NhbPlXcg/66IG/lisq88GXac28kMw9MlT/h+td/RRyIfOzxvU9Lu7efybqF4kB53Dh/YHoRUJ3LXs80Uc0ZSZFkQ9VYZBrnNV8JWlypayP2eX06ofw6j8PyqHT7Fqp3PPUuWXqakkviqhU5kbhR/Wnazptxpkuy7iZCc7SBkN9COtZCB1cyPwegH90VnY0vc6G1uBFEqZ6dz396trcg9zXNpOR3qdLk+tILHQifPeo3kknzHGhZQ2HOQOMZxyayVuvU1JYXpaGRwcBpTj3GAKYjZMkueYn/ADH+NJ5kvaBz+I/xqmt0T1apFuD60AWC83/Pu/8A30v+NJ5soGTbygfUH+tRic+tOEzetACNdxrxIWj/AN9SKjtSJZE29GlJ/L/9VF3NstZXJ+6hP6VN4dtR5UQzlYkCZHdup/z71cNLsmWuh0cKhkGBUc8WQeKs2xzCPyokAxWbRpFnOzl7K7juof8AWRNux6+o/EcV6BDIs0KSxnKOoYH2NcRqiDa1b/g+5+0aKik5aFjGf5j9CKdF2bQV1eKkbdFFFdJyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR1y7+w6Ne3WcGKFmH1xx+tXq5X4mXX2bwpOgPzTukQ/PJ/QVM3aLZdOPNNI8OGmyzXc7rpjyM54IeMh+Ou5kJX6Cu08GJ5WlsCGV/PcFXfzGBB24LfxdBz6YrlfMS+tEaBUuSNxUmKcrzwMMgPGBXZeHoRaaBZxOjRuE+667Sp+n+PPrzXGtj0J/EbEavcSYJZUA9MVsWMYjUBck+pqjZK2wb2DZ6YrUgxnHerRjIsAA1DMgwT61YAwKjlHymmyEc3qsQYk46UeAZvJ8RSwk8TRED6gg/yzVrUUyprG0V/sviexk6ZlCf99fL/Ws72mmbpXg0erUUUV3HnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAR3EEVzC0VxGskbdVYZBriNf8GMMy6US694WbkfQnr+Nd3RScU9xptbHhV1byQSMkiMjqcFWGCD9KqmRlNe065oNnq6ZmXZOBhZkHzD2PqPb8sV5l4k8PXekv+9TfGxwkifdY+/p/nrWMotG0ZpnPyzl8RKcZ+8fQVZtLnECgcAsSPpnj+VUpbd4kPeVzjPqaf5RQBR0UACpKNNbn3qZbisddwqVXNAG1HcE96tRSZrEhc8Vfhf60AaEjBtiHozDP4c10NiqRWqnozZb8zXN2EL3mohV/1cK5c59e36V0ZPIHpTbskghG7uaUJKqvPAqRyMdaggPyU26G2PKk7u1TuPZlLURlTTfAt15Wp3Vox4lXeo9x/wDWP6U+5+ePOc8c1iWM/wBh1+1nY4USAMfY8H+dQnyyTNbc0Gj1Ciiiu04AooooAKKKKACiiigAooooAKKKKACiiigAooooAK82+MN3j+zLX5jy0rBQSewHH516TXjnxOujL4qKBFkESxwAMcLlvX/vqsa79yx0YVXqX7HCWukbNTEskm4TMzKJLeQHjnHDID+Rr0W0UyxQBsttUYVVKjp6HpXLT6QII471LbTgbb5mUW33lIw2eew5/Cuwi8+KPaRGXHTylKrj0xk1hFnTLc09Pcx4SUY9PatmBMc1jQ2ryOpdxsBzgCtyLoKsxZL2qOQcVKKjk6UCMq9GRXMX5MFykq9UYMPwNdTedK5nV1zk1lM6KZ60CCAR0NFVdLl87TLWT+/Ep/SrVd61POas7BRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApksUc0bRzIro3BVhkGn0UAc3qfg7TLsh4ENrMucFOV5/2T/TFc1eeC76Jj5SRzr2KOAfyOP5mvSaKlwTKUmjyGbw5fxnDWVxn/AGYy38s1B/Yl4D/x5XX/AH4f/CvZaKn2aK9ozyCHQ75j8tjdfjCw/pWvZ+F9Tkxm3EQ9ZHA/lk/pXpFQX84tbG4uG6RRtIfwGaPZoOds8X0PUZrbVJozJujaQhsdCemcV2RfLAivNtFBa55PJNejQ8woT6VgzttY1rVsgUXUTOvBI+lRWp4FXe1NGMkZEiujBSBt6msPVo+Sa6S/TehxgH1rE1GP5D3xWc0a0md9od19s0i0nJyzRjcf9ocH9QavVy/gC48zTJoCeYZMgezDP8wa6iuyDvFM4qkeWbQUUUVRAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4xrcaajr+ptMoeN5WUg9wDgfyr2evHbZd800h6u5P61z1+h14Xdsjt9LnljaA38ptXGGVkDPt7qG/qQT710SoG4Tg1VtVxj3rQgTDZrKJtMmsdyZ8zr9K042IKgjg1XhHSriAcZq0YskFMk6U8cD1pj96ZKMy8rnNUGVNdHeVz+oDIasZnRTO+8LP5nh6wP/TID8uK1aw/BLbvDdr7bh/48a3K7YfCjhqaTYUUUVRAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWH44l8nwnqTA4LRbP++jj+tblcj8Tp/L8PLDnmeZVx7Dn+gqZu0WzSkrzSPMtEhIlBrurcFoVFczpEGxd2M45rprQ7kHOK5Ed8y/A+2QJ2xkmtAfdrNtwDnJzmtCMnGAM4qkc8inffLGCxxg5x61k3mXjyRgkVuSw7kLOAX6ism7A8vjOPelIqm9STwBN5eqXUB/5aRhh/wABP/167yvMNAm+zeJLR88M+w/QjFen1tQd42MsSvfv3CiiitjnCiiigAooooAKKKKACiiigAooooAKKKKAGyNsjZvQE15JZLhQK9Xvjtsrg+kbfyrzKCIjtXPX6HXhtEy1CPu4rQhFU4V5q/CKyRrIuQirSdKrwirKirRix4pknengU1xTEjKve9YV8M5roLxax7mLPaspI3gzp/ApP9gID/DI4/WuhrA8FLs0h1PaVv5Ct+uun8KOOr8bCiiirMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvO/iZN52p2FqD/AKtDIR7k4H8q9ErybxLcfbPF14wOViYRD/gI5/XNY13aNjpwsbzv2JLGMKorSRxGuTVO2TkZqZtpk2yDd9DzWCOmTLdoZZJFcJhfUmtqEYQDvVK3XAAHQVeQHHFUjGQkylkYetZF/F8hxxitxulZV6vBokKJyspaC4jl/iRww/A5r1yJxJGjr0YAivKtSTqa9E8NTfaNCsnJ5EYU/hx/SqoPVoeJXupmnRRRXScYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFdrvtJ1HdGH6VxxsCvau2YZBHrVV7VT2qJx5jSnPlOVW1IPSrEcJHatxrMelJ9kA7Vn7M09rczo4jxVhUNXFt8dqeIvanyEuZTCGkaM+lX/Ko8qnyi5jGnty3aqj2RPauiMGaBbD0pcg1UsV/D8Pk2ki/wC2T+grTqOCMRqQPXNSVqlZWMpO7uFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACMQqlmOABk14vYMbi8mnflpHLn8TmvVvE0/wBm0C/kBwfKZR9TwP515npMO1c4rmr6tI7cKrRbNRCsUe45z2ApLSRo5AZP4j930p/lh48kkYpIjGoZQmSOvHNQipM3Ih8oK1diGFArN0kuVYsCEz8oNaq1SMmDdKz7xc5rRbpVK6HWhjic7qEeVNdZ4Gfdoez/AJ5ysv8AI/1rnbxMqa1/AbYjvovRlf8AMEf0pUtJlVtaZ1dFFFdZxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYpMClooATApcCiigAwKMCiigAwKMUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOePHxogiHWWVQfoMn+grlLGHbGOK6nxkhlNpGOg3Mf0/wDr1kQ2+1elc1RXkdlJ2gRCPKFexpsOIZMBPmPHrmrbxHbx1qaGAMo3LyKSQ2y1DgAZq0nIGOahghCnufrU8cfljFOxm2KRxVW4XNXtvFQyx5osCZjXEWQat+EFMeo3K9mjz+R/+vUrwZHSptFi8rUt395Cv8j/AEojG0kypSvFo6Giiiuk5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDI1eHzbpP8AZT+pqoLbA6VszJumJ9gKYYhWbjdmqnZWMhYMg5HIqZIMdq0fJFAipcoc5VSL2qQR1YCU4JT5RcxWEQGfekMWat7KXZRyhzFLyfanW0Wy5Rvr/KreylVcODTSFzEtFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIVySaQrRRQAbaNoxRRSANtLtoopgG2jbRRQAYoxRRQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is a&nbsp;basic example of the application of a compression bandage for the treatment of chronic venous insufficiency. The bandage is applied from the toes to the tibial tuberosity, moving from distal to proximal in an overlapping manner. Care is taken to avoid bunching or wrinkling of the dressing&nbsp;during application which can cause localized pressure.&nbsp;Multilayer&nbsp;compression bandages have two to four layers including a layer of soft padding and at leasat one elastic layer; each layer is applied in a similar manner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7074=[""].join("\n");
var outline_f6_58_7074=null;
var title_f6_58_7075="Chronic eosinophilic pneu Light";
var content_f6_58_7075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intermediate power photomicrograph showing a combination of air space filling and interstitial thickening in a patient with chronic eosinophilic pneumonia. The air space infiltrate compromises a combination of histiocytes and eosinophils. A similar inflammatory infiltrate is responsible for the associate alveolar septal thickening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7075=[""].join("\n");
var outline_f6_58_7075=null;
var title_f6_58_7076="AIP phlebitis Light HP";
var content_f6_58_7076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a pancreas biopsy in a patient with autoimmune pancreatitis. Obliterative phlebitis is present focally (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7076=[""].join("\n");
var outline_f6_58_7076=null;
var title_f6_58_7077="Assessment of cancer pain";
var content_f6_58_7077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of cancer pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Lara K Dhingra, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7077/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7077/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain due to cancer is a complex symptom that affects most aspects of a person's life, including physical functioning, the performance of activities of daily living, psychological and emotional status, and social interactions.",
"   </p>",
"   <p>",
"    The prevalence of pain among cancer patients varies widely and is influenced by numerous factors, including the population evaluated, the specific type of cancer and its extent, and the treatment setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/1\">",
"     1",
"    </a>",
"    ]. The estimated prevalence of chronic pain in populations undergoing cancer treatment ranges from 33 to 50 percent, and it is considerably higher (over 70 percent) in patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high prevalence of cancer pain and its potential for profound adverse consequences, all patients with active malignancy should be routinely screened for pain. Patients who report pain require a more comprehensive assessment and specific treatment.",
"   </p>",
"   <p>",
"    This topic review will cover cancer pain assessment. Classification of the different syndromes of pain in cancer patients and treatment of cancer-related pain are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANCER PAIN ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer pain assessment is a complex undertaking. The evaluation begins with a thorough history of both the pain and the underlying malignancy as well as its treatment. Because of the potential impact of pain on quality of life, it is also essential to determine the adverse effects of pain on physical and psychosocial well being, as well as the spiritual impact of the pain. Cancer pain may linger after the cancer is removed (as examples, post mastectomy, post amputation or post thoracotomy syndrome), and this may have important psychological and spiritual impact [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of cancer pain syndromes\", section on 'Postsurgical pain syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, other physical symptoms and both medical and psychiatric comorbidities should be characterized, as they may be independent targets for therapy. The painful site should be examined in detail and other physical findings relevant to the patient's medical status (both in terms of the cancer and medical comorbidities) should be noted.",
"   </p>",
"   <p>",
"    The patient's description of the pain, findings on physical examination, objective data from imaging and other tests, and information about the extent of the malignant disease and its treatment are all utilized to assess the likely etiology and underlying pathophysiology of the pain, and if possible, identify a specific cancer pain syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pain characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a subjective and multidimensional experience. To optimize care, the pain report should be characterized in terms of multiple domains, beginning with clinically relevant descriptors: intensity, temporal features, location and patterns of radiation, quality, and factors that provoke or relieve the pain. This information may be sufficient to identify a specific pain syndrome (ie, a constellation of clinically meaningful signs and symptoms) that may help to elucidate the etiology, direct the diagnostic evaluation, clarify the prognosis, and suggest the appropriate therapeutic interventions. While the disease process may not be reversible, particularly for metastatic disease, the pain is often reversible with specific treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This information may also allow for inferences regarding the underlying pathophysiology, or it may suggest and guide the need for more information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinical setting, pain intensity is often measured simply by using a verbal rating scale (eg, \"mild,\" \"moderate,\" or \"severe\") or a numeric scale (eg, \"how severe has your pain been, on average, during the past week, on a scale of zero to ten, where zero is no pain and ten is the worst pain you can imagine?\", (",
"    <a class=\"graphic graphic_form graphicRef82442 \" href=\"UTD.htm?42/4/43084\">",
"     form 1",
"    </a>",
"    )). A visual analogue scale (VAS), which is a continuous line, usually 10 cm long and anchored on the ends by \"no pain\" and \"worst possible pain\", also may be used. Pain intensity should be tracked over time using the same rating scale and specific time frame (eg, \"pain right now\", \"during the past day\", or during the past week\").",
"   </p>",
"   <p>",
"    Formal instruments also have been developed that describe pain in multiple dimensions. An example is the Brief Pain Inventory (BPI), a patient self-rating scale that assesses pain intensity and pain interference in various areas of function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/3\">",
"     3",
"    </a>",
"    ]. A short-form version of the BPI is available",
"    <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"     (BPI-SF)",
"    </a>",
"    . An older tool is the McGill Pain Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/4\">",
"     4",
"    </a>",
"    ], which assesses the sensory, affective and evaluative components of pain. Yet another is the Memorial Pain Assessment Card, which measures pain intensity, pain relief and mood on simple VAS's and verbal scales [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Temporal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal assessment of the pain may include information about type of onset, duration, course, and daily fluctuation. Acute pain syndromes usually have a well-defined onset and a readily identifiable cause (eg, surgery). The pain is expected to run its course in a short time frame and management typically focuses on symptomatic relief until this happens.",
"   </p>",
"   <p>",
"    In contrast, chronic pain is often characterized by an ill-defined onset and a prolonged, fluctuating course. Overt pain behaviors (eg, grimacing) and sympathetic hyperactivity are typically absent, but vegetative signs, including lassitude, sleep disturbance, and anorexia, may be present. The patient usually does not appear to be in pain, and the only definitive way to determine the presence of pain is to obtain a verbal report from the patient.",
"   </p>",
"   <p>",
"    Most patients with chronic cancer pain also experience periodic flares of pain, often referred to as \"breakthrough pain\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/6\">",
"     6",
"    </a>",
"    ]. One important subtype of breakthrough pain is \"incident pain\", which is a pain flare that is precipitated by voluntary activity. The recognition of breakthrough pain as a significant problem in cancer patients led to the concept of so-called \"rescue\" dosing, ie, doses of a short-acting opioid administered on an as-needed basis to manage pain flares during long-term opioid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H20#H20\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Management of breakthrough pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other pain characteristics are important to assess. The quality of the pain (eg, aching, sharp, stabbing, burning, etc.) provides information that may help distinguish between nociceptive and neuropathic pain syndromes (see below). The assessment of pain location and referral patterns, and identification of specific factors that can provoke or reduce pain may help to clarify the etiology and elucidate a treatment approach that includes management of precipitants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pain etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain in a cancer patient usually, but not always, has a cause related to the disease itself or its diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment (ie, chemotherapy, radiation therapy, surgery). Identifying the etiology can clarify the status of disease, potentially altering the prognosis or informing the plan of care for treatment. Furthermore, clarifying the etiology of pain can sometimes reveal an opportunity for disease-modifying therapy that may provide some analgesic benefit. As an example, radiation therapy is often performed with pain relief as the primary goal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the etiology of pain is related to the disease, it usually involves direct invasion of pain-sensitive structures by the neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/7\">",
"     7",
"    </a>",
"    ]. Bone is the most common pain-sensitive structure affected by the tumor. Other etiologies include injury to or invasion of a component of the nervous system, obstruction of a hollow viscus, distention of organ capsules, distortion or occlusion of blood vessels, or infiltration of adjacent soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inferred pathophysiology (types of cancer pain)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effort to identify an etiology for the pain implies the characterization of a medically verifiable lesion or disorder that is driving the neural processes that culminate in the experience of pain. In contrast, the effort to characterize the pathophysiology of pain does not attempt to identify a verifiable disease state, but rather, supports an inference about the types of pathophysiological processes that may be sustaining the pain.",
"   </p>",
"   <p>",
"    Although these processes cannot be definitively determined in patients, clinicians are able to integrate findings from the pain history, physical examination, and objective tests to draw these inferences and apply broad labels, such as \"nociceptive\" or \"neuropathic\" pain. These labels represent a gross simplification of very complex neurophysiologic and neurochemical processes, but are conventionally accepted because clinical experience and a large body of clinical research literature indicates that this categorization can be useful in suggesting specific treatment approaches.",
"   </p>",
"   <p>",
"    The inferred pathophysiologies for cancer pain may be designated as nociceptive, neuropathic, or psychogenic; mixed disorders are extremely common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/8\">",
"     8",
"    </a>",
"    ]. Those disorders that cannot be categorized are called idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nociceptive pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nociceptive pain is sustained predominantly by ongoing tissue injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatic nociceptive pain involves injury to somatic structures like bone, joints, or muscles. It is often described by patients as \"aching\", \"stabbing\", \"throbbing\", or \"pressure-like\" in quality.",
"     </li>",
"     <li>",
"      Visceral nociceptive pain involves injury to viscera. It is usually characterized as \"gnawing\" or \"crampy\" when arising from the obstruction of a hollow viscus (eg, the bowel lumen), and as \"aching\" or \"stabbing\" when arising from other visceral structures, such as organ capsules, myocardium, or pleura.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is labeled as neuropathic if the results of the evaluation suggest that it is sustained by abnormal somatosensory processing in the peripheral or central nervous system. Neuropathic mechanisms are involved in approximately 40 percent of cancer pain syndromes, and can be caused by either the disease or its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysesthesias, uncomfortable sensations that are perceived as abnormal and described using terms such as \"burning\", \"shock-like\" or \"electrical\", suggest an underlying neuropathic mechanism for the pain. Physical examination findings of allodynia (ie, pain induced by non-painful stimuli), hyperalgesia (ie, increased perception of painful stimuli), or other sensory findings also suggest the presence of neuropathic pain. Patients may have other concomitant neurological findings, such as weakness or changes in reflexes, and some patients have autonomic dysfunction within the anatomic distribution of the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Psychogenic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"psychogenic pain\" is used to describe pain that is believed to be sustained predominantly by psychological factors. It does not refer to the common observation that pain experienced by some patients is exacerbated by psychological factors, or that they have pain-related distress or comorbid psychiatric disease. Rather, the term should be considered a generic label to be applied to a number of psychiatric syndromes (eg, Somatization Disorder, Pain Disorder Associated with Psychological Factors, and Pain Disorder Associated with Both Psychological Factors and a General Medical Condition) that are described in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition Text Revision (DSM-IV-TR) by the American Psychiatric Association [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7077/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychogenic pain appears to be rare in the cancer population. The label should not be applied unless the assessment reveals evidence of psychopathology that is believed to be specifically related to the occurrence of the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain in the patient with a history of cancer is a complex symptom that affects most aspects of a person's life, including physical functioning, the performance of activities of daily living, psychological and emotional status, and social interactions.",
"   </p>",
"   <p>",
"    Assessment of an acute (eg, postsurgical) pain is usually straightforward. If the cause is apparent, no further assessment may be needed. On the other hand, cancer patients with chronic pain are more challenging because of the heterogeneity in specific cancer diagnoses, disease activity, past and present history of disease-modifying therapies, prior evaluation and efforts at pain control, impact of pain on quality of life, and existence of relevant medical and psychiatric comorbidities.",
"   </p>",
"   <p>",
"    This complexity calls for a systematic approach to assessment. The major goals of the assessment are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characterize the pain and its impact on physical functioning and quality of life (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pain characteristics'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Become aware of prior testing and treatments performed specifically for the pain",
"     </li>",
"     <li>",
"      Understand the pain in terms of etiology (disease-related, treatment-related, or neither), inferred pathophysiology (nociceptive, neuropathic, psychogenic or mixed), and identify a specific pain syndrome, if possible (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Inferred pathophysiology (types of cancer pain)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clarify the extent of neoplastic disease and opportunities for antineoplastic treatment",
"     </li>",
"     <li>",
"      Note comorbidities, including other symptoms, medical disorders, and",
"      <span class=\"nowrap\">",
"       psychiatric/psychosocial",
"      </span>",
"      problems that may be targets for treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The information obtained from the history, physical examination, and imaging studies can lead to changes in the plan of care, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recommendations for additional evaluation to clarify the etiology or pathophysiology of the pain, or disease extent",
"     </li>",
"     <li>",
"      Recommendations concerning a disease-modifying therapy (eg, radiation) that may address the etiology of the pain. Recognition that a new pain might indicate a serious new morbidity, eg, back pain related to epidural spinal cord compression, may also suggest the need for urgent treatment.",
"     </li>",
"     <li>",
"      Developing a short-term and longer-term plan for symptomatic analgesic therapy",
"     </li>",
"     <li>",
"      Addressing other symptoms or medical or",
"      <span class=\"nowrap\">",
"       psychiatric/psychosocial",
"      </span>",
"      comorbidities that may be contributing to suffering",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/1\">",
"      Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/2\">",
"      Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 2002; 24:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/3\">",
"      Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/4\">",
"      Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/5\">",
"      Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.",
"     </a>",
"    </li>",
"    <li>",
"     Fine PG. Breakthrough pain. In: Cancer Pain, Bruera E, Portenoy R (Eds), Cambridge University Press, New York 2003. p.408.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7077/abstract/7\">",
"      Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82:263.",
"     </a>",
"    </li>",
"    <li>",
"     Foley KM. Acute and chronic cancer pain syndromes: Oxford Textbook of Palliative Medicine, 3rd, Oxford University Press, New York 2004. p.298.",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, 4th, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2795 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7077=[""].join("\n");
var outline_f6_58_7077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANCER PAIN ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pain characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Intensity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Temporal assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pain etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inferred pathophysiology (types of cancer pain)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nociceptive pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Psychogenic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2795|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?42/4/43084\" title=\"form 1\">",
"      Visual analog pain scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7078="Treatment of bicuspid aortic valve stenosis in adults";
var content_f6_58_7078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of bicuspid aortic valve stenosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Martin G Keane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Martin G St. John Sutton, MBBS, FRCP, FACC, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7078/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only definitive therapy for aortic stenosis is aortic valve replacement. A congenitally bicuspid valve is a common cause of aortic stenosis requiring surgery in all age groups. This was illustrated in a report of 932 adults with isolated nonrheumatic aortic stenosis who underwent operative excision of the stenotic valve; none underwent mitral valve replacement, none had mitral stenosis, and none had undergone previous aortic valvulotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/1\">",
"     1",
"    </a>",
"    ]. A congenitally malformed valve was present in 54 percent: 49 percent had a bicuspid valve and 4 percent had a unicuspid valve (mostly in patients &le;50 years of age).",
"   </p>",
"   <p>",
"    The causes according to age at the time of aortic valve replacement were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 7 percent of patients who underwent surgery at &le;50 years of age, approximately two-thirds had a bicuspid valve and one-third had a unicuspid valve.",
"     </li>",
"     <li>",
"      Among the 40 percent of patients who underwent surgery between the ages of 50 and 70, approximately two-thirds had a bicuspid valve and one-third a tricuspid valve; a unicuspid valve was rare.",
"     </li>",
"     <li>",
"      Among the remaining patients over age 70, approximately 60 percent had a tricuspid valve and 40 percent had a bicuspid valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different aspects of therapy of bicuspid aortic valve stenosis in adults will be briefly summarized here with links to more complete discussions in the appropriate general topics on aortic stenosis. The management of congenital aortic stenosis in children and the etiology, natural history, and clinical manifestations of congenital aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only effective treatment for symptomatic aortic stenosis is valve replacement. In patients who refuse or are not candidates for surgical intervention, therapeutic options are limited and of only marginal benefit.",
"   </p>",
"   <p>",
"    Among asymptomatic patients with aortic stenosis, many have concurrent cardiac conditions that require medical therapy, including hypertension, coronary heart disease, atrial fibrillation, and left ventricular dysfunction. Prevention of progression of aortic stenosis is another potential goal. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue in patients with bicuspid aortic valves is the possible role for beta blockers in patients with aortic root dilatation who are not candidates for surgical correction. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for screening of relatives of patients with bicuspid aortic valve were not included in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    valve guidelines with 2008 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines recommend echocardiographic screening for the presence of bicuspid aortic valve for first-degree relative of patients with bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for physical activity and exercise in patients with bicuspid aortic valves need to take into account three issues: the presence and severity of aortic stenosis, the presence of severity of aortic regurgitation, and the presence of aortic root dilatation. Issues related to aortic stenosis and aortic regurgitation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link&amp;anchor=H16#H16\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Physical activity and exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H14#H14\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Physical activity and exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to aortic root dilatation in patients with bicuspid aortic valves, the 36th Bethesda Conference made the following recommendations according to the intensity and type of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with no aortic root dilatation (diameter less than 40 mm or the equivalent adjusted for body surface area in adolescents) and no significant aortic stenosis or aortic regurgitation can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Patients with increased aortic root diameters between 40 and 45 mm can participate in low and moderate static or dynamic sports (class IA, IB, IIA, IIB) as long as there is no potential for bodily collision or trauma (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with aortic root diameter greater than 45 mm should participate only in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic stenosis in women of child-bearing age is, in developed countries, primarily due to a congenital bicuspid aortic valve; rheumatic heart disease is now a rare cause. Issues related to pregnancy in women with bicuspid aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NONCARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unoperated aortic stenosis may require noncardiac surgery. This may be associated with increased risk, since significant aortic stenosis may be a risk factor for perioperative fatal or major nonfatal cardiac events. The management of such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/14/13544?source=see_link\">",
"     \"Noncardiac surgery in patients with aortic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of progressive aortic valve and aortic disease in patients with a bicuspid aortic valve, we recommend the following approach to serial monitoring that is based upon the severity of aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ) and the severity of aortic regurgitation, which is defined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Severity of AR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every year for aortic jet velocity &gt;4.0",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      (severe aortic stenosis) or severe aortic regurgitation.",
"     </li>",
"     <li>",
"      Every one to two years for aortic jet velocity 3.0 to 4.0",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      (moderate aortic stenosis) or moderate aortic regurgitation.",
"     </li>",
"     <li>",
"      Every two to five years for aortic jet velocity &lt;3",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      (mild aortic stenosis) or mild aortic regurgitation.",
"     </li>",
"     <li>",
"      Every year if the ascending aorta maximum dimension is &gt;40 mm (normal &le;35 mm). If the aortic root (sinuses of Valsalva, sinotubular junction, and ascending aorta) are not well visualized on echocardiography, cardiac CT or MRI imaging should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with normal aortic valves, the valve area is 3.0 to 4.0 cm2. As aortic stenosis develops, a minimal valve gradient is present until the orifice area falls by more than 50 percent.",
"   </p>",
"   <p>",
"    In general, symptoms in patients with aortic stenosis and normal left ventricular systolic function rarely occur until the valve area is &lt;1.0 cm2, the aortic jet velocity is over 4.0",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the mean transvalvular gradient exceeds 40 mmHg (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ). However, many patients do not develop symptoms until even more severe valve obstruction is present, while some patients become symptomatic when the stenosis is less severe, particularly if there is coexisting aortic regurgitation.",
"   </p>",
"   <p>",
"    The major symptoms associated with aortic stenosis, which typically occur with exertion, are dizziness or syncope, chest pain that may be typical of angina, and heart failure (eg, dyspnea). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Average survival after the onset of symptoms is only two to three years, with a high risk of sudden death (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, correction of the aortic stenosis is recommended in symptomatic patients. In addition, surgery may required for aortic root abnormalities. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Valve and aortic root replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for aortic valve replacement, the choice of valve, and the role of transcatheter aortic valve replacement are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef68344 \" href=\"UTD.htm?29/2/29740\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Balloon valvotomy in young adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the limited role for balloon valvotomy in older adults, it is often used in children with congenital valvar aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link&amp;anchor=H18#H18\">",
"     \"Valvar aortic stenosis in children\", section on 'Balloon valvotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of valvular heart disease concluded that balloon valvotomy also has a role in adolescents and young adults in a variety of settings (",
"    <a class=\"graphic graphic_table graphicRef51270 \" href=\"UTD.htm?6/35/6716\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"     2",
"    </a>",
"    ]. An age definition of young adults was not provided as there were insufficient data to determine an age cut-off.",
"   </p>",
"   <p>",
"    The potential efficacy of balloon valvotomy in young adults with congenital aortic stenosis was illustrated in a report of 18 patients aged 17 to 40 (mean age 23) in whom balloon valvotomy produced a significant acute decrease in the gradient across the valve and an increase in aortic valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/6\">",
"     6",
"    </a>",
"    ]. There were no deaths, myocardial infarctions, or embolic events. Short- and intermediate-term follow-up (38 months) were encouraging, with 50 percent of patients requiring no further intervention. Absence of valve calcifications was the most important predictor of remaining incident-free.",
"   </p>",
"   <p>",
"    A second report evaluated balloon valvotomy in 15 patients who were 16 to 24 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/7\">",
"     7",
"    </a>",
"    ]. Three patients required aortic valve replacement: two for a residual gradient &ge;70 mmHg, and one for severe aortic regurgitation four years later. The remaining 12 patients underwent elective follow-up catheterization at 1.2 to 2.5 years. The mean peak systolic aortic valve gradient fell from 73 mmHg preoperatively to 35 mmHg immediately after valvotomy to 30 mmHg at follow-up. The outcomes were similar to those in 70 children (mean age six years) who underwent aortic balloon valvotomy at the same institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valve and aortic root replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;An area of some controversy in patients with a bicuspid aortic valve who require aortic valve replacement is whether the aortic root should be replaced at the some procedure. Proximal aortic abnormalities and enlargement are common in these patients and carry a long-term risk of dissection and aneurysm formation. However, the potential benefit of proximal aortic root replacement must be balanced against the added operative morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines made the following recommendations for therapy in patients with bicuspid aortic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"     2",
"    </a>",
"    ]. For each of the threshold aortic root or ascending aorta diameters, lower values may be considered in men or women of small stature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients undergoing aortic valve replacement, concurrent repair of the aortic root or replacement of the ascending aorta is indicated if the aortic root and ascending aorta diameter is greater than 45 mm. We feel that, in patients with a maximum aortic root dimension between 40 and 45 mm who undergo aortic valve replacement, the potential benefit of proximal aortic root replacement at the same procedure must be weighed against the increased operative morbidity and mortality.",
"     </li>",
"     <li>",
"      Independent of the need for aortic valve replacement, repair of the aortic root or replacement of the ascending aorta is indicated if the aortic root and ascending aorta diameter is greater than 50 mm or the rate of increase is &ge;5 mm per year.",
"     </li>",
"     <li>",
"      Patients with aortic root or ascending aorta diameter greater than 40 mm should undergo yearly imaging with echocardiography, cardiac magnetic resonance, or CT to assess the size and morphology of the aortic root and ascending aorta. We suggest that among patients with a maximum aortic root dimension &gt;40 mm who undergo aortic valve replacement, the potential benefit of proximal aortic root replacement must be weighed against the added operative morbidity and mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for this approach comes from a follow-up study of almost 200 patients with bicuspid aortic valve who underwent aortic valve replacement and were followed for a mean of 10.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/8\">",
"     8",
"    </a>",
"    ]. Twenty-two patients had a long-term complication related to the ascending aorta, mostly aortic aneurysm. Estimated 15-year freedom from an aortic complication was 86 percent in the 57 percent of patients with a baseline aortic diameter &lt;40 mm, 81 percent in the 32 percent of patients with a baseline aortic diameter of 40 to 44 mm, and only 43 percent in the 11 percent of patients with a baseline aortic diameter of 45 to 49 mm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with bicuspid aortic valves who have an aortic root diameter greater than 40 mm, are not candidates for surgery, and do not have moderate or severe aortic regurgitation, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence or opinion was in favor of the administration of beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"     2",
"    </a>",
"    ]. Lower threshold values for aortic root diameter may be considered in men or women of small stature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20526591\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A congenitally bicuspid valve is a common cause of severe aortic stenosis in all age groups. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only effective treatment for symptomatic aortic stenosis is valve replacement. In patients who refuse or are not candidates for surgical intervention, therapeutic options are limited and of only marginal benefit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-degree relatives of patients with bicuspid aortic valve should be screened for the presence of a bicuspid aortic valve. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for physical activity and exercise in patients with bicuspid aortic valves need to take into account the presence and severity of aortic stenosis, the presence of severity of aortic regurgitation, and the presence of aortic root dilatation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical activity and exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial echocardiographic monitoring for assessment of aortic valve disease and ascending aorta dilation is recommended in patients with bicuspid aortic valve. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Echocardiographic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for aortic valve replacement and choice of valve are discussed separately (",
"      <a class=\"graphic graphic_table graphicRef68344 \" href=\"UTD.htm?29/2/29740\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"       \"Indications for valve replacement in aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to the limited role for balloon valvotomy in older adults, it is often used in children with congenital valvar aortic stenosis and it also has a role in selected young adults. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Balloon valvotomy in young adults'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link&amp;anchor=H18#H18\">",
"       \"Valvar aortic stenosis in children\", section on 'Balloon valvotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision on whether a patient with bicuspid aortic valve who requires aortic valve replacement should undergo concomitant aortic root replacement depends upon the size of the aortic root. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Valve and aortic root replacement'",
"      </a>",
"      above.) Concomitant aortic root replacement is generally recommended if the aortic root and ascending aorta diameter is greater than 45 mm. Lower threshold values may be considered in individuals of small stature. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Valve and aortic root replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/1\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/2\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/3\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/4\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/5\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/6\">",
"      Rosenfeld HM, Landzberg MJ, Perry SB, et al. Balloon aortic valvuloplasty in the young adult with congenital aortic stenosis. Am J Cardiol 1994; 73:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/7\">",
"      Sandhu SK, Lloyd TR, Crowley DC, Beekman RH. Effectiveness of balloon valvuloplasty in the young adult with congenital aortic stenosis. Cathet Cardiovasc Diagn 1995; 36:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7078/abstract/8\">",
"      Borger MA, Preston M, Ivanov J, et al. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? J Thorac Cardiovasc Surg 2004; 128:677.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8155 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7078=[""].join("\n");
var outline_f6_58_7078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20526591\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL ACTIVITY AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NONCARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ECHOCARDIOGRAPHIC MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Balloon valvotomy in young adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valve and aortic root replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20526591\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8155|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4094\" title=\"figure 2\">",
"      Natural history of AS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 1\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/2/29740\" title=\"table 2\">",
"      ACC AHA AVR in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10204\" title=\"table 3\">",
"      ACC AHA selection aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/35/6716\" title=\"table 4\">",
"      BAV AS adolescents young adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/14/13544?source=related_link\">",
"      Noncardiac surgery in patients with aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7079="Approach to the child with persistent tearing";
var content_f6_58_7079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with persistent tearing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7079/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Michael Cassidy, COT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7079/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct obstruction is the most common cause of persistent tearing, infection, and ocular discharge in children. The other causes range from mild self-limited conditions to sight-threatening ocular emergencies (",
"    <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"     table 1",
"    </a>",
"    ). Associated signs and symptoms usually help to narrow the differential diagnosis and permit appropriate triage of children with these complaints.",
"   </p>",
"   <p>",
"    The anatomy of the lacrimal system and the differential diagnosis, evaluation, and treatment for persistent tearing in infants and children are reviewed here. Nasolacrimal duct obstruction and conjunctivitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29350?source=see_link\">",
"     \"Nasolacrimal duct obstruction (dacryostenosis) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE LACRIMAL SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of tears is to keep the ocular surface moist and flushed clear of debris and bacteria. The tear film is partly responsible for corneal clarity and the transmission of a focused image to the retina.",
"   </p>",
"   <p>",
"    Tears are produced by the lacrimal and accessory lacrimal glands and drain through the lacrimal drainage system, which begins at the punctum, a small opening on the medial surface of each eyelid (",
"    <a class=\"graphic graphic_figure graphicRef53429 \" href=\"UTD.htm?20/48/21252\">",
"     figure 1",
"    </a>",
"    ). The punctum is the opening of the canaliculus, which drains into the common canaliculus and then into the lacrimal sac. There are two canaliculi for each eye. Tears that collect in the lacrimal sac drain through the nasolacrimal duct and into the nose via the inferior meatus, located below the inferior turbinate. The valve of Hasner, a mucosal flap at the distal end of the nasolacrimal duct, prevents air from entering the lacrimal sac when the nose is blown; the valve of Hasner is called the \"membrane of Hasner\" if it hasn't opened. Tears are swallowed after they pass from the nose into the posterior pharynx.",
"   </p>",
"   <p>",
"    Tear drainage is both passive and active. Gravity is responsible for passive drainage. Blinking facilitates active drainage by causing negative pressure in the canaliculus and lacrimal sac; the negative pressure draws tears into the lacrimal drainage system [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tear production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tears are produced by the lacrimal and accessory lacrimal glands. The lacrimal glands are located in the",
"    <span class=\"nowrap\">",
"     upper/outer",
"    </span>",
"    quadrant of the orbit and produce \"reflex\" tears when the eye is irritated or stimulated by emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/2\">",
"     2",
"    </a>",
"    ]. The accessory lacrimal glands are scattered along the conjunctiva of the eyelid and produce the basal (resting) tears that keep the eye moist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tear composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tear film is composed of three layers, each of different composition. The inner mucin layer smooths the surface of the eye and makes it wettable. The middle aqueous layer consists primarily of water and provides the bulk of the tear film. The outer lipid layer coats the other layers to slow evaporation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tear film has several functions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of drying of the cornea and mucosal surfaces",
"     </li>",
"     <li>",
"      Smoothing of the refractive surface of the eye (the cornea)",
"     </li>",
"     <li>",
"      Lubrication of the ocular surface for ease of eyelid closure",
"     </li>",
"     <li>",
"      Protection from infection through secretory antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tear meniscus or tear lake is a small layer of tears above the lower eyelid that rests against the cornea and conjunctiva. Excessive tearing (epiphora) causes the level of the tear meniscus to elevate, and the tears flow over the eyelids onto the face.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF PERSISTENT TEARING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of persistent tearing range from mild self-limited conditions to sight-threatening ocular emergencies (",
"    <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"     table 1",
"    </a>",
"    ). Associated signs and symptoms usually help to narrow the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nasolacrimal duct obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct (NLD) obstruction (dacryostenosis) is the most common cause of tearing in children, occurring up to 20 percent of all normal newborns and causing symptoms in up to 6 percent of children during the first year of life.",
"   </p>",
"   <p>",
"    Infants with NLD obstruction present with a history of chronic or intermittent tearing, debris on the eyelashes (mattering), and occasionally redness of the conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef62518 \" href=\"UTD.htm?29/6/29806\">",
"     picture 1",
"    </a>",
"    ). On physical examination, the infant may have an increase in the size of the tear meniscus. Palpation of the lacrimal sac may cause reflux of tears",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucoid discharge into the eye through the puncta.",
"   </p>",
"   <p>",
"    Nasolacrimal duct obstruction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29350?source=see_link\">",
"     \"Nasolacrimal duct obstruction (dacryostenosis) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital or early-onset glaucoma is a sight-threatening condition and usually requires surgery for definitive treatment. It typically presents with chronic or intermittent tearing, photophobia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corneal clouding. The corneal clouding is caused by corneal edema resulting from increased intraocular pressure and endothelial cell dysfunction. Corneal edema causes tremendous glare, which leads to photophobia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"     \"Overview of glaucoma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=see_link\">",
"     \"Primary infantile glaucoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased intraocular pressure also can cause stretching of the cornea and sclera in children younger than three years. This stretching increases the size of the globe (buphthalmos, or \"ox eye\"). Increased corneal size that occurs with buphthalmos helps to distinguish congenital or early-onset glaucoma from other conditions that cause tearing. The normal corneal diameter is 10 mm in infants and increases to 12 mm by two years of age. A horizontal corneal diameter of more than 12 mm or diameters that differ between the two eyes is abnormal and is suggestive of glaucoma. Infants and children with these findings require prompt referral to an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis is an inflammation of the pigmented portion of the eye (the iris, ciliary body, and choroid). This condition is also called iritis or iridocyclitis. Uveitis can occur after blunt ocular trauma and in association with certain rheumatologic or systemic conditions (eg, juvenile idiopathic arthritis, Kawasaki disease, lupus, granulomatosis with polyangiitis [Wegener's], HLA-B27). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with uveitis typically complain of photophobia; deep, boring ocular pain; redness; tearing; and other signs. The onset may be acute or insidious.",
"   </p>",
"   <p>",
"    On examination, the eyes are of normal size. Conjunctival injection, particularly of the area surrounding the limbus (ciliary injection), may be present. Slit lamp findings include anterior chamber cells and flare, posterior synechia, and keratic precipitants. Band keratopathy may occur in patients with chronic uveitis.",
"   </p>",
"   <p>",
"    The first episode of uveitis is typically treated with topical or systemic antiinflammatory medications and cycloplegic agents. Recurrent uveitis often is associated with autoimmune disorders (eg, juvenile idiopathic arthritis, systemic lupus erythematosus, HLA-B27-related spondyloarthropathies) or infections (eg, tuberculosis, syphilis). Laboratory evaluation for these disorders should be performed in children with recurrent uveitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctivitis (inflammation of the conjunctiva) is caused by infection, allergy, chemical exposure, or mechanical aggravation. The signs, symptoms, and treatment vary depending upon the etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial infection typically causes a purulent discharge and diffuse conjunctival injection. It is treated with topical, and sometimes systemic, antibiotics.",
"   </p>",
"   <p>",
"    Viral infection typically causes a watery or stringy discharge, itching,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild photophobia. It is often preceded by a respiratory infection; an enlarged, tender preauricular lymph node may be present. Viral conjunctivitis is treated with symptomatic relief, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38131?source=see_link\">",
"     artificial tears",
"    </a>",
"    and cold compresses.",
"   </p>",
"   <p>",
"    Allergic conjunctivitis typically is pruritic; patients also have other allergic stigmata (eg, allergic shiners). Allergic conjunctivitis is treated with topical antihistamines and topical mast cell suppressors and stabilizers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical and chemical conjunctivitis usually are indicated by the history. Mechanical and chemical conjunctivitis typically are treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38131?source=see_link\">",
"     artificial tears",
"    </a>",
"    and lubrication for symptomatic relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ophthalmia neonatorum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmia neonatorum is a specific conjunctivitis that occurs during the first month of life. It may be associated with systemic illness and typically is caused by gonorrhea, chlamydia, or bacteria resident to the skin or gastrointestinal system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonococcal conjunctivitis usually presents with copious discharge at two to five days of age. The discharge is hyperpurulent (ie, reaccumulates in a matter of minutes). Gonococcal conjunctivitis must be treated immediately because it can lead to corneal ulceration and perforation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link&amp;anchor=H6#H6\">",
"       \"Gonococcal infection in the newborn\", section on 'Ophthalmia neonatorum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chlamydial conjunctivitis typically presents with a stringy mucopurulent discharge within the first 10 to 14 days of life. It can be associated with pneumonitis and other systemic infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"       \"Chlamydia trachomatis infections in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conjunctivitis caused by bacteria of the skin or gastrointestinal tract can mimic gonococcal conjunctivitis with purulent discharge and onset between two and five days of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ophthalmia neonatorum is treated aggressively because neonates have a high risk for sepsis and other secondary complications. Determination of specific treatment depends upon the etiologic agent. Cultures of the eye discharge and other potential sites of infection should be obtained to confirm the diagnosis and determine antimicrobial sensitivity. However, empiric therapy to treat gonorrhea and chlamydia should be started immediately after cultures are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"     \"Chlamydia trachomatis infections in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link\">",
"     \"Gonococcal infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Occult foreign body or abrasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have an occult corneal foreign body or abrasion usually present with photophobia, tearing, redness, and a history that is suggestive of a mechanism of injury. Foreign bodies may be present on the surface of the cornea or on the bulbar or palpebral conjunctiva. Those that are under the upper eyelid may cause vertically oriented linear corneal abrasions.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    examination may reveal the corneal abrasions; the foreign body is viewed either directly or with the slit lamp. Eversion of the upper lid should be performed if the foreign body is not evident on the cornea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corneal foreign bodies should be removed by an ophthalmologist if they are not easily removed with irrigation or a cotton-tipped applicator. Topical antibiotics are indicated if infection is suspected (after culture is obtained). Corneal abrasions may be treated with a pressure patch (for comfort) only if no sign or risk of infection is present. The child with either of these conditions should be followed until all abrasions and other corneal defects heal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Eyelid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic abnormalities of the eyelids may cause tearing, redness, and foreign body sensation. Trichiasis (ingrown eyelashes) can irritate the cornea, causing reflex tearing and redness, and may be caused by entropion or epiblepharon. Entropion is the in-turning of the eyelid; epiblepharon is a fold of skin along the lower lid margin, just below the eyelashes (",
"    <a class=\"graphic graphic_picture graphicRef75573 \" href=\"UTD.htm?22/36/23119\">",
"     picture 2",
"    </a>",
"    ). Both of these conditions can be associated with trichiasis. Entropion, if significant, is treated with surgical repair. Children usually outgrow epiblepharon by two to three years of age without needing to undergo surgery.",
"   </p>",
"   <p>",
"    Blepharitis, inflammation or infection of the eyelids, can cause mattering, itching, burning, tearing, and redness. The treatment is determined by the cause but may include lid scrubs and antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to the canaliculus or the nasolacrimal duct (eg, as may occur with a lid laceration or facial bone fracture) may lead to complete or partial obstruction of the lacrimal system if the nasolacrimal duct or lacrimal sac is injured, repositioned, or heals with stenosis. These injuries require surgical treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stent placement to reestablish and preserve a patent lacrimal drainage system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE CHILD WITH PERSISTENT TEARING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertinent features of the patient's history will help to distinguish the likely diagnosis among the possible causes of tearing in infants and children (",
"    <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"     table 1",
"    </a>",
"    ). The age of the child will help to narrow the differential diagnosis. As an example, NLD obstruction is the most common cause of tearing in children younger than one year of age, whereas conjunctivitis is more common in school-age children. The examiner should ask about the timing and duration of the symptoms, what remedies have been tried, and whether the remedies were successful.",
"   </p>",
"   <p>",
"    The presence or absence of associated signs or symptoms and exacerbating factors also are helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photophobia is common in uveitis and glaucoma",
"     </li>",
"     <li>",
"      Ocular itching is common in allergic conjunctivitis",
"     </li>",
"     <li>",
"      The color, quantity, and quality of the discharge help to distinguish among blepharitis, viral conjunctivitis, bacterial conjunctivitis, or NLD obstruction",
"     </li>",
"     <li>",
"      Deep, boring pain may occur with uveitis or acute glaucoma",
"     </li>",
"     <li>",
"      Foreign body sensation occurs with corneal abrasion, occult foreign body, and trichiasis",
"     </li>",
"     <li>",
"      Upper respiratory tract symptoms often are present with viral conjunctivitis",
"     </li>",
"     <li>",
"      Onset of tearing during an upper respiratory infection suggests obstruction from nasal congestion; this obstruction usually is temporary",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The past medical history should be obtained and recorded.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Juvenile idiopathic arthritis, systemic lupus erythematosus, and other autoimmune disorders are associated with uveitis",
"     </li>",
"     <li>",
"      Bony obstruction of the lacrimal drainage system occurs commonly in children with craniofacial syndromes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link\">",
"       \"Syndromes with craniofacial abnormalities\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Past facial or orbital trauma or facial surgery may contribute to obstruction of the lacrimal drainage system",
"     </li>",
"     <li>",
"      Children with asthma and allergic rhinitis often have allergic conjunctivitis",
"     </li>",
"     <li>",
"      Systemic and topical medications may affect tear production and drainage, cause conjunctival or corneal toxicity, and contribute to increased tearing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, visual acuity testing should be performed in all children with persistent tearing. Abnormal visual behavior in a child with tearing can indicate a vision-threatening disease (eg, congenital glaucoma). A comprehensive eye examination includes examination of the ocular adnexa, the anterior segment, pupils, confrontation visual fields, ocular motility, intraocular pressure, and fundus. Findings in the ocular adnexa and anterior segment are particularly important in the child with persistent tearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ocular adnexa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the ocular adnexa includes examination of the eyelids (for blepharitis), eyelashes (for trichiasis), eyebrows, lacrimal glands, and lacrimal fossa, as well as palpation of the orbital bones. The examination of the lacrimal drainage apparatus is critical because most problems that cause tearing in children are related to lacrimal drainage apparatus abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The eyelids can be gently everted to evaluate for the presence of a punctum in the medial corner of each eyelid",
"     </li>",
"     <li>",
"      The presence of anomalous lacrimal ducts that exit to the skin should be noted (",
"      <a class=\"graphic graphic_picture graphicRef64530 \" href=\"UTD.htm?31/59/32703\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The presence of redness or swelling near the punctum and discharge from the punctum should be noted",
"     </li>",
"     <li>",
"      The lacrimal sac, beneath the medial canthal tendon, should be inspected and palpated; swelling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      redness of the lacrimal sac and discharge expressed from the punctum should be noted",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anterior segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior segment consists of the conjunctiva, cornea, anterior chamber, iris, and lens. Although the anterior chamber is best examined with a slit lamp, the pediatric health care provider can use a penlight with or without a magnifying lens (eg, a 20 diopter condensing lens).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The conjunctiva is examined for signs of inflammation (eg, redness, chemosis, discharge).",
"     </li>",
"     <li>",
"      The cornea is inspected for corneal abrasion, foreign body, scar, or signs of uveitis (eg, keratic precipitants, band keratopathy). The diameter of the cornea should be measured; a horizontal corneal diameter greater than 12 mm or a diameter that is different for each eye is suggestive of glaucoma.",
"     </li>",
"     <li>",
"      The anterior chamber is examined for inflammation (eg, cells and flare) or a cloudy appearance in the normally clear aqueous humor caused by white blood cells and proteinaceous exudate in the anterior chamber.",
"     </li>",
"     <li>",
"      The intraocular pressure should be measured to rule out glaucoma in children with tearing who also have photophobia and increased corneal diameter, or cloudiness of the cornea consistent with corneal edema. Tactile intraocular pressure may be assessed by digital examination by experienced examiners, but tonometry is preferred. Cooperation of the child is essential. Examination under anesthesia may be necessary if a strong suspicion of glaucoma exists. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"       \"Overview of glaucoma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SPECIAL TESTING OF THE LACRIMAL SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special tests of tear function and drainage may be indicated if an abnormality of the lacrimal drainage system is suspected. Numerous tests are available to determine if the composition and function of the tears are normal and if the drainage system is working properly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dye disappearance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dye disappearance test is used to determine if tears are draining at the proper rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/1\">",
"     1",
"    </a>",
"    ]. The dye disappearance test is not always necessary. It is particularly helpful when the symptoms are intermittent. The test is performed in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a drop of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      -stained saline in the inferior cul-de-sac of each of the patient's eyes.",
"     </li>",
"     <li>",
"      Wipe away the excess tears from the eyelids.",
"     </li>",
"     <li>",
"      Observe the patient for five minutes. The eyes should not be rubbed; the tears that drain to the cheeks should not be wiped.",
"     </li>",
"     <li>",
"      After five minutes, inspect the eyes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    should drain into the nose within five minutes if the lacrimal drainage system has no obstruction. One of two events occurs if the nasolacrimal system is obstructed: the dye may remain in the eye and be visible as a bright green tear meniscus, or the dye may escape over the eyelid and drain down the cheek. The test is normal if most of the dye is gone within five minutes and abnormal if a large amount of the dye persists or has drained over the lower eyelid and down the cheek.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Basal secretion test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basal secretion test is used to evaluate basal tear production by the accessory lacrimal glands [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/1\">",
"     1",
"    </a>",
"    ]. The test is performed in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a drop of topical anesthetic in the inferior cul-de-sac of each eye to anesthetize the eye and decrease the production of reflex tears.",
"     </li>",
"     <li>",
"      Wipe away the excess tears.",
"     </li>",
"     <li>",
"      Place a Whatman 41 filter paper strip, also called a Schirmer strip, into each inferior cul-de-sac between the eyelid and the conjunctiva near the temporal corner of the lower eyelid (",
"      <a class=\"graphic graphic_picture graphicRef52623 \" href=\"UTD.htm?26/17/26896\">",
"       picture 4",
"      </a>",
"      ). Fold the strips at the notch and place the small side in the cul-de-sac.",
"     </li>",
"     <li>",
"      Leave the strips in the inferior cul-de-sac for five minutes. An advancing line of wetness on the strip becomes visible as basal tears are absorbed.",
"     </li>",
"     <li>",
"      After five minutes, carefully remove the strips. The distance from the notch in the filter paper to the edge of the tear line is measured in millimeters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal basal tear secretion is 8 to 15 mm after five minutes. Overproduction of tears is indicated by a strip that becomes soaked by more than 15 mm during the test; dry eyes are indicated by a basal secretion rate of less than 8 mm.",
"   </p>",
"   <p>",
"    Deficient tear formation can be caused by collagen vascular diseases (eg, juvenile idiopathic arthritis, systemic lupus erythematosus), graft-versus-host disease in bone marrow transplant patients, Graves' disease, and other diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Schirmer 1 test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Schirmer 1 test measures reflex tearing from the orbital and palpebral lobes of the lacrimal gland [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/1\">",
"     1",
"    </a>",
"    ]. This test is performed in the same manner as the basal secretion test, except that the topical anesthetic is omitted. Reflex tearing is considered normal if between 10 and 25 mm of the strip is moistened after five minutes; greater than 25 mm of wetting indicates excessive tearing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Tear breakup time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tear breakup time test provides information about the composition and function of the tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7079/abstract/1\">",
"     1",
"    </a>",
"    ]. The tear breakup time is the length of time that the tear film forms an unbroken sheet of fluid over the cornea. The normal tear film forms an unbroken sheet of fluid over the cornea for at least 10 seconds before separating into its component layers. The tear breakup time is reduced in patients with an imbalance of components in the tear film; patients with such an imbalance often blink at an increased rate. The tear breakup time test requires a cooperative child and a slit lamp; it is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Place a drop of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      -stained saline in the inferior cul-de-sac of each of the patient's eyes",
"     </li>",
"     <li>",
"      Wipe away the excess tears",
"     </li>",
"     <li>",
"      Place the child's head into the slit lamp in the normal fashion",
"     </li>",
"     <li>",
"      Focus on the cornea using the cobalt blue light of the slit lamp",
"     </li>",
"     <li>",
"      Have the child blink two or three times and then keep his or her eyes open for approximately 15 seconds",
"     </li>",
"     <li>",
"      Observe the tear film",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surface of the tear film should remain smooth, and the green color of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye should remain uniform for at least 10 seconds. Dry spots eventually develop on the cornea and appear as dark areas surrounded by the green of the fluorescein in the remainder of the tear film. The tear composition may be out of balance if dry spots are seen sooner than 10 seconds after the last blink.",
"   </p>",
"   <p>",
"    Imbalance of tear composition is caused by autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, Graves' disease, and scleroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/54/25441?source=see_link\">",
"       \"Patient information: Blocked tear duct (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tears are produced by the lacrimal and accessory lacrimal glands, and drain through the lacrimal drainage system (",
"      <a class=\"graphic graphic_figure graphicRef53429 \" href=\"UTD.htm?20/48/21252\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy of the lacrimal system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of persistent tearing range from mild self-limited conditions to sight-threatening ocular emergencies (",
"      <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"       table 1",
"      </a>",
"      ). Associated signs and symptoms usually help to narrow the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology of persistent tearing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history in the child with persistent tearing include age; associated signs and symptoms (photophobia, itching, pain); color, quantity, and quality of the discharge; foreign body sensation; associated illnesses (eg, upper respiratory infection); and past medical history (chronic illness, trauma, craniofacial abnormalities, medications). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comprehensive eye examination in the child with persistent tearing includes visual acuity testing, examination of the ocular adnexa, the anterior segment, pupils, confrontation visual fields, ocular motility, intraocular pressure, and fundus. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Special tests of tear function and drainage may be indicated if an abnormality of the lacrimal drainage system is suspected. These include the dye disappearance test, basal secretion test, Schirmer 1 test, and tear breakup time. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Special testing of the lacrimal system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Newell FW. The lacrimal apparatus. In: Ophthalmology: Principles and Concepts, 6th, CV Mosby, St. Louis 1986. p.254.",
"    </li>",
"    <li>",
"     Lemp MA, Chacko B. Diagnosis and treatment of tear deficiencies. In: Duane's Clinical Ophthalmology, Tasman W, Jaeger EA (Eds), Lippincott-Raven, Philadelphia 1997. Vol 4.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6262 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7079=[""].join("\n");
var outline_f6_58_7079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF THE LACRIMAL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tear production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tear composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY OF PERSISTENT TEARING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nasolacrimal duct obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ophthalmia neonatorum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Occult foreign body or abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Eyelid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION OF THE CHILD WITH PERSISTENT TEARING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ocular adnexa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anterior segment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SPECIAL TESTING OF THE LACRIMAL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dye disappearance test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Basal secretion test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Schirmer 1 test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Tear breakup time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6262|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/48/21252\" title=\"figure 1\">",
"      Anatomy of lacrimal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6262|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29806\" title=\"picture 1\">",
"      Nasolacrimal duct obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/36/23119\" title=\"picture 2\">",
"      Epiblepharon with trichiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/59/32703\" title=\"picture 3\">",
"      Accessory lacrimal duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/17/26896\" title=\"picture 4\">",
"      Basal secretion test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/30/41452\" title=\"table 1\">",
"      Causes persistent tearing in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29350?source=related_link\">",
"      Nasolacrimal duct obstruction (dacryostenosis) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/54/25441?source=related_link\">",
"      Patient information: Blocked tear duct (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7080="Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis";
var content_f6_58_7080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Richard Bryant, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7080/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6576004\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stress disorder (ASD) is characterized by acute stress reactions that may occur in the initial month after a person is exposed to a traumatic event. The disorder includes dissociative, reexperiencing, avoidance, and arousal symptoms. Some patients who experience ASD go on to experience posttraumatic stress disorder (PTSD), which is diagnosed only after four weeks following exposure to trauma.",
"   </p>",
"   <p>",
"    Treatment for ASD, which is principally trauma-focused cognitive-behavioral therapy, is aimed at curtailing symptoms of acute stress responses and preventing their development into PTSD.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, course, diagnosis, and treatment of ASD are described here. The treatment of ASD is discussed separately. The epidemiology, pathogenesis, clinical manifestations, course, diagnosis, and treatment of PTSD are also discussed separately. Dissociation associated with PTSD, and substance abuse associated with PTSD are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41177?source=see_link&amp;anchor=H17734023#H17734023\">",
"     \"Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis\", section on 'Posttraumatic stress disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576011\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576019\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The point prevalence of acute stress disorder (ASD) following trauma exposure has been estimated at between five and twenty percent, depending on the nature and severity of trauma and the instrument used to identify the disorder. Rates of ASD following specific types of trauma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Motor vehicle accident: 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/1\">",
"       1",
"      </a>",
"      ], 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mild traumatic brain injury: 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assault: 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/3\">",
"       3",
"      </a>",
"      ], 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Burn: 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Industrial accident: 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/5\">",
"       5",
"      </a>",
"      ], 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Witnessing a mass shooting: 33 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576026\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is probable that most risk factors for PTSD also apply to ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/7\">",
"     7",
"    </a>",
"    ]. Consistent with this presumption is evidence that ASD is associated with the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of a pre-trauma psychiatric disorder",
"     </li>",
"     <li>",
"      History of traumatic exposures prior to recent exposure",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Trauma severity",
"     </li>",
"     <li>",
"      Neuroticism",
"     </li>",
"     <li>",
"      Avoidant coping",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A problem with most studies of risk factors for ASD is that they assess trauma survivors following trauma exposure. A more accurate assessment of risk would be achieved by testing people prior to trauma exposure. Studies adopting this approach have suggested that individual differences in reactivity to stressors, difficulties in extinction learning, and tendency to engage in catastrophic thinking prior to exposure are linked to worse outcomes following a trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, a study of firefighter recruits found that an elevated acoustic startle response prior to commencing firefighting duties predicted acute stress reactions after exposure to traumatic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576040\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known why some people develop acute stress disorder following a traumatic event. Nor is it fully understood why some people with ASD develop subsequent posttraumatic stress disorder and others do not. However, conceptual models and research studies suggest some underlying factors.",
"   </p>",
"   <p>",
"    When ASD was initially introduced, it was largely influenced by the proposal that dissociative responses to trauma are a pivotal factor in maladaptive responses to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/12\">",
"     12",
"    </a>",
"    ]. In terms of dissociation that occurs at the time of trauma (termed peritraumatic dissociation), it is proposed that dissociating trauma memories and their associated affect from normal awareness impedes processing of these reactions and thereby leads to subsequent PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrary to earlier beliefs that the presence of dissociation in the acute stress reaction was pivotal in predicting future PTSD, it has become clear that, the influence of dissociation appears to be moderated by other variables [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. One model posits that peritraumatic dissociation is a function of the elevated arousal that occurs in the wake of trauma, and so it is elevated arousal in the acute phase that may drive the dissociation, and it is arousal that fuels later PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/15\">",
"     15",
"    </a>",
"    ]. This interpretation accords with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dissociative phenomena (eg, flashbacks) occur in PTSD in response to yohimbine-induced arousal [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/16\">",
"       16",
"      </a>",
"      ],",
"     </li>",
"     <li>",
"      Dissociative reactions are commonly reported during panic attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Panic attacks are very common during trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dissociative responses can be induced with a hyperventilation task in individuals with ASD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The relationship between peritraumatic dissociation and acute stress depends on the level of peritraumatic panic [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding that panic plays a role in the etiology of ASD is consistent with the prevailing model of ASD and PTSD. Fear conditioning models posit that the fear elicited during a traumatic event results in conditioning in which subsequent reminders of the trauma elicit anxiety in response to trauma reminders [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/21\">",
"     21",
"    </a>",
"    ]. This model proposes that extreme sympathetic arousal at the time of a traumatic event may result in the release of stress neurochemicals (including norepinephrine and epinephrine) that results in overconsolidation of trauma memories [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/22\">",
"     22",
"    </a>",
"    ]. According to this model, most trauma survivors successfully engage in extinction learning in the days and weeks after trauma as they learn that the reminders are not signaling further threat. In terms of responses in the acute phase there is much evidence that people who eventually develop PTSD display elevated heart rate in the days after the trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/23-28\">",
"     23-28",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Further, there is evidence that people with elevated respiration rate after trauma are more likely to develop PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/23\">",
"     23",
"    </a>",
"    ]. These findings underscore the proposal that elevated arousal in the acute phase is important in the etiology of ASD and PTSD.",
"   </p>",
"   <p>",
"    The other major conceptual model for ASD involves cognitive processes, which posit that extremely negative and unrealistic appraisals about the traumatic event, one&rsquo;s response to the event, and the likelihood of future harm will influence the extent to which PTSD develops [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/29\">",
"     29",
"    </a>",
"    ]. Supporting this model is evidence that people with ASD",
"    <strong>",
"    </strong>",
"    exaggerate the probability of future negative events [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Catastrophic appraisals in the initial period after trauma exposure predict subsequent PTSD in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] and children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576047\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stress disorder (ASD) typically presents with severe levels of reexperiencing and anxiety in response to reminders of the recent trauma. As an example, a patient presented in treatment two weeks after being assaulted and robbed at his store. He reported that he was experiencing frequent nightmares of the assault, as well as terrifying dreams of being attacked in other situations. He reported daily intrusive memories of the experience, including vivid recollections of the assailant sliding a knife against his throat. He reported having strong perceptual memories that included smelling the assailant&rsquo;s breath and feeling the scraping sensation of the knife against his skin.",
"   </p>",
"   <p>",
"    These reactions tend to be readily activated by many occurrences and situations, and often lead to generalized fear and vigilance for further threats. As examples, the patient reported intense distress to many reminders, including meeting strangers, people of the same ethnic appearance as the assailant, and even entering his own store. He suffered distressing memories every time he shaved because the sensation of the razor on his skin triggered clear memories of the assailant&rsquo;s knife at his throat. This caused him to tremble with fear, causing him to cut himself while shaving- the resulting blood further exacerbated his memories and fears. He became intensely fearful of all potential threats, and constantly scanned his surroundings for anything that may harm him. He always ensured he had his back to the wall so nobody could approach him from behind, and never entered situations which did not allow for ready escape.",
"   </p>",
"   <p>",
"    Active avoidance of any perceived threat, or even reminders of threat is common in this phase as the patient attempts to minimize distress by reducing exposure to any situations, thoughts, or conversations that will reactivate their fear; this can even generalize to being reluctant to discuss their experience during clinical assessment. As examples, the patient engaged in many obvious, as well as subtle, avoidance strategies. He refused to discuss the experience with his family, refused entry to his store to any male customers, turned news programs off as soon as they mentioned robberies or assaults, and only shaved with an electric razor.",
"   </p>",
"   <p>",
"    Patients who meet the full dissociative criteria for ASD (ie, three or more dissociative symptoms) may present with a flat or blunted affect, described as emotional numbing. These patients can appear to be in shock. Even though patients may display dissociative responses on presentation, when directed to recount their trauma they typically will become highly distressed. Patients may report amnesia of core aspects of the event; amnesia of the entire experience is extremely rare. As an example, the patient initially reported being unable to recall a key aspect of the experience after the assailant told him he was about to slit his throat; his next memory was lying face-down on the floor with the assailant screaming at him.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10316689\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma survivors typically display symptoms of marked distress in the initial days and weeks after a traumatic event, but then the majority of people tend to adapt, and these symptoms remit. This pattern has been observed in survivors of motor vehicle accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/36\">",
"     36",
"    </a>",
"    ], rape [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/37\">",
"     37",
"    </a>",
"    ], non-sexual assault [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/38\">",
"     38",
"    </a>",
"    ], and terrorist attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ASD diagnosis has been proposed as a means to identify among patients experiencing an acute stress reaction to trauma those at higher risk for subsequent PTSD who thus may benefit from early intervention. A systematic review of 22 longitudinal studies of 3,335 adults and children who were assessed within a month, and subsequently at least 3 months later, found that a diagnosis of ASD had a moderately strong positive predictive power to identify patients who would go on to develop PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/1,4,40-60\">",
"     1,4,40-60",
"    </a>",
"    ]. Although there is considerable variability across studies, between 40 and 80 percent of those with ASD develop subsequent PTSD; that is, half or more of people with ASD do not experience chronic PTSD. Only 30 to 60 percent of those who eventually develop PTSD meet criteria for ASD in the acute phase, indicating that most people who develop PTSD are not detected by the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576054\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for acute stress disorder (ASD) from DSM-IV-TR (Diagnostic and statistical manual, Fourth edition, Text revision) are summarized below and shown in a table (",
"    <a class=\"graphic graphic_table graphicRef70263 \" href=\"UTD.htm?34/2/34860\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/61\">",
"     61",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    ASD is diagnosed in persons who have an intensely fearful response to experiencing or witnessing a traumatic event, and who experience associated features described below. The traumatic event should be of sufficient severity to involve the actual or threatened death or serious injury to oneself or others. To meet diagnostic criteria for ASD, the following features must be present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least three dissociative symptoms (such as emotional numbing or detachment, depersonalization, derealization, dissociative amnesia, or reduced awareness of one&rsquo;s surroundings) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link&amp;anchor=H375332765#H375332765\">",
"       \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One reexperiencing symptom (such as intrusive memories, flashbacks, or nightmares)",
"     </li>",
"     <li>",
"      Marked avoidance (including effortful avoidance of situations, conversations, or thoughts that are reminiscent of the trauma)",
"     </li>",
"     <li>",
"      Marked anxiety or increased arousal (such as an elevated startle response, irritability, or hypervigilance)",
"     </li>",
"     <li>",
"      Evidence of significant distress or impairment",
"     </li>",
"     <li>",
"      The disturbance must last for a minimum of two days and a maximum of four weeks, after which a diagnosis of PTSD should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic criteria for ASD differ from the criteria for PTSD in that ASD requires the presence of dissociative symptoms, as noted above.",
"   </p>",
"   <p>",
"    Although the DSM-IV-TR stipulates that ASD can be diagnosed two days after the traumatic event, delaying the diagnosis until a week after the event may better identify patients who can be effectively treated and are at higher risk of developing PTSD. Diagnosis within two days will identify many people who are experiencing a transient stress reaction that will potentially abate in the following week.",
"   </p>",
"   <p>",
"    Symptoms of ASD should be present at a severe level to warrant diagnosis. As an example, many people will display some form of avoidance in the month after trauma; however, to meet the avoidance criterion for ASD, the patient needs to be engaging in effortful avoidance that reflects a pattern of actively not engaging with reminders of the event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689382\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stress disorder (ASD) should be distinguished from other causes of altered awareness in an injured patient following trauma, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effects of analgesic medications",
"     </li>",
"     <li>",
"      Medical conditions involving coma or impaired awareness",
"     </li>",
"     <li>",
"      Effects of substance abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each of these conditions the patient may experience alterations in awareness that can appear similar to dissociative experiences. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    prescribed to manage acute pain can result in reduced awareness, derealization, depersonalization, or amnesia. These states can be easily confused with dissociative symptoms of ASD.",
"   </p>",
"   <p>",
"    An impaired consciousness resulting from mild traumatic brain injury (TBI) can closely mimic a range of ASD symptoms, including depersonalization, derealization, reduced awareness, and dissociative amnesia. There are no reliable means to differentiate between dissociative amnesia and amnesia secondary to mild TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/62\">",
"     62",
"    </a>",
"    ], and for this reason it is wise to not interpret amnesia in the aftermath of mild TBI as a symptom of ASD. Mild TBI can co-occur with ASD (and later PTSD). Longitudinal studies of mild TBI patients have found that meeting ASD criteria is predictive of subsequent PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/45\">",
"     45",
"    </a>",
"    ]. It appears that satisfying the reexperiencing, avoidance, and arousal symptoms of ASD, even when the person has only partial memory of the traumatic event because of mild TBI, can nonetheless reflect the early signs of subsequent PTSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to mild TBI, diagnosing ASD in patients with moderate or severe TBI is not recommended because these patients, by definition, have more pervasive disturbances in consciousness that will overlap markedly with stress reactions, and typically have difficulty monitoring and reporting their psychological states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17995758\">",
"    <span class=\"h2\">",
"     Subsyndromal ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsyndromal ASD has been defined by the same criteria as ASD without the requirement of dissociative symptoms. Rates of subsyndromal ASD are expectedly higher than for ASD; prevalence rates following specific types of trauma include: motor vehicle accidents (21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/1\">",
"     1",
"    </a>",
"    ]), traumatic injury (20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/40\">",
"     40",
"    </a>",
"    ]), and injury-related trauma in children (32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/41-43\">",
"     41-43",
"    </a>",
"    ])",
"   </p>",
"   <p>",
"    Identifying trauma survivors with subsyndromal ASD has been found to have greater sensitivity for predicting the subsequent development of PTSD compared to the ASD diagnostic criteria in the DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/1,4,40,58\">",
"     1,4,40,58",
"    </a>",
"    ]. Requiring dissociation to be present limits identification of many high-risk individuals and possibly deprives them of receiving treatment that they could benefit from. These analyses suggest that identifying trauma survivors at increased risk for PTSD can be achieved more efficiently by assessing general PTSD symptoms rather than using the ASD criteria, which emphasizes dissociation.",
"   </p>",
"   <p>",
"    It appears that there are multiple pathways to developing PTSD, and whereas some people may display initial dissociation, others do not. Persons with ASD appear to have stronger dissociative tendencies, as measured by hypnotizability, relative to those with subsyndromal ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/63\">",
"     63",
"    </a>",
"    ]. This suggests that people with dissociative tendencies may respond this way to a trauma, however many others who do not have this dissociative tendency will be equally likely to develop PTSD.",
"   </p>",
"   <p>",
"    Overall, the current evidence suggests that identifying people with elevated scores on PTSD or ASD measures, regardless of the specific constellation of symptoms, is a reasonable marker for increased risk for PTSD development",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1236997\">",
"    <span class=\"h2\">",
"     PTSD assessment instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently three structured measures specifically designed to assess for ASD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Stanford Acute Stress Reaction Questionnaire, a 30-item self-report inventory, encompasses each of the ASD symptoms that has been validated against a DSM-IV-TR diagnosis.",
"     </li>",
"     <li>",
"      The Acute Stress Disorder Interview, a 19-item structured clinical interview that is based on DSM-IV-TR criteria, possesses good internal consistency (r = .90), test-retest reliability (r = .88), sensitivity (91 percent) and specificity (93 percent) relative to independent clinician diagnosis of ASD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Acute Stress Disorder Scale is a self-report inventory that is based on the same items described in the ASDI [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7080/abstract/65\">",
"       65",
"      </a>",
"      ]. The scale is widely used as a clinical screen for people who may have ASD; however it is optimally used as a tool to measure severity of acute stress severity rather than an ASD diagnosis. &nbsp;Some studies have employed an overall cut-off core on the ASDS to identify people who are high risk for PTSD; a score of 50 or more may identify severe acute stress reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6576083\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute stress disorder (ASD) is characterized by acute stress reactions that may occur in the initial month after a person is exposed to a traumatic event. The disorder includes dissociative, reexperiencing, avoidance, and arousal symptoms. (See",
"      <a class=\"local\" href=\"#H6576004\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of ASD after a traumatic event has been estimated at between five and twenty percent, depending on the nature and severity of trauma, and the instrument used to identify the disorder. (See",
"      <a class=\"local\" href=\"#H6576019\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD typically presents with severe levels of reexperiencing and anxiety in response to reminders of the recent trauma. These reactions tend to be readily activated by many occurrences and situations. This will often lead to generalized fear, vigilance for further threats, and active avoidance of situations that stimulate recollections of the trauma. (See",
"      <a class=\"local\" href=\"#H6576047\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD is diagnosed in persons who have an intensely fearful response to experiencing or witnessing a traumatic event, and who experience associated symptoms of dissociation, reexperiencing, avoidance,",
"      <span class=\"nowrap\">",
"       anxiety/arousal,",
"      </span>",
"      and significant distress or impairment. DSM-IV-TR diagnostic criteria for ASD are shown in a table (",
"      <a class=\"graphic graphic_table graphicRef70263 \" href=\"UTD.htm?34/2/34860\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6576054\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/1\">",
"      Harvey AG, Bryant RA. The relationship between acute stress disorder and posttraumatic stress disorder: a prospective evaluation of motor vehicle accident survivors. J Consult Clin Psychol 1998; 66:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/2\">",
"      Harvey AG, Bryant RA. Acute stress disorder after mild traumatic brain injury. J Nerv Ment Dis 1998; 186:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/3\">",
"      Harvey AG, Bryant RA. Acute stress disorder across trauma populations. J Nerv Ment Dis 1999; 187:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/4\">",
"      Brewin CR, Andrews B, Rose S, Kirk M. Acute stress disorder and posttraumatic stress disorder in victims of violent crime. Am J Psychiatry 1999; 156:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/5\">",
"      Creamer M, Manning C. Acute stress disorder following an industrial accident. Aust Psycholog 1998; 33:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/6\">",
"      Classen C, Koopman C, Hales R, Spiegel D. Acute stress disorder as a predictor of posttraumatic stress symptoms. Am J Psychiatry 1998; 155:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/7\">",
"      Ozer EJ, Best SR, Lipsey TL, Weiss DS. Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis. Psychol Bull 2003; 129:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/8\">",
"      Barton KA, Blanchard EB, Hickling EJ. Antecedents and consequences of acute stress disorder among motor vehicle accident victims. Behav Res Ther 1996; 34:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/9\">",
"      Harvey AG, Bryant RA. Predictors of acute stress following motor vehicle accidents. J Trauma Stress 1999; 12:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/10\">",
"      Harvey AG, Bryant RA. Predictors of acute stress following mild traumatic brain injury. Brain Inj 1998; 12:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/11\">",
"      Guthrie RM, Bryant RA. Auditory startle response in firefighters before and after trauma exposure. Am J Psychiatry 2005; 162:283.",
"     </a>",
"    </li>",
"    <li>",
"     Spiegel D, Koopmen C, Cardena C, Classen C. Dissociative symptoms in the diagnosis of acute stress disorder. In: Handbook of Dissociation, Michelson LK, Ray WJ.  (Eds), Plenum Press, New York 1996. p.367.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/13\">",
"      Breh DC, Seidler GH. Is peritraumatic dissociation a risk factor for PTSD? J Trauma Dissociation 2007; 8:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/14\">",
"      van der Velden PG, Kleber RJ, Christiaanse B, et al. The independent predictive value of peritraumatic dissociation for postdisaster intrusions, avoidance reactions, and PTSD symptom severity: a 4-year prospective study. J Trauma Stress 2006; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/15\">",
"      Friedman MJ. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? J Clin Psychiatry 2000; 61 Suppl 7:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/16\">",
"      Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/17\">",
"      Krystal JH, Woods SW, Hill CL, Charney DS. Characteristics of panic attack subtypes: assessment of spontaneous panic, situational panic, sleep panic, and limited symptom attacks. Compr Psychiatry 1991; 32:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/18\">",
"      Bryant RA, Panasetis P. Panic symptoms during trauma and acute stress disorder. Behav Res Ther 2001; 39:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/19\">",
"      Nixon RDV, Bryant RA. Dissociation in acute stress disorder after a hyperventilation provocation test. Behav Cog Psychother 2006; 34:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/20\">",
"      Fikretoglu D, Brunet A, Best S, et al. The relationship between peritraumatic distress and peritraumatic dissociation: an examination of two competing models. J Nerv Ment Dis 2006; 194:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/21\">",
"      Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research--past, present, and future. Biol Psychiatry 2006; 60:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/22\">",
"      Charney DS, Deutch AY, Krystal JH, et al. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/23\">",
"      Bryant RA, Creamer M, O'Donnell M, et al. A multisite study of initial respiration rate and heart rate as predictors of posttraumatic stress disorder. J Clin Psychiatry 2008; 69:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/24\">",
"      Bryant RA, Harvey AG, Guthrie RM, Moulds ML. A prospective study of psychophysiological arousal, acute stress disorder, and posttraumatic stress disorder. J Abnorm Psychol 2000; 109:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/25\">",
"      Bryant RA, Marosszeky JE, Crooks J, Gurka JA. Elevated resting heart rate as a predictor of posttraumatic stress disorder after severe traumatic brain injury. Psychosom Med 2004; 66:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/26\">",
"      Bryant RA, Salmon K, Sinclair E, Davidson P. Heart rate as a predictor of posttraumatic stress disorder in children. Gen Hosp Psychiatry 2007; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/27\">",
"      Kassam-Adams N, Garcia-Espa&ntilde;a JF, Fein JA, Winston FK. Heart rate and posttraumatic stress in injured children. Arch Gen Psychiatry 2005; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/28\">",
"      Shalev AY, Sahar T, Freedman S, et al. A prospective study of heart rate response following trauma and the subsequent development of posttraumatic stress disorder. Arch Gen Psychiatry 1998; 55:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/29\">",
"      Ehlers A, Clark DM. A cognitive model of posttraumatic stress disorder. Behav Res Ther 2000; 38:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/30\">",
"      Warda G, Bryant RA. Cognitive bias in acute stress disorder. Behav Res Ther 1998; 36:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/31\">",
"      Smith K, Bryant RA. The generality of cognitive bias in acute stress disorder. Behav Res Ther 2000; 38:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/32\">",
"      Ehlers A, Mayou RA, Bryant B. Psychological predictors of chronic posttraumatic stress disorder after motor vehicle accidents. J Abnorm Psychol 1998; 107:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/33\">",
"      Dunmore E, Clark DM, Ehlers A. A prospective investigation of the role of cognitive factors in persistent posttraumatic stress disorder (PTSD) after physical or sexual assault. Behav Res Ther 2001; 39:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/34\">",
"      Bryant RA, Salmon K, Sinclair E, Davidson P. A prospective study of appraisals in childhood posttraumatic stress disorder. Behav Res Ther 2007; 45:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/35\">",
"      Meiser-Stedman R. Towards a cognitive-behavioral model of PTSD in children and adolescents. Clin Child Fam Psychol Rev 2002; 5:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/36\">",
"      Blanchard EB, Hickling EJ, Barton KA, et al. One-year prospective follow-up of motor vehicle accident victims. Behav Res Ther 1996; 34:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/37\">",
"      Rothbaum BO, Foa EB, Riggs DS, et al. A prospective examination of post-traumatic stress disorder in rape victims. J Traum Stress 1992; 5:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/38\">",
"      Riggs DS, Rothbaum BO, Foa EB. A prospective examination of symptoms of posttraumatic stress disorder in victims of nonsexual assault. J Interper Viol 1995; 10:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/39\">",
"      Galea S. The long-term health consequences of disasters and mass traumas. CMAJ 2007; 176:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/40\">",
"      Bryant RA, Creamer M, O'Donnell ML, et al. A multisite study of the capacity of acute stress disorder diagnosis to predict posttraumatic stress disorder. J Clin Psychiatry 2008; 69:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/41\">",
"      Dalgleish T, Meiser-Stedman R, Kassam-Adams N, et al. Predictive validity of acute stress disorder in children and adolescents. Br J Psychiatry 2008; 192:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/42\">",
"      Kassam-Adams N, Winston FK. Predicting child PTSD: the relationship between acute stress disorder and PTSD in injured children. J Am Acad Child Adolesc Psychiatry 2004; 43:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/43\">",
"      Bryant RA, Salmon K, Sinclair E, Davidson P. The relationship between acute stress disorder and posttraumatic stress disorder in injured children. J Trauma Stress 2007; 20:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/44\">",
"      Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. J Clin Psychiatry 2011; 72:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/45\">",
"      Bryant RA, Harvey AG. Relationship between acute stress disorder and posttraumatic stress disorder following mild traumatic brain injury. Am J Psychiatry 1998; 155:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/46\">",
"      Holeva V, Tarrier N, Wells A. Prevalence and predictors of acute stress disorder and PTSD following road traffic accidents: Thought control strategies and social support. Behav Ther 2001; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/47\">",
"      Staab JP, Grieger TA, Fullerton CS, Ursano RJ. Acute stress disorder, subsequent posttraumatic stress disorder and depression after a series of typhoons. Anxiety 1996; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/48\">",
"      Kangas M, Henry JL, Bryant RA. The relationship between acute stress disorder and posttraumatic stress disorder following cancer. J Consult Clin Psychol 2005; 73:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/49\">",
"      Harvey AG, Bryant RA. The relationship between acute stress disorder and posttraumatic stress disorder: a 2-year prospective evaluation. J Consult Clin Psychol 1999; 67:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/50\">",
"      Harvey AG, Bryant RA. Two-year prospective evaluation of the relationship between acute stress disorder and posttraumatic stress disorder following mild traumatic brain injury. Am J Psychiatry 2000; 157:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/51\">",
"      Elklit A, Brink O. Acute stress disorder as a predictor of post-traumatic stress disorder in physical assault victims. J Interpers Violence 2004; 19:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/52\">",
"      Hamanaka S, Asukai N, Kamijo Y, et al. Acute stress disorder and posttraumatic stress disorder symptoms among patients severely injured in motor vehicle accidents in Japan. Gen Hosp Psychiatry 2006; 28:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/53\">",
"      Ginzburg K, Solomon Z, Dekel R, Bleich A. Longitudinal study of acute stress disorder, posttraumatic stress disorder and dissociation following myocardial infarction. J Nerv Ment Dis 2006; 194:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/54\">",
"      Fullerton CS, Ursano RJ, Wang L. Acute stress disorder, posttraumatic stress disorder, and depression in disaster or rescue workers. Am J Psychiatry 2004; 161:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/55\">",
"      Murray J, Ehlers A, Mayou RA. Dissociation and post-traumatic stress disorder: two prospective studies of road traffic accident survivors. Br J Psychiatry 2002; 180:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/56\">",
"      Fuglsang AK, Moergeli H, Schnyder U. Does acute stress disorder predict post-traumatic stress disorder in traffic accident victims? Analysis of a self-report inventory. Nord J Psychiatry 2004; 58:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/57\">",
"      Balluffi A, Kassam-Adams N, Kazak A, et al. Traumatic stress in parents of children admitted to the pediatric intensive care unit. Pediatr Crit Care Med 2004; 5:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/58\">",
"      Kassam-Adams N, Fleisher CL, Winston FK. Acute stress disorder and posttraumatic stress disorder in parents of injured children. J Trauma Stress 2009; 22:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/59\">",
"      Elklit A, Christiansen DM. ASD and PTSD in rape victims. J Interpers Violence 2010; 25:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/60\">",
"      K&uuml;hn M, Ehlert U, Rumpf HJ, et al. Onset and maintenance of psychiatric disorders after serious accidents. Eur Arch Psychiatry Clin Neurosci 2006; 256:497.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/62\">",
"      Bryant RA. Posttraumatic stress disorder and traumatic brain injury: can they co-exist? Clin Psychol Rev 2001; 21:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/63\">",
"      Bryant RA, Guthrie RM, Moulds ML. Hypnotizability in acute stress disorder. Am J Psychiatry 2001; 158:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/64\">",
"      Bryant RA, Harvey AG, Dang ST, Sackville T. Assessing acute stress disorder: Psychometric properties of a structured clinical interview. Psychol Assess 1998; 10:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7080/abstract/65\">",
"      Bryant RA, Moulds ML, Guthrie RM. Acute Stress Disorder Scale: a self-report measure of acute stress disorder. Psychol Assess 2000; 12:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14616 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7080=[""].join("\n");
var outline_f6_58_7080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6576083\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576004\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576011\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6576019\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6576026\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576040\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576047\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10316689\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576054\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H689382\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17995758\">",
"      Subsyndromal ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1236997\">",
"      PTSD assessment instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6576083\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/2/34860\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for acute stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41177?source=related_link\">",
"      Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=related_link\">",
"      Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7081="Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation";
var content_f6_58_7081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7081/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic sinusoidal obstruction syndrome (hepatic SOS), previously called hepatic veno-occlusive disease, is one of the most feared complications of allogeneic and autologous hematopoietic cell transplantation (HCT). It accounts for a significant fraction of transplant-related mortality and, in its severe form, is almost always fatal.",
"   </p>",
"   <p>",
"    The incidence of hepatic SOS varies significantly from center to center. It has been reported to occur in up to 54 percent of allogeneic transplants and 30 to 50 percent of autologous transplants, depending upon which diagnostic criteria are used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fortunately, only a minority of cases are severe. However, mortality in patients with severe disease is extremely high.",
"   </p>",
"   <p>",
"    There is no well-established therapy for SOS that has been shown to be effective in a controlled study, although studies using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    appear promising. As a result, treatment of this disorder is largely supportive. Several studies have attempted to modify the course of severe SOS with the use of antithrombin and fibrinolytic agents based upon the hypothesis that damage to the vascular endothelium produces localized hypercoagulability and clotting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although success has been reported, it is well recognized that severe SOS is associated with high mortality without clear effective therapy.",
"   </p>",
"   <p>",
"    Interventions to prevent the development of SOS have also been studied. These include the synthetic bile acid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA), for which the data are most convincing, low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    , and perhaps the use of peripheral blood progenitor cells as a stem cell source.",
"   </p>",
"   <p>",
"    The studies that have evaluated the efficacy of these modalities in the treatment and prevention of SOS will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/6\">",
"     6",
"    </a>",
"    ]. The pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the problems in assessing the efficacy of therapy in SOS is that mild to moderate disease may do well without any particular treatment other than supportive care. In one series, for example, survival at day +100 was 91 percent with mild SOS and 77 percent with moderate disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/2\">",
"     2",
"    </a>",
"    ]. Most patients who recover from SOS of any severity regain normal liver function and do not develop sequelae of liver dysfunction such as portal hypertension or esophageal varices.",
"   </p>",
"   <p>",
"    In contrast, the prognosis is much worse in severe SOS, which occurs in 25 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/2\">",
"     2",
"    </a>",
"    ]. This disorder is typically fulminant with acute liver failure, coagulopathy, hepatic encephalopathy, hepatorenal syndrome, and multiorgan failure. The expected mortality rate in patients who develop multiorgan failure is very high [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In one series, for example, there were no survivors among patients with SOS who also had lung injury warranting mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have attempted to identify risk factors associated with disease progression and death in patients who develop clinical features of SOS. In one study, risk factors associated with the development of severe SOS at different time points during bone marrow transplantation were ascertained in a cohort of 355 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/10\">",
"     10",
"    </a>",
"    ]. The model was then validated prospectively by predicting outcomes in a separate cohort of 392 patients undergoing hematopoietic cell transplantation. A logistic regression model identified the serum bilirubin and percent of weight gain within one to two weeks of transplantation as the most important independent predictors of progression to severe disease. Evaluation of the performance of these models demonstrated high specificity and moderate sensitivity.",
"   </p>",
"   <p>",
"    The prognosis can also be predicted by renal function. In a retrospective analysis, the mortality rate was 17 percent in patients with a normal serum creatinine, 37 percent in those with a doubling of the serum creatinine, and 84 percent in those with acute renal failure requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coagulation factors also may have predictive value. In one report, plasma levels of cross-linked fibrin degradation products (D-dimer) and soluble endothelial adhesion molecules were measured in 10 patients undergoing allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/11\">",
"     11",
"    </a>",
"    ]. Four episodes of SOS occurred, two of which were severe and fatal. Concentrations of D-dimer rose substantially and reached levels above 1000",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    in these two patients. The marked increase in D-dimer levels appeared earlier in the course than marked elevations in serum bilirubin. In contrast, there were no significant changes in the levels of endothelial adhesion molecules.",
"   </p>",
"   <p>",
"    Other markers have been associated with increased risk of developing SOS. Clearly patients with a history of viral hepatitis, especially chronic active disease with ongoing liver function abnormalities, are at increased risk of SOS. Carriers of the hemochromatosis C282Y allele are also at significantly increased risk (RR 1.7 for heterozygotes and 8.6 for homozygotes) of developing SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms of the glutathione S-transferase gene have also been associated with the risk of developing SOS. This gene is associated with catabolizing chemotherapeutic agents such as busulphan and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    metabolites via conjugation with glutathione. In 114 consecutive patients with beta-thalassemia major undergoing BMT there was a significantly increased risk of SOS in patients with the GSTM1-null genotype compared with those with the GSTM1-positive genotype (46 versus 18 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previous treatment also has an impact of the risk of developing SOS. Prior use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     Gemtuzumab ozogamicin",
"    </a>",
"    (Myelotarg) has been associated with increased risk of SOS in some but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Due to this risk, treatment with myeloablative transplantation in patients previously treated with Myelotarg should be pursued with significant caution. The use of intravenous as compared with oral busulphan has been found to result in a reduced risk of developing SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major modalities that have been assessed for the treatment of SOS are human tissue-type plasminogen activator and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    . Of these, defibrotide is most promising and undergoing review by regulatory agencies for approval of this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alteplase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the treatment of SOS. In general a response rate of approximately 30 to 40 percent was seen in association with a significant risk of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, for example, 42 patients with SOS were treated with varying doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (median 60 mg total dose administered over two to four days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (1000 units bolus followed by continuous intravenous infusion of 150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day for 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/17\">",
"     17",
"    </a>",
"    ]. Response was defined as a reduction in total serum bilirubin by 50 percent or more within 10 days of starting therapy. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twelve patients responded to therapy and 30 did not. The nonresponders were more likely to have required dialysis or mechanical ventilation before or at the start of therapy.",
"     </li>",
"     <li>",
"      Hemorrhage occurred in 10 patients; it was fatal in three and may have contributed to death in an additional three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these findings, the authors recommended that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with severe SOS who have already developed multiorgan dysfunction. Higher dose alteplase is associated with a greater risk of bleeding and does not appear to improve the response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results have been obtained in children. In a small series, nine children with severe SOS were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two to four days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/19\">",
"     19",
"    </a>",
"    ]. Five had complete resolution of SOS, while three developed bleeding that required discontinuation of the heparin infusion but was not life-threatening. Due to the increased risk of bleeding and its modest efficacy, alteplase is rarely used for the treatment of SOS in our clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Defibrotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     Defibrotide",
"    </a>",
"    (DF) is a polydeoxyribonucleotide derived from mammalian tissue with multiple antithrombotic, fibrinolytic, and angiogenic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/21\">",
"     21",
"    </a>",
"    ]. It is an adenosine receptor agonist, increases levels of endogenous prostaglandins (PGI2 and E2), reduces levels of leukotriene B4, stimulates expression of thrombomodulin in endothelial cells, modulates platelet activity, and stimulates fibrinolysis by increasing endogenous tPA function and decreasing the activity of PAI-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In addition, DF has little systemic anticoagulant activity, demonstrating that it has a therapeutic advantage over the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Encouraging results have been obtained in a retrospective study of 19 patients with severe SOS and multiorgan dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/26\">",
"     26",
"    </a>",
"    ]. Treatment began a median of six days after diagnosis. DF was given intravenously in doses ranging from 5 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 14 days. Resolution was seen in eight patients (42 percent) and six (32 percent) survived past day +100. There was no significant treatment-related toxicity.",
"   </p>",
"   <p>",
"    Other reports have shown similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/5\">",
"     5",
"    </a>",
"    ]; the largest of these, including early results from a phase II dose-finding trial, indicated survival past day +100 in 35 to 46 percent of poor-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Predictors of survival included younger age, autologous (versus allogeneic) HCT, abnormal portal flow, and decreases in creatinine and plasminogen activator inhibitor 1 levels during the first 10 days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/28\">",
"     28",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -based conditioning and the presence of encephalopathy predicted for worse outcomes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     Defibrotide",
"    </a>",
"    has also been utilized for the treatment of children with SOS. In one report 45 patients (age range 0.2 to 20 years) with hepatic SOS were treated with defibrotide. Thirty-four patients (76 percent) achieved a complete response, with a survival rate of 64 percent at 100 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/30\">",
"     30",
"    </a>",
"    ]. Defibrotide has also been reported to be successful in treating SOS associated with prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These encouraging results are tempered by the difficulty in obtaining this agent in a timely manner. This agent is under review by the United States FDA for approval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antithrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin (AT) concentrate has been used in patients with SOS who have documented deficiency of AT. In one report, 10 patients with severe SOS and AT levels of less than 88 percent of normal were treated with AT (loading dose of 50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    every eight hours for three doses followed by 50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day for 3 to 12 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/32\">",
"     32",
"    </a>",
"    ]. Clinical improvement was seen in all patients from 1 to 10 days after beginning therapy.",
"   </p>",
"   <p>",
"    Two children with ultrasound evidence of SOS (ie, reversed portal venous flow) were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and a continuous infusion AT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/33\">",
"     33",
"    </a>",
"    ]. Both recovered with clinical and radiographic resolution of SOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prostaglandin E1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin E1, which has both vasodilator and antiplatelet activity, and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    were used to successfully treat three infants with SOS confirmed by duplex ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/34\">",
"     34",
"    </a>",
"    ]. The rationale for the use of prostaglandin E1 (alprostadil) is the vasodilatory and platelet inhibitory activity of this reagent. The regimen began with continuous infusion of prostaglandin E1 (initial dose 0.075",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per hour) and low dose heparin (100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day). Treatment was continued at the maximum tolerated dose of PGE1 (0.3 to 0.5",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per hour) until normal portal vein flow was restored in all three children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutathione is an important cytosolic antioxidant. To the extent that free radical damage is an important component of SOS, glutathione depletion may occur. Glutamine infusion in animal studies has been shown to maintain glutathione levels. In one report, two patients with established SOS were successfully treated with intravenous glutamine and oral vitamin E, suggesting that further study of the role of antioxidant therapy in the prophylaxis and treatment of SOS is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a prospective randomized trial of N-acetyl-L-cysteine, an antioxidant glutathione precursor, did not improve liver toxicity in 160 patients following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transjugular intrahepatic portosystemic stent-shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of a transjugular intrahepatic portosystemic stent-shunt (TIPS) has been performed in small numbers of patients with SOS; some patients had regression of the hepatic and renal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Patients with milder disease may be more likely to respond; long-term survival appears to be uncommon, but has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplantation has been successfully performed in small numbers of patients with SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/20,42\">",
"     20,42",
"    </a>",
"    ]. However, the majority of patients with severe SOS are not capable of undergoing such a rigorous surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of specific, effective therapy, efforts have been made to develop nontoxic prophylactic regimens to reduce the incidence and severity of SOS. Protocols using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA), low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    appear promising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study and a subsequent randomized controlled trial demonstrated that UDCA used prophylactically can reduce the incidence of SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In the pilot study, 22 consecutive patients undergoing HCT for hematologic malignancies received a",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"      busulfan",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    preparative regimen and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"      methotrexate",
"     </a>",
"    </span>",
"    for GVHD prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/43\">",
"     43",
"    </a>",
"    ]. UDCA (600 to 900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was begun at least one day prior to beginning the preparative regimen. Results for this pilot group were compared with a control group of 28 consecutive patients transplanted with the same regimen without UDCA. The administration of UDCA was associated with a lower incidence of SOS (9 versus 64 percent) and death (5 versus 21 percent).",
"   </p>",
"   <p>",
"    In the controlled study, 67 patients undergoing allogeneic bone marrow transplantation were randomly assigned to receive either UDCA (300 mg twice daily or 300 mg every morning and 600 mg every evening if body weight exceeded 90 kg) or placebo",
"    <strong>",
"     prior",
"    </strong>",
"    to induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/44\">",
"     44",
"    </a>",
"    ]. All patients received induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and prophylaxis against graft-versus-host disease with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . The incidence of SOS was significantly lower in patients assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (15 versus 40 percent, P = 0.03). The risk of relapse in patients with chronic myeloid leukemia and nonhepatic toxicities did not differ between the groups. There was a trend, which did not reach statistical significance, towards improved overall survival in the patients who were treated with UDCA.",
"   </p>",
"   <p>",
"    The efficacy and safety of UDCA has led some centers to use this drug routinely for the prevention of SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of a low-dose continuous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been evaluated in a prospective randomized clinical trial of 161 patients who underwent allogeneic or autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients were randomized to either low dose heparin (100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day by continuous intravenous infusion) or placebo. The infusion of heparin was initiated prior to the start of the preparative regimen and continued until 30 days after the transplant. A lower incidence of SOS was noted in the heparin group (2.5 versus 13.7 percent, P&lt;0.01); this benefit was most pronounced in those undergoing allogeneic HCT (0 versus 18 percent). There was no increase in bleeding risk or other toxicities in the patients treated with heparin.",
"   </p>",
"   <p>",
"    A second phase II study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prophylaxis in children also found a statistically significant reduction in SOS in patients who received heparin prophylaxis as compared with a historic control group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, another randomized trial did not confirm the benefit of heparin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/47\">",
"     47",
"    </a>",
"    ]. In this trial, however, heparin was initiated on the day of stem cell infusion, not at the beginning of the preparative regimen as in the randomized trial discussed above.",
"   </p>",
"   <p>",
"    Low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) is also being evaluated. In a pilot study, 61 patients undergoing HCT were randomized to receive LMWH (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo from prior to conditioning until day +40 posttransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/48\">",
"     48",
"    </a>",
"    ]. LMWH was associated with less SOS parameters (a shorter duration of jaundice and a lower frequency of hepatomegaly) and less bleeding than patients receiving placebo.",
"   </p>",
"   <p>",
"    However, a benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has not been confirmed in all series. In one report that included 1652 transplants from 73 European centers, the use of prophylactic unfractionated heparin in a subset of 66 patients was not associated with a lower incidence of SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/49\">",
"     49",
"    </a>",
"    ]. Similar findings were observed in another retrospective series that included 249 patients, of whom 46 percent had received heparin prophylaxis given from the start of the conditioning regimen until one month after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/50\">",
"     50",
"    </a>",
"    ]. The incidence and mortality of SOS in these patients was similar to patients who had received no prophylaxis (incidence 9 versus 10 percent, one year mortality among SOS patients 72 versus 79 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Defibrotide prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies in both adults and children have reported significant reductions in the incidence of post-HCT SOS following the prophylactic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, the incidence of SOS in 52 patients who received prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"       defibrotide",
"      </a>",
"      between days &ndash;7 and +20 was compared with historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/51\">",
"       51",
"      </a>",
"      ]. None of the 52 patients receiving defibrotide prophylaxis developed SOS, significantly better than the historical controls where 19 percent developed SOS along with three deaths. There was also a trend towards improved survival in this report.",
"     </li>",
"     <li>",
"      Similar results were obtained in a study of 58 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"       defibrotide",
"      </a>",
"      prophylaxis without concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/52\">",
"       52",
"      </a>",
"      ]. No patient fulfilled criteria for SOS or developed hemorrhagic complications secondary to defibrotide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multicenter phase III, open-label trial, 356 children (mean age 6.6 years) undergoing myeloablative HCT who had one or more risk factor for SOS were randomly assigned to receive prophylactic intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    or not [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    use was permitted for patients with central venous access and approximately one-third of patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    . All patients who developed SOS were treated with defibrotide. Patients assigned to defibrotide prophylaxis had a significantly lower cumulative incidence of SOS at 30 days post-HCT (12 versus 20 percent) and a lower incidence of renal failure (1 versus 6 percent). Mortality at 100 and 180 days post-HCT were similar. Defibrotide was well tolerated with no increase in hemorrhage.",
"   </p>",
"   <p>",
"    These results suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    prophylaxis decreases the incidence of SOS in children at high risk for SOS. It is not known whether these results may be extrapolated to the adult population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Peripheral blood progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing autologous transplant, it is possible that the source of stem cells (peripheral blood progenitor cells versus bone marrow) can influence the likelihood of developing SOS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .) In a retrospective study of women with metastatic breast cancer who underwent autologous transplantation, the 100-day transplant-related mortality fell from 20 to 6 percent following the introduction of PBPCs, largely due to a reduction in mortality from SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/55\">",
"     55",
"    </a>",
"    ]. SOS was responsible for 50 percent of deaths in the bone marrow alone group; in comparison, there was only one SOS-related death in patients receiving PBPCs. This benefit is presumably due to the more rapid hematologic recovery and reduced infection risk with the use of PBPCs or perhaps to patient selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     T cell depleted donor marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective T cell depletion of donor bone marrow can reduce the incidence of graft-versus host-disease. In an uncontrolled study of 97 patients undergoing T cell depleted allogeneic bone marrow transplant, only three patients developed SOS, which is lower than would have been expected for this sized cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Parenteral glutamine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is associated with depletion of antioxidant glutathione, which may predispose to hepatic endothelial cell injury. Glutamine infusion may help maintain glutathione levels and, as noted above, has been used in the treatment of established SOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/35\">",
"     35",
"    </a>",
"    ]. The prophylactic use of intravenous glutamine has also been evaluated. In a pilot study, 34 patients undergoing bone marrow transplantation were randomly assigned to intravenous glutamine supplementation or an isonitrogenous mixture of non-essential amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7081/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients randomized to glutamine were significantly more likely to have preserved levels of protein C and albumin, suggesting a potential hepatoprotective role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic sinusoidal obstruction syndrome (SOS), previously called hepatic veno-occlusive disease (VOD), is one of the most feared complications of allogeneic and autologous hematopoietic cell transplantation (HCT). It accounts for a significant fraction of transplant-related mortality and, in its severe form, is almost always fatal.",
"     </li>",
"     <li>",
"      Prevention of SOS is far preferable to treatment. The use of either low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      (UDCA) is appropriate for the prophylaxis of patients undergoing HCT. Our choice of agent is largely dependent upon the type of HCT. For patients undergoing myeloablative HCT, we suggest UDCA for prophylaxis. For patients undergoing autologous HCT, we suggest low dose heparin for prophylaxis. Prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"       defibrotide",
"      </a>",
"      is of interest and deserves further investigation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of established SOS is more problematic. The two major modalities that have been assessed for the treatment of SOS are human tissue-type plasminogen activator and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"       defibrotide",
"      </a>",
"      . Of these, defibrotide is most promising and undergoing review by regulatory agencies for approval of this indication. It is hoped that future studies will use prognostic parameters to make an earlier diagnosis, which may increase the response rate to the administration of these agents. &nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/1\">",
"      Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/2\">",
"      McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/3\">",
"      Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/4\">",
"      Terra SG, Spitzer TR, Tsunoda SM. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation. Pharmacotherapy 1997; 17:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/5\">",
"      Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999; 107:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/6\">",
"      Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003; 10:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/7\">",
"      Haire WD, Ruby EI, Gordon BG, et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 1995; 274:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/8\">",
"      Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996; 125:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/9\">",
"      Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/10\">",
"      Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/11\">",
"      S&uuml;dhoff T, Heins M, S&ouml;hngen D, et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol 1998; 60:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/12\">",
"      Kallianpur AR, Hall LD, Yadav M, et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/13\">",
"      Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/14\">",
"      Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/15\">",
"      Nabhan C, Rundhaugen L, Jatoi M, et al. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol 2004; 15:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/16\">",
"      Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/17\">",
"      Bearman SI, Lee JL, Bar&oacute;n AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/18\">",
"      Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/19\">",
"      Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/20\">",
"      H&aacute;gglund H, Ringd&eacute;n O, Ericzon BG, et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/21\">",
"      Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008; 112:4343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/22\">",
"      Evangelista V, Piccardoni P, de Gaetano G, Cerletti C. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. Thromb Haemost 1992; 67:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/23\">",
"      Berti F, Rossoni G, Biasi G, et al. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990; 40:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/24\">",
"      Bacher P, Kindel G, Walenga JM, Fareed J. Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug \"defibrotide\". A dual mechanism in the control of vascular pathology. Thromb Res 1993; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/25\">",
"      Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994; 71:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/26\">",
"      Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/27\">",
"      Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/28\">",
"      Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/29\">",
"      Richardson PG, Soiffer R, Antin JH, et al. Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT) [abstract]. Blood 2002; 100:112a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/30\">",
"      Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/31\">",
"      Saviola A, Luppi M, Potenza L, et al. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. Br J Haematol 2003; 123:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/32\">",
"      Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/33\">",
"      Patton DF, Harper JL, Wooldridge TN, et al. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Bone Marrow Transplant 1996; 17:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/34\">",
"      Schlegel PG, Haber HP, Beck J, et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998; 76:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/35\">",
"      Goringe AP, Brown S, O'Callaghan U, et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998; 21:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/36\">",
"      Barkholt L, Remberger M, Hassan Z, et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/37\">",
"      Smith FO, Johnson MS, Scherer LR, et al. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/38\">",
"      L&eacute;vy V, Azoulay D, Rio B, et al. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS). Bone Marrow Transplant 1996; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/39\">",
"      Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/40\">",
"      Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/41\">",
"      Annaloro C, Robbiolo L, Pozzoli E, et al. Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leuk Lymphoma 2004; 45:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/42\">",
"      Rosen HR, Martin P, Schiller GJ, et al. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996; 2:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/43\">",
"      Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/44\">",
"      Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/45\">",
"      Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79:2834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/46\">",
"      Rosenthal J, Sender L, Secola R, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/47\">",
"      Marsa-Vila L, Gorin NC, Laporte JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/48\">",
"      Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/49\">",
"      Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92:3599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/50\">",
"      H&auml;gglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/51\">",
"      Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/52\">",
"      Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/53\">",
"      Cappelli B, Chiesa R, Evangelio C, et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009; 147:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/54\">",
"      Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/55\">",
"      Fisher DC, Vredenburgh JJ, Petros WP, et al. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant 1998; 21:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/56\">",
"      Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992; 10:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7081/abstract/57\">",
"      Brown SA, Goringe A, Fegan C, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998; 22:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3541 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7081=[""].join("\n");
var outline_f6_58_7081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alteplase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Defibrotide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antithrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prostaglandin E1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transjugular intrahepatic portosystemic stent-shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Defibrotide prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Peripheral blood progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      T cell depleted donor marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Parenteral glutamine supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7082="Dermatophyte (tinea) infections";
var content_f6_58_7082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatophyte (tinea) infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/58/7082/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/58/7082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatophyte infections are common disorders worldwide, and dermatophytes represent the prevailing type of fungi that cause infection of the skin and nails [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These infections lead to a variety of clinical manifestations, including tinea capitis, tinea pedis, tinea corporis, tinea cruris, and Majocchi&rsquo;s granuloma.",
"   </p>",
"   <p>",
"    This topic discusses the clinical features, diagnosis, and treatment of dermatophyte infections of the skin and hair. Dermatophyte infections of the nails are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link\">",
"     \"Onychomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of dermatophytes account for the majority of infections:",
"    <em>",
"     Epidermophyton",
"    </em>",
"    ,",
"    <em>",
"     Trichophyton",
"    </em>",
"    , and",
"    <em>",
"     Microsporum",
"    </em>",
"    . Dermatophytoses have varied presentations, are named by location, and have similar treatments.",
"   </p>",
"   <p>",
"    Dermatophytes have acquired in the evolutionary process the ability to metabolize and subsist upon keratin, a protein resistant to most other organisms. The fungi attack skin, nails, and hair, where keratin is the major structural protein, leading to a wide variety of disease states.",
"   </p>",
"   <p>",
"    The major types of dermatophyte infections include: involvement of the scalp (tinea capitis), feet (tinea pedis), groin (tinea cruris), and other body surfaces (tinea corporis). These are typically superficial, involving the epidermis. However, in some patients dermatophyte infections may penetrate the hair follicle and involve the dermis; this condition is termed Majocchi's granuloma. The diagnosis and management of the more common types of infestations are described here.",
"   </p>",
"   <p>",
"    Dermatophyte infections routinely affect individuals who are otherwise healthy, but people with compromised immune systems are particularly susceptible. Bizarre presentations and failure to respond to treatment should alert care providers to the possibility of an underlying immunologic problem [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most important considerations when evaluating superficial dermatophyte infections is confirming the diagnosis with a laboratory specimen, either a potassium hydroxide (KOH) preparation or culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common mistake that many clinicians make is to prescribe combination antifungal corticosteroid products (eg, Lotrisone&reg;) for the treatment of common fungal skin infections without confirming the diagnosis. This course of action is not recommended for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical corticosteroids can exacerbate tinea infections and may contribute to treatment failure, especially when infections are due to",
"      <em>",
"       Microsporum",
"      </em>",
"      species [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. If the patient fails to improve, it is unclear why, and the use of a potent corticosteroid preparation in a combination product may alter the clinical appearance of a dermatophyte infection. This makes the diagnosis of the underlying disease more difficult. Lotrisone&reg; contains clotrimazole and betamethasone dipropionate, a high potency topical corticosteroid.",
"     </li>",
"     <li>",
"      Some conditions, like tinea cruris, may require antifungal treatment for several weeks; using a combination product puts the patient at risk unnecessarily for side effects, such as skin atrophy, from topical corticosteroids.",
"     </li>",
"     <li>",
"      Combination products are far more expensive than simple antifungal agents, or even generically available corticosteroid preparations. In one study, nondermatologists were more likely than dermatologists to prescribe combination products (34 versus 4 percent), leading to excess medical costs of $10 to 25 million [",
"      <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, clinicians should avoid the use of nystatin for the treatment of tinea infections. Nystatin is effective for cutaneous candidal infections, but not for the treatment of dermatophytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TINEA CAPITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea capitis, dermatophyte infection of the scalp, almost always occurs in small children. A clinical diagnosis of tinea capitis in adults is often incorrect, and frequently turns out to be seborrheic dermatitis or another inflammatory condition. The major exception to this rule is the development of tinea capitis in immunocompromised or immunosuppressed adults.",
"   </p>",
"   <p>",
"    Tinea capitis can occur in three distinctly different forms, \"gray patch,\" \"black dot\" and favus. Black dot tinea capitis, most often caused by",
"    <em>",
"     Trichophyton tonsurans",
"    </em>",
"    , is the form predominantly seen in the United States. Favus, most often due to",
"    <em>",
"     Trichophyton schoenleinii",
"    </em>",
"    , is rarely seen in the United States and Europe, but may be seen in countries where",
"    <em>",
"     Trichophyton schoenleinii",
"    </em>",
"    infection is endemic, such as Iran, China, and Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/9\">",
"     9",
"    </a>",
"    ]. Immigration and travel may contribute to the occurrence of favus in patients who live in nonendemic areas.",
"   </p>",
"   <p>",
"    Tinea capitis is most often an endothrix infection due to",
"    <em>",
"     Trichophyton",
"    </em>",
"    species; nonfluorescent arthroconidia are located within the hair shaft. Spores are identifiable by KOH examination of the hair shaft, not by KOH scraping of the scale, though hyphae may be seen on occasion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Black dot tinea capitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gray patch tinea capitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gray patch tinea capitis (GPTC) occurs in epidemic and endemic forms. Formerly common, the epidemic form has virtually disappeared from North America. The endemic form caused by",
"    <em>",
"     Microsporum canis",
"    </em>",
"    and contracted usually from cats and dogs, continues to be seen. Person to person spread is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection begins with an erythematous, scaling, well-demarcated patch on the scalp that spreads centrifugally for a few weeks or months, ceases to spread, and persists indefinitely, sometimes for years. One or several lesions may be present (",
"    <a class=\"graphic graphic_picture graphicRef86686 \" href=\"UTD.htm?25/35/26167\">",
"     picture 1",
"    </a>",
"    ). The inflammation subsides, and the hairs within the patch break off a millimeter or two above the level of the scalp. The short, broken hairs take on a frosted appearance. Typical areas of tinea corporis may also be found on glabrous skin.",
"   </p>",
"   <p>",
"    In a few cases the lesions change abruptly to become boggy, elevated, tender nodules (kerion). The surface of these lesions, largely devoid of hair, is covered with viscid exudate (",
"    <a class=\"graphic graphic_picture graphicRef86627 \" href=\"UTD.htm?42/62/44007\">",
"     picture 2",
"    </a>",
"    ). Kerion is a form of immune response to the fungus, but secondary staphylococcal infection with regional adenitis may also complicate the picture. Posterior cervical lymphadenopathy often occurs with kerion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/10\">",
"     10",
"    </a>",
"    ], but is also seen with more routine presentations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spores in patients with GPTC are readily identifiable by KOH examination of manually epilated hair (",
"    <a class=\"graphic graphic_picture graphicRef62438 \" href=\"UTD.htm?5/56/6023\">",
"     picture 3",
"    </a>",
"    ). Infected hair fragments infected with",
"    <em>",
"     Microsporum canis",
"    </em>",
"    may also fluoresce bright green under a Wood's ultraviolet (UV) lamp. Culture of hairs on Sabouraud's medium can confirm the diagnosis in questionable cases, but is not usually necessary if either of the prior methods yields positive findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Black dot tinea capitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Black dot tinea capitis (BDTC) is the most common form of tinea capitis in the United States. It is largely a disease of childhood, although adults, especially the elderly, are occasionally affected. All ethnic groups may be infected, but African-American children are particularly susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/11\">",
"     11",
"    </a>",
"    ], possibly because of increased coiling of hair shafts. Spread is usually from child to child contact. Fomites (shared hats, combs, brushes, barrettes, rollers, etc) may play an important role. Asymptomatic carriers in the household may also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study compared the hair care practices of children with culture-proven",
"    <em>",
"     Trichophyton tonsurans",
"    </em>",
"    scalp infection and those without tinea capitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/13\">",
"     13",
"    </a>",
"    ]. Exposure to",
"    <em>",
"     Trichophyton tonsurans",
"    </em>",
"    was associated with scalp infection, while hairstyling, frequency of washing, use of oils or grease, and other hair care practices did not appear to play a major role in the acquisition of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;BDTC usually begins as an asymptomatic, erythematous, scaling patch on the scalp, which slowly enlarges. Lesions may be single or multiple. Early lesions are easily overlooked and the disease is not usually noticed until areas of alopecia become evident. Hairs within the patches break off flush with the scalp; detritus within the follicular opening formerly occupied by the hair appears as a black dot (",
"    <a class=\"graphic graphic_picture graphicRef86628 \" href=\"UTD.htm?9/47/9976\">",
"     picture 4",
"    </a>",
"    ). In some cases inflammation is prominent, and the lesions can resemble pyoderma or discoid lupus erythematosus. Painful lymphadenopathy can also occur in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/10\">",
"     10",
"    </a>",
"    ]. Left untreated, scarring with permanent alopecia can occur and the disease can last indefinitely. Patches of tinea corporis may appear on glabrous skin, and the nails are sometimes involved. As in gray patch tinea capitis, a sudden transition to kerion may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of BDTC is made by performing KOH examination of spores on the hair shaft. Occasionally, hyphae may be seen in scale. In contrast to GPTC caused by",
"    <em>",
"     Microsporum canis",
"    </em>",
"    , the organisms that cause BDTC do not fluoresce green under Woods Light. Diagnosis can be confirmed by culture on Sabouraud's medium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176813\">",
"    <span class=\"h2\">",
"     Favus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favus (also known as tinea favosa) is a form of endothrix tinea capitis that has decreased in incidence worldwide, but remains endemic in China, Nigeria, and Iran [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <em>",
"     Trichophyton schoenleinii",
"    </em>",
"    is the most common cause of favus. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176727\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients initially develop perifollicular erythema on the scalp, which progresses to the characteristic finding of concave, cup-shaped yellow crusts called scutula. Scutula are composed of fungi, neutrophils, dried serum, and epidermal cells. As the disease advances, the scutula coalesce into confluent and adherent masses which overlay severe alopecia. Untreated infections may persist into adulthood.",
"   </p>",
"   <p>",
"    Transmission usually does not occur with casual contact; rather, prolonged exposure appears to be required for acquisition. Familial cases are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176734\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;KOH examination of lesional hairs demonstrates fungal hyphae arranged in a longitudinal direction within the hair shafts. Culture can be performed on Sabouraud&rsquo;s medium and Wood&rsquo;s lamp examination of infected hairs reveals a characteristic sliver-blue fluorescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gray patch, black dot, and favus forms of tinea capitis all respond to the same medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Griseofulvin has a long history of safety and efficacy in tinea capitis in children. Oral terbinafine, itraconazole, and fluconazole are additional therapeutic options that allow shorter courses of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/15-22\">",
"     15-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The comparative efficacy of terbinafine and griseofulvin for tinea capitis has been evaluated in multiple randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In a meta-analysis of randomized trials (n = 2163), the drugs were similarly effective for the treatment of tinea capitis when all variants of the disease were considered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/24\">",
"     24",
"    </a>",
"    ]. However, subgroup analysis revealed that efficacy varied with the type of infection: terbinafine was less effective than griseofulvin for infections due to",
"    <em>",
"     Microsporum",
"    </em>",
"    species (odds ratio [OR] 0.41, 95% CI 0.25-0.66), and more effective for infections due to",
"    <em>",
"     Trichophyton",
"    </em>",
"    species (OR 1.62, 95% CI 1.27-2.05). The doses of griseofulvin used in the trials (&lt;20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) were lower than the doses used by many clinicians (including ourselves) for the treatment of tinea capitis, precluding conclusions about the relative efficacy of griseofulvin for",
"    <em>",
"     Trichophyton",
"    </em>",
"    infections when given at higher doses. There was only one serious adverse effect, reversible neutropenia, in a patient treated with terbinafine. There were no serious episodes of liver transaminitis in patients treated with terbinafine.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis restricted to five randomized trials that utilized similar doses of terbinafine (3.125 to 6.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for four weeks) and griseofulvin (6.25 to 12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for eight weeks) found similar results regarding the comparative efficacy of terbinafine and griseofulvin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the two treatments appeared to have similar efficacy overall, terbinafine was superior for the treatment of infections from",
"    <em>",
"     Trichophyton",
"    </em>",
"    species and griseofulvin was superior for the treatment of infections due to",
"    <em>",
"     Microsporum",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    A few randomized trials have investigated the use of oral azole antifungals for tinea capitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. The efficacy of itraconazole and fluconazole for tinea capitis appears to be similar to griseofulvin.",
"   </p>",
"   <p>",
"    Griseofulvin is our first choice for the treatment of patients with",
"    <em>",
"     Microsporum",
"    </em>",
"    tinea capitis and patients in whom the inciting cause of tinea capitis is uncertain due to its long history of safety in children. Terbinafine is an alternative first line agent in patients with tinea capitis that is highly likely or known to be due to",
"    <em>",
"     Trichophyton",
"    </em>",
"    species, particularly when a shorter duration of therapy is desired. The release of a generic formulation of terbinafine has significantly reduced the cost of this agent in the United States.",
"   </p>",
"   <p>",
"    Griseofulvin treatment schedules for children are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      (microsize formulation) for 6 to 12 weeks",
"     </li>",
"     <li>",
"      10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      (ultramicrosize formulation) for 6 to 12 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Terbinafine tablet treatment schedules are based on weight [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      10 to 20 kg: 62.5 mg daily for two to four weeks",
"     </li>",
"     <li>",
"      20 to 40 kg: 125 mg daily for two to four weeks",
"     </li>",
"     <li>",
"      Above 40 kg: 250 mg daily for two to four weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If terbinafine is used for the treatment of",
"    <em>",
"     Microsporum",
"    </em>",
"    tinea capitis, longer courses of treatment (8 to 10 weeks) may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/15,27\">",
"     15,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Terbinafine is also manufactured as a granule formulation, which can be sprinkled onto non-acidic foods (eg, pudding or mashed potatoes). The dose regimen for terbinafine granules is the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 25 kg: 125 mg daily for six weeks",
"     </li>",
"     <li>",
"      25 to 35 kg: 187.5 mg daily for six weeks",
"     </li>",
"     <li>",
"      Above 35 kg: 250 mg daily for six weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Itraconazole can be used in children as continuous therapy at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for four to six weeks. Alternatively, pulse therapy with itraconazole capsules can be given at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <strong>",
"     daily for one week each month",
"    </strong>",
"    for two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. The suggested dose for pulse therapy with the oral solution of itraconazole is 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tinea capitis may be treated with fluconazole 6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for three to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. Intermittent dosing is another option for fluconazole therapy (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <strong>",
"     once weekly",
"    </strong>",
"    for 8 to 12 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up visits should be scheduled to assess the response to treatment. Treatment may need to be extended if active disease remains at the end of a prescribed course of therapy.",
"   </p>",
"   <p>",
"    Topical treatment of tinea capitis is futile and a common cause of treatment failure. Treatment or removal of an animal is important only when the diagnosis is gray patch tinea capitis caused by",
"    <em>",
"     M. canis",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Identification of asymptomatic carriers and household fomites is an important part of the management of BDTC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/12\">",
"     12",
"    </a>",
"    ]. Culture on Sabouraud's medium of hairs and scalp dander (collected by brushing the area with a tooth brush) facilitates carrier identification. Carriers should be treated with selenium sulfide shampoo or with oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Household members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohabitants of patients with tinea capitis can be asymptomatic carriers of dermatophytes, and it has been speculated that these individuals may be sources of reinfection for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/12\">",
"     12",
"    </a>",
"    ]. In one cross-sectional study in which scalp cultures were taken from 209 household contacts of patients with tinea capitis, 44 percent were found to be asymptomatic carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/29\">",
"     29",
"    </a>",
"    ]. Culture specimens were obtained via rubbing multiple areas of the scalp with a disposable toothbrush followed by inoculation onto agar.",
"   </p>",
"   <p>",
"    Although high quality evidence regarding the impact of household members who are asymptomatic carriers on the development of recurrent or persistent disease is not available, some authors have suggested identifying and treating asymptomatic carriers with antifungal shampoo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/12,29\">",
"     12,29",
"    </a>",
"    ]. Routine treatment of all household contacts without performing preliminary cultures has also been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/30\">",
"     30",
"    </a>",
"    ]. Selenium sulfide 2.5% or ketoconazole 2% shampoo applied for at least five minutes, three times weekly, can be prescribed.",
"   </p>",
"   <p>",
"    Sharing of fomites, such as hats, combs, or brushes should be avoided in households with an affected patient. If transmission of",
"    <em>",
"     Microsporum canis",
"    </em>",
"    from a pet is suspected, the pet should be referred for treatment of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Kerion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kerion is managed by treating the underlying fungal disorder. Some advocate the use of systemic glucocorticoid therapy in patients with a kerion, but randomized trials of oral or intralesional steroids plus oral antifungal agents versus oral antifungal agents alone showed no difference in cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, glucocorticoid therapy may improve discomfort from kerion.",
"   </p>",
"   <p>",
"    Inappropriate hospitalization sometimes occurs because clinicians mistakenly believe the patient with a kerion has severe secondary bacterial infection, conditions not borne out by diagnostic cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/33\">",
"     33",
"    </a>",
"    ]. Only limited evidence exists for combining antifungal treatment with oral administration of antibiotics active against staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/34\">",
"     34",
"    </a>",
"    ], and the majority of cases can be treated successfully without antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     In infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea capitis is rare in children younger than one year of age, but does occur. Most affected infants are immunologically normal, but the possibility of immunodeficiency should be kept in mind. Contacts of the infant with tinea capitis should be carefully examined to identify and treat the source of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical treatment is generally ineffective. Successful treatment of infants with tinea capitis has been reported with griseofulvin, terbinafine, ketoconazole, and fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, fluconazole is the only oral antifungal agent approved for children younger than two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TINEA PEDIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea pedis (athlete's foot) is the most common dermatophyte infection encountered in practice. It is often accompanied by tinea manuum, onychomycosis (tinea unguium), or tinea cruris (dermatophyte infection of the hands, nails, or groin).",
"   </p>",
"   <p>",
"    Tinea pedis presents in two readily distinguishable clinical forms, acute and chronic. Both are contagious, contracted by contact with arthrospores shed by infected individuals onto the floors of swimming pool facilities, locker rooms, etc. The acute form is usually caused by",
"    <em>",
"     Trichophyton mentagrophytes, var. interdigitale",
"    </em>",
"    , and the chronic form by",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute tinea pedis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attacks of acute tinea pedis are self-limited, intermittent, and recurrent. They often follow activities that cause the feet to sweat. Acute tinea pedis begins with the appearance of intensely pruritic, sometimes painful, erythematous vesicles or bullae between the toes or on the soles, frequently extending up the instep (",
"    <a class=\"graphic graphic_picture graphicRef54214 graphicRef62902 \" href=\"UTD.htm?18/54/19302\">",
"     picture 5A-B",
"    </a>",
"    ). The disease may be unilateral or bilateral. Secondary staphylococcal infections with lymphangitis often complicate the picture.",
"   </p>",
"   <p>",
"    Secondary eruptions at distant sites may occur simultaneously due to a presumed immunologic reaction to the fungus. This is a sterile vesicular eruption that often occurs on the palms and fingers, referred to as a dermatophytid reaction. This improves as the primary infection is treated. (See",
"    <a class=\"local\" href=\"#H4733135\">",
"     'Dermatophytid (id) reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and clinical picture combination is characteristic, but dyshidrotic eczema can resemble acute tinea pedis, and the diagnosis should be confirmed by KOH examination of scrapings from the lesions (",
"    <a class=\"graphic graphic_picture graphicRef75738 graphicRef60102 \" href=\"UTD.htm?35/17/36120\">",
"     picture 6A-B",
"    </a>",
"    ). The roof of a vesicle can provide an adequate specimen. Culture on Sabouraud's medium is also helpful in difficult cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic tinea pedis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic tinea pedis is the most common form of tinea pedis encountered in practice. Untreated it usually persists indefinitely. The disease begins with slowly progressive, pruritic, erythematous erosions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scales between the toes, especially in the third and fourth digital interspaces (",
"    <a class=\"graphic graphic_picture graphicRef76067 graphicRef80436 \" href=\"UTD.htm?16/35/16953\">",
"     picture 7A-B",
"    </a>",
"    ). Interdigital fissures are often present. Extension onto the sole, sides of the foot, and in some cases the top of the foot follows, presenting as chronic scaling (\"moccasin ringworm\") with variable degrees of underlying erythema (",
"    <a class=\"graphic graphic_picture graphicRef68583 graphicRef67076 \" href=\"UTD.htm?2/51/2873\">",
"     picture 8A-B",
"    </a>",
"    ). The border between involved and uninvolved skin is usually quite sharp, and the normal creases and markings of the skin (dermatoglyphics) tend to accumulate scale. In many cases the palms and flexor aspects of the fingers (tinea manuum) may be unilaterally involved (two feet, one hand) (",
"    <a class=\"graphic graphic_picture graphicRef57816 \" href=\"UTD.htm?9/17/9492\">",
"     picture 9",
"    </a>",
"    ). Mycotic nail dystrophy (onychomycosis) is also often present (",
"    <a class=\"graphic graphic_picture graphicRef78711 \" href=\"UTD.htm?33/42/34468\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The appearance of tinea pedis, cruris, and corporis can be modified in patients who have inappropriately been treated with topical steroids. This is referred to as tinea incognito. Patients can have diminished erythema without the typical scaling erythematous border, or can develop a deep-seated folliculitis (Majocchi granuloma) that may require oral antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and clinical picture combination is characteristic, but the diagnosis should be confirmed by KOH examination of scrapings from the lesions (",
"    <a class=\"graphic graphic_picture graphicRef60102 \" href=\"UTD.htm?4/2/4132\">",
"     picture 6B",
"    </a>",
"    ), as foot eczema and plantar psoriasis may be difficult to differentiate clinically from tinea pedis. Interdigital erythrasma may also resemble interdigital tinea pedis, but can be distinguished by the appearance of coral red fluorescence upon illumination with a Wood's lamp (",
"    <a class=\"graphic graphic_picture graphicRef71848 \" href=\"UTD.htm?32/29/33233\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=see_link\">",
"     \"Erythrasma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea pedis can usually be treated with a topical antifungal cream for four weeks; interdigital tinea pedis may only require one week of therapy. A review of the available evidence found strong evidence that topical treatments increase cure rates for tinea pedis compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of topical antifungal creams are available over the counter; some prescription agents have a broader spectrum of action and may be administered once instead of twice daily, but generally all of the creams that treat dermatophyte infections can be effective (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/37\">",
"     37",
"    </a>",
"    ]. A meta-analysis of 11 randomized trials concluded that treatment with allylamines (terbinafine or naftifine) produces a slightly higher cure rate than treatment with an azole [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/37\">",
"     37",
"    </a>",
"    ]. Nystatin is not effective for the treatment of dermatophyte infections.",
"   </p>",
"   <p>",
"    Patients with chronic or extensive disease may require oral antifungal therapy with terbinafine (250 mg daily for two weeks), itraconazole (200 mg twice daily for one week), or fluconazole (150 mg once weekly for two to six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26,38\">",
"     26,38",
"    </a>",
"    ]. Griseofulvin (1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of microsize, 660 or 750",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of ultramicrosize) can also treat tinea pedis, but may be less effective than other oral antifungals, and requires four to eight weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"     26",
"    </a>",
"    ]. In a systematic review in which treatment regimens varied from the above, terbinafine was found to be more effective than griseofulvin, while the efficacy of terbinafine and itraconazole were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/39\">",
"     39",
"    </a>",
"    ]. Nail involvement is another indication for oral therapy; however, different treatment regimens are required to cure tinea infections of the nail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link&amp;anchor=H15#H15\">",
"     \"Onychomycosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric dosing options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Terbinafine:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      10 to 20 kg: 62.5 mg daily",
"     </li>",
"     <li>",
"      20 to 40 kg: 125 mg daily",
"     </li>",
"     <li>",
"      Above 40 kg: 250 mg daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Itraconazole 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily",
"     </li>",
"     <li>",
"      Fluconazole 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      weekly",
"     </li>",
"     <li>",
"      Griseofulvin 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily or in divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to antifungal therapy, Burow's (1% aluminum acetate or 5% aluminum subacetate) wet dressings, applied for 20 minutes two to three times per day, may be helpful if vesiculation or maceration is present. Secondary infection should be treated with oral antibiotics. Other adjunctive therapies include use of foot powder to prevent maceration, treatment of shoes with antifungal powders, and avoidance of occlusive footwear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TINEA CORPORIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea corporis, dermatophyte infection of the body, is an entity less amenable to strict categorization, because it can present as a part of the clinical picture of any of other forms of dermatophytosis described in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea corporis often begins as a pruritic, circular or oval, erythematous, scaling patch or plaque that spreads centrifugally. Central clearing follows, while the active advancing border, a few millimeters wide, retains its red color and with cross lighting can be seen to be slightly raised. The result is a lesion shaped like a ring (annular), from which the disease derives its common name (",
"    <a class=\"graphic graphic_picture graphicRef71226 graphicRef53271 graphicRef66102 \" href=\"UTD.htm?42/21/43353\">",
"     picture 12A-C",
"    </a>",
"    ). Multiple lesions may run together to produce \"flower petal\" configurations (",
"    <a class=\"graphic graphic_picture graphicRef76839 \" href=\"UTD.htm?28/36/29250\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tinea corporis can be seen in adults caring for children with tinea capitis (most commonly seen in association with black dot tinea capitis caused by",
"    <em>",
"     Trichophyton tonsurans",
"    </em>",
"    ). It is also often seen in association with",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    infections. Extensive presentations should alert the examiner to the possibility of an underlying problem that has compromised the patient's immunologic system, for example, diabetes mellitus or HIV infection. Tinea corporis contracted from infected animals, particularly kittens and puppies, is often intensely inflammatory.",
"   </p>",
"   <p>",
"    Tinea corporis can also occur in outbreaks among athletes who have skin-to-skin contact [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/40\">",
"     40",
"    </a>",
"    ], such as wrestlers (tinea corporis gladiatorum). Most cases of tinea gladiatorum appear to be caused by",
"    <em>",
"     Trichophyton tonsurans",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appearance of tinea pedis, cruris, and corporis can be modified in patients who have inappropriately been treated with topical steroids. This is referred to as tinea incognito (",
"    <a class=\"graphic graphic_picture graphicRef54298 \" href=\"UTD.htm?8/46/8933\">",
"     picture 14",
"    </a>",
"    ). Patients can have diminished erythema without the typical scaling erythematous border, or can develop a folliculitis (Majocchi's granuloma) that may require oral antifungal therapy. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Majocchi's granuloma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A KOH preparation will show the segmented hyphae and arthrospores characteristic of all dermatophyte infections (",
"    <a class=\"graphic graphic_picture graphicRef60102 \" href=\"UTD.htm?4/2/4132\">",
"     picture 6B",
"    </a>",
"    ). Highest yields are obtained from material taken from the active border of the lesion. Cultures (on Sabouraud's medium) can also be used to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H9#H9\">",
"     \"Dermatologic procedures\", section on 'Fungal culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other cutaneous disorders may have clinical features that resemble tinea corporis. Localized granuloma annulare is a benign inflammatory condition which classically presents with one or more erythematous or violaceous annular plaques on the extremities (",
"    <a class=\"graphic graphic_picture graphicRef62354 graphicRef76216 \" href=\"UTD.htm?15/63/16375\">",
"     picture 15A-B",
"    </a>",
"    ). Unlike tinea corporis, scale is absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=see_link&amp;anchor=H35143181#H35143181\">",
"     \"Granuloma annulare\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythema annulare centrifugum, an inflammatory skin disorder of unknown etiology, also exhibits annular erythematous plaques (",
"    <a class=\"graphic graphic_picture graphicRef80998 graphicRef59741 \" href=\"UTD.htm?10/33/10774\">",
"     picture 16A-B",
"    </a>",
"    ). A trailing rim of scale is often evident in the superficial variant of this disorder. Patients with nummular eczema, psoriasis, subacute cutaneous lupus erythematosus, and pityriasis rosea may also possess lesions that resemble the annular scaly plaques associated with tinea corporis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea corporis usually responds well to the daily application of topical antifungals (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/42\">",
"     42",
"    </a>",
"    ]. Topical nystatin is ineffective due to its inactivity against dermatophytes. For individuals with extensive cases or patients who are severely immunocompromised, a systemic agent may be preferable. Systemic therapy is also appropriate in patients who have failed topical therapy.",
"   </p>",
"   <p>",
"    Appropriate systemic agents include oral terbinafine, fluconazole, and itraconazole; all of these agents appear to have greater efficacy and fewer side effects than oral griseofulvin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Reasonable regimens in adults include: terbinafine 250 mg daily for one to two weeks; fluconazole 150 mg once weekly for two to four weeks; itraconazole 200 mg daily for one to two weeks; griseofulvin 250 mg three times daily for two weeks.",
"   </p>",
"   <p>",
"    Athletes with tinea (corporis) gladiatorum are generally not allowed to participate in matches or practice because of concerns about the spread of infection. The appropriate duration of treatment before returning to the sport is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/41\">",
"     41",
"    </a>",
"    ]. A randomized trial in 22 wrestlers compared topical clotrimazole cream (1 percent twice daily) with oral fluconazole (200 mg weekly) each for three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/47\">",
"     47",
"    </a>",
"    ]. Clinical response rates were similar. The time to when half of wrestlers had negative cultures was longer in the topical treatment group (23 versus 11 days); however, this result was not statistically significant in this small study. In a second study by the same authors, in which 21 wrestlers who developed tinea corporis gladiatorum were treated with open label fluconazole 200 mg weekly, all patients had negative cultures by the third week of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of more definitive information, we suggest that patients with tinea gladiatorum be treated with an oral agent. Ten to 15 days is probably a reasonable time period to restrict participation in sports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/49\">",
"     49",
"    </a>",
"    ]. It is possible that data on culture negativity may overestimate the time to resolution of infectivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TINEA CRURIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea cruris (jock itch) is a special form of tinea corporis involving the crural fold. In North America the most common cause is T rubrum. A few cases are caused by",
"    <em>",
"     Epidermophyton floccosum",
"    </em>",
"    and occasionally",
"    <em>",
"     Trichophyton mentagrophytes",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Tinea cruris is far more common in men than women. The disease often begins after physical activity that results in copious sweating, and the source of the infecting fungus is usually the patient's own tinea pedis with or without onychomycosis. Obesity predisposes to tinea cruris, as do diabetes and immunodeficient states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea cruris begins with an erythematous patch high on the inner aspect of one or both thighs (opposite the scrotum in men). It spreads centrifugally, with partial central clearing and a slightly elevated, erythematous, sharply demarcated border that may show tiny vesicles that are visible only with a hand glass (",
"    <a class=\"graphic graphic_picture graphicRef56684 graphicRef63322 \" href=\"UTD.htm?4/6/4202\">",
"     picture 17A-B",
"    </a>",
"    ). When caused by",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    , the disease may extend well down on the thighs and up into the pubic region. In some cases it is extremely chronic and progressive, extending onto the perineum and perianal areas, into the gluteal cleft, and onto the buttocks (",
"    <a class=\"graphic graphic_picture graphicRef76169 \" href=\"UTD.htm?25/31/26100\">",
"     picture 18",
"    </a>",
"    ). In males, the scrotum is typically spared. This is an important clinical distinction between tinea cruris and candidal intertrigo, as candidiasis in males often involves scrotal skin.",
"   </p>",
"   <p>",
"    Tinea cruris caused by",
"    <em>",
"     T. mentagrophytes",
"    </em>",
"    is usually less extensive, but acutely inflammatory, and may clear spontaneously. Those that are caused by",
"    <em>",
"     Epidermophyton floccosum",
"    </em>",
"    are moderately inflammatory and sometimes occur in small case clusters that can be traced to fomites such as shared towels, contaminated exercise machines, etc.",
"   </p>",
"   <p>",
"    The appearance of tinea pedis, cruris, and corporis can be modified in patients who have inappropriately been treated with topical steroids. This is referred to as tinea incognito. Patients can have diminished erythema without the typical scaling erythematous border, or can develop a folliculitis (Majocchi granuloma) that may require oral antifungal therapy. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Majocchi's granuloma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;KOH examination of scales scraped from the lesion will show the segmented hyphae and arthrospores characteristic of all dermatophyte infections. Highest yields are obtained from material taken from the active border of the lesion. Cultures (on Sabouraud's medium) can also be used to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Other common skin disorders that may present with erythematous patches or plaques in the inguinal region include inverse psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef76200 \" href=\"UTD.htm?3/19/3381\">",
"     picture 19",
"    </a>",
"    ), erythrasma (",
"    <a class=\"graphic graphic_picture graphicRef51713 \" href=\"UTD.htm?42/36/43587\">",
"     picture 20A",
"    </a>",
"    ), seborrheic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef68137 \" href=\"UTD.htm?19/8/19591\">",
"     picture 21",
"    </a>",
"    ), and candidal intertrigo. A KOH preparation positive for hyphae rules out the first three disorders. Candidiasis is suggested by the presence of erythematous patches with satellite papules and pustules (",
"    <a class=\"graphic graphic_picture graphicRef80146 graphicRef72073 \" href=\"UTD.htm?2/27/2489\">",
"     picture 22A-B",
"    </a>",
"    ). Candidal pseudohyphae, hyphae,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    yeast cells are visualized on KOH preparation (",
"    <a class=\"graphic graphic_picture graphicRef51081 graphicRef64872 \" href=\"UTD.htm?19/58/20394\">",
"     picture 23A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link\">",
"     \"Candidal intertrigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of erythrasma is confirmed by the appearance of coral red fluorescence upon illumination with a Wood's lamp (",
"    <a class=\"graphic graphic_picture graphicRef51713 graphicRef62143 \" href=\"UTD.htm?5/52/5960\">",
"     picture 20A-B",
"    </a>",
"    ). Although not always present, the identification of lesions consistent with seborrheic dermatitis or psoriasis in other locations is useful for diagnosing these two conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=see_link\">",
"     \"Erythrasma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antifungal treatment will suffice for the ordinary case (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    ). Nystatin is not effective for the treatment of tinea cruris. Lesions resistant to topical medications can be treated with griseofulvin by mouth, 250 mg three times daily for 14 days, or any of the other systemic agents.",
"   </p>",
"   <p>",
"    Tinea pedis and onychomycosis are risk factors for tinea cruris, and failure to treat concomitant tinea pedis usually results in prompt recurrence. Subsequent episodes of tinea pedis should be treated promptly. Treatment of onychomycosis may also reduce the risk for recurrent disease.",
"   </p>",
"   <p>",
"    Daily application of talcum or other desiccant powders to keep the area dry will help prevent recurrences. Itching can be alleviated by over the counter preparations such as Sarna or Prax, although these can be irritating if applied to inflamed or excoriated skin. Patients should also be advised to avoid hot baths and tight-fitting clothing; men should be advised to wear boxer shorts rather than briefs, and women to wear cotton underwear and avoid tight-fitting pants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MAJOCCHI'S GRANULOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatophyte infections are usually limited to the epidermis. Majocchi's granuloma is an uncommon condition in which the dermatophyte invades the dermis and subcutaneous tissue.",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    is the most frequent etiologic agent, although other dermatophytes have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The condition is thought to be precipitated by trauma to the skin or occlusion of hair follicles, leading to the disruption of hair follicles and passage of the dermatophyte into the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Shaving the legs can be an inciting factor in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompetent patients, the clinical findings are typically characterized by a localized area with erythematous, perifollicular papules or small nodules (",
"    <a class=\"graphic graphic_picture graphicRef71373 \" href=\"UTD.htm?37/0/37889\">",
"     picture 24",
"    </a>",
"    ). Pustules may also be present.",
"   </p>",
"   <p>",
"    Immunocompromised patients can also develop Majocchi's granuloma. They may present similarly to immunocompetent patients, or with subcutaneous nodules and abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. Trauma is also thought to be an inciting factor in these cases. The depression of cell-mediated immunity and the inflammatory response, important for the inhibition of dermatophyte infections, may contribute to progression of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/52,55,60,61\">",
"     52,55,60,61",
"    </a>",
"    ]. Rarely, systemic dissemination may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/52,62\">",
"     52,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In immunocompetent patients, topical corticosteroid use on a superficial dermatophyte infection can lead to local immunosuppression, and promote the development of Majocchi's granuloma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/54,63,64\">",
"     54,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis is made based on the patient's history and clinical findings, and can be confirmed with a skin biopsy exhibiting fungal forms in the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/52\">",
"     52",
"    </a>",
"    ]. Tissue culture can identify the causative organism. A KOH preparation, which identifies fungal forms only within the stratum corneum, may be negative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/52,60,65,66\">",
"     52,60,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antifungals are unlikely to penetrate deeply enough to effectively treat Majocchi's granuloma. Treatment with an oral antifungal is recommended, and multiple treatment regimens have been proposed, although no randomized trials or large case series are available.",
"   </p>",
"   <p>",
"    Terbinafine 250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two to four weeks has been used for the treatment of Majocchi's granuloma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. A case series of seven successfully treated patients, including one patient receiving systemic immunosuppressants for chronic lymphocytic leukemia, led to the recommendation of pulse therapy with itraconazole 200 mg twice daily for 1 week per month for 2 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/69\">",
"     69",
"    </a>",
"    ]. Treatment regimens with griseofulvin and daily itraconazole have also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients have been successfully treated with oral antifungals. Treatment by local excision has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], but may not be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4733135\">",
"    <span class=\"h1\">",
"     DERMATOPHYTID (ID) REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoeczematization reactions (also known as id reactions) are secondary dermatitic eruptions that occur in association with primary, often inflammatory, skin disorders. The term dermatophytid reaction describes this occurrence in relation to a dermatophyte infection. The pathogenesis may involve an immunologic reaction to fungal antigens similar to a delayed-type hypersensitivity response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermatophytid reactions can occur in patients with tinea pedis, tinea manuum, tinea cruris, tinea corporis, or tinea capitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/70-76\">",
"     70-76",
"    </a>",
"    ]. Patients typically present with pruritic, papulovesicular eruptions that can be quite distant from the site of infection (",
"    <a class=\"graphic graphic_picture graphicRef52664 graphicRef63421 \" href=\"UTD.htm?35/7/35960\">",
"     picture 25A-B",
"    </a>",
"    ). In one series of 213 patients with tinea pedis, 37 (17 percent) were diagnosed with dermatophytid reactions characterized by vesicular eruptions on the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/71\">",
"     71",
"    </a>",
"    ]. A separate series of five children with dermatophytid reactions due to tinea capitis found that in addition to involvement on the head and neck, trunk and extremity lesions were common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/58/7082/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of dermatophytid reactions involves the successful treatment of the dermatophyte infection; this may be compromised if the reaction is mistaken for a drug eruption related to antifungal therapy. Topical corticosteroids and antipruritic agents are typically used for acute management. In rare cases, systemic glucocorticoids may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/0/33793?source=see_link\">",
"       \"Patient information: Ringworm, athlete&rsquo;s foot, and jock itch (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=see_link\">",
"       \"Patient information: Fungal nail infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/19/3377?source=see_link\">",
"       \"Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial fungal infections are most commonly caused by dermatophytes in the",
"      <em>",
"       Epidermophyton",
"      </em>",
"      ,",
"      <em>",
"       Trichophyton",
"      </em>",
"      , and",
"      <em>",
"       Microsporum",
"      </em>",
"      genera. These organisms metabolize keratin and cause a range of pathologic clinical presentations, including tinea capitis, tinea pedis, tinea corporis, tinea cruris, and Majocchi's granuloma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A potassium hydroxide (KOH) preparation should be used to confirm the diagnosis of a dermatophyte infection. Failing to accurately diagnose a dermatophyte infection may lead to inappropriate treatment with topical corticosteroids. The indiscriminate use of a combination antifungal and corticosteroid product, such as Lotrisone&reg;",
"      <span class=\"nowrap\">",
"       (clotrimazole/betamethasone",
"      </span>",
"      dipropionate) should be avoided. Dermatophyte infections are not susceptible to nystatin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tinea capitis most commonly occurs in children. Black dot tinea capitis is usually caused by",
"      <em>",
"       Trichophyton tonsurans",
"      </em>",
"      , and is the predominant form of tinea capitis seen in the United States. When performing a KOH for tinea capitis, hairs should be examined for the presence of fungal spores within or surrounding the hair shaft. Topical antifungals are ineffective for the treatment of tinea capitis. Patients should be treated with oral antifungals such as griseofulvin, terbinafine, or itraconazole. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tinea capitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tinea capitis may evolve to form an inflammatory reaction called a kerion, which can be mistaken for a secondary bacterial infection. Posterior cervical lymphadenopathy is often seen with this variant, although lymphadenopathy may also occur in non-kerion tinea capitis. Kerion should respond to treatment with an oral antifungal alone. In some cases, systemic glucocorticoid therapy may help improve the patient's discomfort. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tinea capitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tinea pedis is a common type of dermatophyte infection involving the feet. A vesicobullous form is occasionally seen. Topical antifungals are usually sufficient for treatment tinea pedis, although oral antifungals may be required in certain cases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tinea pedis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tinea corporis can usually be managed with topical antifungals. Extensive cases and patients who are severely immunocompromised may warrant treatment with an oral antifungal. Patients with a confirmed diagnosis who have failed topical therapy are also candidates for oral therapy. Patients with extensive cases of tinea corporis may suffer from underlying diseases such as diabetes mellitus or immunologic disorders, and may warrant further evaluation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Tinea corporis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tinea cruris is a dermatophyte infection of the groin. Topical antifungal therapy is usually sufficient for resolving the local infection. Preventive behavioral changes and treatment of concomitant tinea pedis or onychomycosis reduce the risk for future recurrences. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Tinea cruris'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Majocchi's granuloma is a condition in which the dermatophyte invades the dermal and subcutaneous tissue via penetration of hair follicles. Inflammatory perifollicular papules, small nodules, or pustules are typically seen. A KOH preparation may be negative. Trauma, such as shaving legs, and topical corticosteroid use may be precipitating factors. Immunosuppressed patients may present with subcutaneous nodules and abscesses. Treatment requires the use of an oral antifungal. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Majocchi's granuloma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/1\">",
"      Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51 Suppl 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/2\">",
"      Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia 2008; 166:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/3\">",
"      Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     Crissey JT, Lang H, Parish LC. Manual of Medical Mycology, Blackwell Science, Cambridge 1995. p.36.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/5\">",
"      Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. Pediatrics 2003; 111:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/6\">",
"      Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/7\">",
"      Rosen T, Elewski BE. Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol 1995; 32:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/8\">",
"      Smith ES, Fleischer AB Jr, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol 1998; 39:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/9\">",
"      Ilkit M. Favus of the scalp: an overview and update. Mycopathologia 2010; 170:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/10\">",
"      Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and management of scalp ringworm. BMJ 2003; 326:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/11\">",
"      Abdel-Rahman SM, Farrand N, Schuenemann E, et al. The prevalence of infections with Trichophyton tonsurans in schoolchildren: the CAPITIS study. Pediatrics 2010; 125:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/12\">",
"      Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med 1999; 153:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/13\">",
"      Sharma V, Silverberg NB, Howard R, et al. Do hair care practices affect the acquisition of tinea capitis? A case-control study. Arch Pediatr Adolesc Med 2001; 155:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/14\">",
"      Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol 2000; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/15\">",
"      Kakourou T, Uksal U, European Society for Pediatric Dermatology. Guidelines for the management of tinea capitis in children. Pediatr Dermatol 2010; 27:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/16\">",
"      C&aacute;ceres-R&iacute;os H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol 2000; 42:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/17\">",
"      Gupta AK, Nolting S, de Prost Y, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 1999; 199:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/18\">",
"      Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/19\">",
"      Foster KW, Friedlander SF, Panzer H, et al. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol 2005; 53:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/20\">",
"      Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics 2004; 114:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/21\">",
"      Gonz&aacute;lez U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev 2007; :CD004685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/22\">",
"      Elewski BE, C&aacute;ceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008; 59:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/23\">",
"      Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002; 146:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/24\">",
"      Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 2011; 64:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/25\">",
"      Gupta AK, Drummond-Main C. Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. Pediatr Dermatol 2013; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/26\">",
"      Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/27\">",
"      Chan YC, Friedlander SF. New treatments for tinea capitis. Curr Opin Infect Dis 2004; 17:97.",
"     </a>",
"    </li>",
"    <li>",
"     Sobera JO, Elewski BE. Fungal Diseases. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/29\">",
"      White JM, Higgins EM, Fuller LC. Screening for asymptomatic carriage of Trichophyton tonsurans in household contacts of patients with tinea capitis: results of 209 patients from South London. J Eur Acad Dermatol Venereol 2007; 21:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/30\">",
"      Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol 1999; 40:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/31\">",
"      Hussain I, Muzaffar F, Rashid T, et al. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Med Mycol 1999; 37:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/32\">",
"      Ginsburg CM, Gan VN, Petruska M. Randomized controlled trial of intralesional corticosteroid and griseofulvin vs. griseofulvin alone for treatment of kerion. Pediatr Infect Dis J 1987; 6:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/33\">",
"      Pomeranz AJ, Fairley JA. Management errors leading to unnecessary hospitalization for kerion. Pediatrics 1994; 93:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/34\">",
"      Honig PJ, Caputo GL, Leyden JJ, et al. Treatment of kerions. Pediatr Dermatol 1994; 11:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/35\">",
"      Gilaberte Y, Rezusta A, Gil J, et al. Tinea capitis in infants in their first year of life. Br J Dermatol 2004; 151:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/36\">",
"      Romano C, Gianni C, Papini M. Tinea capitis in infants less than 1 year of age. Pediatr Dermatol 2001; 18:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/37\">",
"      Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007; :CD001434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/38\">",
"      Gupta AK, Doncker PD, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol 1997; 36:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/39\">",
"      Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2012; 10:CD003584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/40\">",
"      Shiraki Y, Hiruma M, Hirose N, et al. A nationwide survey of Trichophyton tonsurans infection among combat sport club members in Japan using a questionnaire form and the hairbrush method. J Am Acad Dermatol 2006; 54:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/41\">",
"      Adams BB. Tinea corporis gladiatorum. J Am Acad Dermatol 2002; 47:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/42\">",
"      Bonifaz A, Sa&uacute;l A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol 2000; 10:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/43\">",
"      Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989; 28:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/44\">",
"      Cole GW, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol 1989; 125:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/45\">",
"      Panagiotidou D, Kousidou T, Chaidemenos G, et al. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Int Med Res 1992; 20:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/46\">",
"      Faergemann J, M&ouml;rk NJ, Haglund A, Odeg&aring;rd T. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol 1997; 136:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/47\">",
"      Kohl TD, Martin DC, Berger MS. Comparison of topical and oral treatments for tinea gladiatorum. Clin J Sport Med 1999; 9:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/48\">",
"      Kohl TD, Martin DC, Nemeth R, et al. Fluconazole for the prevention and treatment of tinea gladiatorum. Pediatr Infect Dis J 2000; 19:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/49\">",
"      Beller M, Gessner BD. An outbreak of tinea corporis gladiatorum on a high school wrestling team. J Am Acad Dermatol 1994; 31:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/50\">",
"      Akinwale SO. Personal hygiene as an alternative to griseofulvin in the treatment of tinea cruris. Afr J Med Med Sci 2000; 29:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/51\">",
"      Pandey SS, Chandra S, Guha PK, et al. Dermatophyte infection of the penis. Association with a particular undergarment. Int J Dermatol 1981; 20:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/52\">",
"      Smith KJ, Neafie RC, Skelton HG 3rd, et al. Majocchi's granuloma. J Cutan Pathol 1991; 18:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/53\">",
"      Gill M, Sachdeva B, Gill PS, et al. Majocchi's granuloma of the face in an immunocompetent patient. J Dermatol 2007; 34:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/54\">",
"      Cho HR, Lee MH, Haw CR. Majocchi's granuloma of the scrotum. Mycoses 2007; 50:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/55\">",
"      Tse KC, Yeung CK, Tang S, et al. Majocchi's granuloma and posttransplant lymphoproliferative disease in a renal transplant recipient. Am J Kidney Dis 2001; 38:E38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/56\">",
"      Elmets CA. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol 1994; 31:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/57\">",
"      Gupta S, Kumar B, Radotra BD, Rai R. Majocchi's granuloma trichophyticum in an immunocompromised patient. Int J Dermatol 2000; 39:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/58\">",
"      Burg M, Jaekel D, Kiss E, Kliem V. Majocchi's granuloma after kidney transplantation. Exp Clin Transplant 2006; 4:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/59\">",
"      Liao YH, Chu SH, Hsiao GH, et al. Majocchi's granuloma caused by Trichophyton tonsurans in a cardiac transplant recipient. Br J Dermatol 1999; 140:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/60\">",
"      Kim ST, Baek JW, Kim TK, et al. Majocchi's granuloma in a woman with iatrogenic Cushing's syndrome. J Dermatol 2008; 35:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/61\">",
"      Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/62\">",
"      Novick NL, Tapia L, Bottone EJ. Invasive trichophyton rubrum infection in an immunocompromised host. Case report and review of the literature. Am J Med 1987; 82:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/63\">",
"      Jacobs PH. Majocchi's granuloma (due to therapy with steroid and occlusion). Cutis 1986; 38:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/64\">",
"      Elgart ML. Tinea incognito: an update on Majocchi granuloma. Dermatol Clin 1996; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/65\">",
"      Feng WW, Chen HC, Chen HC. Majocchi's granuloma in a 3-year-old boy. Pediatr Infect Dis J 2006; 25:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/66\">",
"      Sequeira M, Burdick AE, Elgart GW, Berman B. New-onset Majocchi's granuloma in two kidney transplant recipients under tacrolimus treatment. J Am Acad Dermatol 1998; 38:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/67\">",
"      Gupta AK, Prussick R, Sibbald RG, Knowles SR. Terbinafine in the treatment of Majocchi's granuloma. Int J Dermatol 1995; 34:489.",
"     </a>",
"    </li>",
"    <li>",
"     McMichael A, Sanchez DG, Kelly P. Folliculitis and the follicular occlusion tetrad. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/69\">",
"      Gupta AK, Groen K, Woestenborghs R, De Doncker P. Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. Clin Exp Dermatol 1998; 23:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/70\">",
"      Cheng N, Rucker Wright D, Cohen BA. Dermatophytid in tinea capitis: rarely reported common phenomenon with clinical implications. Pediatrics 2011; 128:e453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/71\">",
"      Veien NK, Hattel T, Laurberg G. Plantar Trichophyton rubrum infections may cause dermatophytids on the hands. Acta Derm Venereol 1994; 74:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/72\">",
"      Romano C, Rubegni P, Ghilardi A, Fimiani M. A case of bullous tinea pedis with dermatophytid reaction caused by Trichophyton violaceum. Mycoses 2006; 49:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/73\">",
"      Al Aboud K, Al Hawsawi K, Alfadley A. Tinea incognito on the hand causing a facial dermatophytid reaction. Acta Derm Venereol 2003; 83:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/74\">",
"      Gianni C, Betti R, Crosti C. Psoriasiform id reaction in tinea corporis. Mycoses 1996; 39:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/75\">",
"      Derebery J, Berliner KI. Foot and ear disease--the dermatophytid reaction in otology. Laryngoscope 1996; 106:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/58/7082/abstract/76\">",
"      Iglesias ME, Espa&ntilde;a A, Idoate MA, Quintanilla E. Generalized skin reaction following tinea pedis (dermatophytids). J Dermatol 1994; 21:31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4030 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-222.169.60.2-DB8828736C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7082=[""].join("\n");
var outline_f6_58_7082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TINEA CAPITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gray patch tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Black dot tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176813\">",
"      Favus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H176727\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H176734\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Household members",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Kerion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      In infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TINEA PEDIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute tinea pedis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic tinea pedis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TINEA CORPORIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TINEA CRURIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MAJOCCHI'S GRANULOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4733135\">",
"      DERMATOPHYTID (ID) REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4030|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/35/26167\" title=\"picture 1\">",
"      Tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/62/44007\" title=\"picture 2\">",
"      Kerion in tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/56/6023\" title=\"picture 3\">",
"      Tinea capitis KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/47/9976\" title=\"picture 4\">",
"      Tinea capitis - black dot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/11/39103\" title=\"picture 5A\">",
"      Acute tinea pedis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/49/31506\" title=\"picture 5B\">",
"      Acute tinea pedis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/4/27715\" title=\"picture 6A\">",
"      Dyshidrotic eczema foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/2/4132\" title=\"picture 6B\">",
"      Dermatophyte KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/34/38435\" title=\"picture 7A\">",
"      Tinea pedis interdigital maceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/1/25621\" title=\"picture 7B\">",
"      Tinea pedis interdigital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/22/26980\" title=\"picture 8A\">",
"      Tinea pedis moccasin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/46/40675\" title=\"picture 8B\">",
"      Tinea pedis dorsal foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/17/9492\" title=\"picture 9\">",
"      Tinea pedis manuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/42/34468\" title=\"picture 10\">",
"      Tinea pedis onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/29/33233\" title=\"picture 11\">",
"      Interdigital erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22751\" title=\"picture 12A\">",
"      Tinea corporis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/24/3459\" title=\"picture 12B\">",
"      Tinea corporis on leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/37/7765\" title=\"picture 12C\">",
"      Tinea corporis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29250\" title=\"picture 13\">",
"      Tinea corporis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/46/8933\" title=\"picture 14\">",
"      Tinea incognito",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/32/19968\" title=\"picture 15A\">",
"      Granuloma annulare foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/51/32563\" title=\"picture 15B\">",
"      Granuloma annulare hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18417\" title=\"picture 16A\">",
"      Erythema annulare centrifugum - light skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/23/28016\" title=\"picture 16B\">",
"      Erythema annulare centrifugum - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/8/6276\" title=\"picture 17A\">",
"      Tinea cruris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/28/14791\" title=\"picture 17B\">",
"      Tinea cruris 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/31/26100\" title=\"picture 18\">",
"      Tinea cruris buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/19/3381\" title=\"picture 19\">",
"      Inverse psoriasis groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43587\" title=\"picture 20A\">",
"      Intertriginous erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/27/38321\" title=\"picture 20B\">",
"      Erythrasma fluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19591\" title=\"picture 21\">",
"      Seborrheic dermatitis groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/16/257\" title=\"picture 22A\">",
"      Abd and inguinal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/34/30246\" title=\"picture 22B\">",
"      Candidal intertrigo groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/11/25783\" title=\"picture 23A\">",
"      Candida KOH low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/40/5766\" title=\"picture 23B\">",
"      Candida pseudohyphae yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/0/37889\" title=\"picture 24\">",
"      Majocchis granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/8/7300\" title=\"picture 25A\">",
"      Autoeczematization on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/24/24963\" title=\"picture 25B\">",
"      Dermatophytid reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/3/19517\" title=\"table 1\">",
"      Topical antifungal agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=related_link\">",
"      Candidal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=related_link\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=related_link\">",
"      Granuloma annulare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=related_link\">",
"      Patient information: Fungal nail infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/19/3377?source=related_link\">",
"      Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/0/33793?source=related_link\">",
"      Patient information: Ringworm, athlete&rsquo;s foot, and jock itch (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_58_7083="Warning signs for terminating exercise in pregnancy";
var content_f6_58_7083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Warning signs for terminating exercise in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Vaginal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea prior to exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lightheadedness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine contractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased fetal movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leakage of amniotic fluid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: ACOG Committee opinion. Number 267, January 2002 Obstet Gynecol 2002; 99:171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7083=[""].join("\n");
var outline_f6_58_7083=null;
var title_f6_58_7084="Stepwise Rx plantar fasciitis";
var content_f6_58_7084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Step-wise therapy for plantar fasciitis in the young athlete",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First-line therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAIDs or steroid burst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Icing (massage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stretching heel cords and gastrocnemius-soleus muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proper shoes for daily and sports activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No barefoot walking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-dye taping or hallux strapping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Over-the-counter orthosis or temporary heelcups,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt and silicone inserts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relative rest*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strengthening of the intrinsic muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Second-line therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iontophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasonography with deep tissue cross friction massage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider orthotics although taping is usually better",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thomas heel (puts the calcaneus into varus and unloads the plantar fascia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Night splints (for patients with persistent first-step symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisone injection (with ultrasound guidance if necessary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short leg walking cast for 2-4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider steel shank rocker bottom shoes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Third-line therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracorporeal shock wave application",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Relative rest: avoidance of activities that cause pain.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7084=[""].join("\n");
var outline_f6_58_7084=null;
var title_f6_58_7085="Selected food sources of folate and folic acid";
var content_f6_58_7085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected food sources of folate and folic acid",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Micrograms (&micro;g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breakfast cereals fortified with 100 percent of the DV, &frac34; cup*",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beef liver, cooked, braised, 3 ounces",
"       </td>",
"       <td>",
"        185",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cowpeas (blackeyes), immature, cooked, boiled, &frac12; cup",
"       </td>",
"       <td>",
"        105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breakfast cereals, fortified with 25 percent of the DV, &frac34; cup*",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinach, frozen, cooked, boiled, &frac12; cup",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Great Northern beans, boiled, &frac12; cup",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asparagus, boiled, 4 spears",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rice, white, long-grain, parboiled, enriched, cooked, &frac12; cup*",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetarian baked beans, canned, 1 cup",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinach, raw, 1 cup",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Green peas, frozen, boiled, &frac12; cup",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broccoli, chopped, frozen, cooked, &frac12; cup",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg noodles, cooked, enriched, &frac12; cup*",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broccoli, raw, 2 spears (each 5 inches long)",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avocado, raw, all varieties, sliced, &frac12; cup sliced",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peanuts, all types, dry roasted, 1 ounce",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lettuce, Romaine, shredded, &frac12; cup",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheat germ, crude, 2 tablespoons",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tomato Juice, canned, 6 ounces",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orange juice, chilled, includes concentrate, &frac34; cup",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turnip greens, frozen, cooked, boiled, &frac12; cup",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orange, all commercial varieties, fresh, 1 small",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bread, white, 1 slice*",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bread, whole wheat, 1 slice*",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg, whole, raw, fresh, 1 large",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cantaloupe, raw, &frac14; medium",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papaya, raw, &frac12; cup cubes",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Banana, raw, 1 medium",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Items marked with an asterisk (*) are fortified with folic acid as part of the Folate Fortification Program.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Department of Agriculture, Agricultural Research Service 2003. USDA National Nutrient Database for Standard Reference, Release 16. Nutrient Data Laboratory Home Page, file://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7085=[""].join("\n");
var outline_f6_58_7085=null;
var title_f6_58_7086="PCN major minor det";
var content_f6_58_7086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penicillin: Major and minor determinants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Penicillin-allergic patients may form IgE molecules against the beta lactam core or against the R groups (shown in red).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7086=[""].join("\n");
var outline_f6_58_7086=null;
var title_f6_58_7087="Immunoglobin pattern MM";
var content_f6_58_7087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunoglobulins in multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electrophoretic pattern of serum proteins in a normal subject is shown in panel A. The area containing proteins of \"gamma\" mobility is shown in the blue boxed area. This area contains most of the immunoglobulins. For the patient with multiple myeloma (panel B), there is a monoclonal immunoglobulin band in the gamma mobility region (asterisk), but little or no protein staining in the rest of the gamma mobility region, suggesting the presence of reduced amounts of normal polyclonal immunoglobulins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_58_7087=[""].join("\n");
var outline_f6_58_7087=null;
